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Abstract
Neuropeptides show dynamic changes in expression after nerve injury, and have been 
implicated in chronic pain states. I sought to compare expression of two peptides which 
are upregulated after nerve injury, galanin and Reg2, and to determine the subtypes of 
dorsal root ganglion (DRG) cells in which they are expressed.
Rats underwent unilateral, L5 spinal nerve ligation (SNL) with recovery for 1 or 
7 days. Galanin and Reg2 were expressed in 20% and 8% of DRG cells at 1 day, and 
49% and 5% at 7 days, respectively. At 1 day, galanin was mainly expressed in CGRP-
positive DRG cells (62% of galanin cells); this expression was maintained at 7 days. At 
1 day, galanin was expressed in few IB4-positive DRG cells (14% of galanin cells), but 
expression in IB4 cells significantly increased by 7 days (30% of galanin cells). Galanin 
was also coexpressed with TRPV2 (9%). Reg2 was coexpressed in 48% of galanin cells 
(7 days) but not coexpressed with TRPV2 and sparsely with CGRP. Using isolated DRG 
cultured in BSF2 supplemented with 2% foetal calf serum (FCS), galanin and Reg2 were 
expressed in 36.5% and 23.3% after 72hrs. Addition of IL6 (40 ng/mL in FCS-
supplemented BSF2) increased galanin expression after 24 and 48hrs growth by 6.7% 
and 13.1%, respectively. ED1-positive cells were shown infiltrating the spinal nerve and 
associated with the ganglion by 7 days post-SNL. 
These results show Reg2 is more selectively expressed after L5 SNL than 
galanin. Both peptides show a complex temporal profile of expression. Galanin is 
upregulated initially in CGRP-cells and then in IB4/P2X3-cells, whereas Reg2 is 
expressed initially in IB4/P2X3-cells and then in larger cells. The factors that 
differentially regulate galanin, and potentially Reg2, in these cell populations remain 
unknown but it is hypothesized that IL6, or a related cytokine, drives-up galanin 
expression in IB4/P2X3-cells by 7 days but that the early upregulation in CGRP-cells is 
a direct consequence of axotomy.
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81. INTRODUCTION
The sensory system consists of neurons having different anatomical, physical and 
neurochemical characteristics, which influence the manner in which they conduct 
sensory impulses from the periphery to the brain. Following injury or trauma, sensory 
impulses may be interpreted by the brain as pain. Pain is defined by the International 
Association for the Study of Pain (IASP) as ‘an unpleasant sensory or emotional 
experience associated with actual or potential tissue damage, or described in terms of 
such damage’. This definition encompasses nociception, pain perception, suffering 
and pain behaviours, and these broad categories have links to anatomical, 
physiological and psychological aspects which accompany the perception of pain 
(Loeser and Melzack 1999). 
Transmission of sensory impulses and their interpretation of pain have
intrigued scholars for decades. Indeed, some fascinating theories have been proposed 
including early records from Descartes (1640) who described that heat from a fire 
‘pulled on delicate threads’ in the foot which opened pores in a ‘common sense 
centre’ located in the pineal gland. These particular ideas turned out to be incorrect, 
and today three primary expression types of ‘pain’ have been described (Basbaum 
and Woolf 1999). 
Firstly, and most simply, there is pain which indicates an injury. The ability to 
recognise an injury through the interpretation of sensory stimuli as pain is a critical 
evolutionary survival mechanism aiming to promote protection of an injury and allow 
healing. Secondly, there is hypersensitivity that occurs during tissue healing, which is 
thought to aid healing by encouraging minimal movement of the injured area. 
Thirdly, there is the phenomenon of neuropathic pain originating from a nerve injury 
and resulting from changes in neuronal processing. Neuropathic pain may also 
involve recruitment of non-nociceptive pathways, resulting in abnormal pain 
sensations. Neuropathic pain persists longer than the temporal course of natural 
healing associated with any predisposing injury, and serves no apparent physiological 
purpose (Basbaum and Woolf 1999). Changes that occur after nerve injury, which 
may then be involved in neuropathic pain, are the focus of the work in this thesis. 
Medical conditions presenting with chronic neuropathic pain constitute a 
significant financial burden to society, with resulting loss of workdays and associated 
healthcare costs (Loeser and Melzack 1999). More pertinently, chronic pain may 
change a patient’s life considerably, in many cases causing a lifetime of disability. As 
9a consequence, underlying mechanisms involved in the formation of neuropathic pain 
conditions are important and relevant to society as a whole.
This study sought to characterise differences between populations of 
nociceptive primary afferent neurons after nerve injury. More specifically, differences 
between peptidergic- and non-peptidergic primary afferent fibres were examined after 
nerve injury, and also the influence of the cytokine, interleukin 6 (IL6), on the 
peptides expressed by primary afferent neurons. As an introduction to the field, 
existing literature discussing the physiology of primary afferent neurons will be 
discussed alongside the influence of injury-generated factors on their phenotype. 
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1.1. Nociception 
Nociception is the process of detecting and relaying tissue damage, initially via 
primary afferent neurons to the dorsal horn. Nociceptive primary afferent neurons are 
specialised sensory fibres activated by high-threshold stimuli generated with injury. 
Second order neurons relay sensory information via a number of parallel sensory 
pathways to third order neurons, linking to higher centres were pain may be 
perceived. Sensory pathways involved in modulation and transmission of nociception 
can be broadly classified as ascending or descending (Figure A) (reviewed by Hunt 
and Mantyh, 2001). 
Briefly, there are two primary ascending nociceptive pathways: the 
spinoparabrachial pathway originates from the superficial dorsal horn and projects to
areas of the brain concerned with affect and emotional response to pain; the 
spinothalamic pathway, probably distributes nociceptive information to areas of the 
cortex concerned with discrimination and affect. The descending pathway originates 
from the amygdala and hypothalamus and projects via the periaqueductal grey (PAG). 
This descending pathway is involved in ‘damping’ sensory impulses, reducing the 
likelihood of transmission to higher centres, through inhibitory interconnections in 
the spinal cord. Stimulation of the PAG activates enkephalin-releasing neurons that 
project to the raphe nuclei in the brainstem. These axons from the raphe nuclei 
containing neurotransmitter, 5HT, and project to the dorsal horn of the spinal cord 
and form excitatory connections with inhibitory interneurons located in substantia 
gelatinosa. When activated these interneurons release mediators, for example 
endogenous opioids or gamma-amino butyric acid (GABA), which act to reduce the 
likelihood of impulses reaching higher centres to be interpreted as pain (see review by
Hunt and Mantyh, 2001). 
In both pathways cell bodies of the primary afferent neurons are located in the 
dorsal root ganglia (DRG), and their central axons project into the spinal cord. The 
synapse forming the first synaptic relay between primary afferent fibers and second 
order central neurons in spinal dorsal horn is essential to the initial processing of 
somatosensory information. The dorsal horn synapse is discussed in more detail,
below. 
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Figure A: Main ascending and descending spinal pathways involved in transmitting 
nociception. (a) The spinoparabrachial pathway (red) originates from the superficial dorsal 
horn and the spinothalamic pathway (blue), which originates from the deep dorsal horn. (b) 
The descending (blue) pathway originates from the amygdala and hypothalamus and projects 
via the periaqueductal grey (PAG) and the rostroventral medulla to the dorsal horn. A, 
adrenergic nucleus; bc, brachium conjunctivum; cc, corpus callosum; Ce, central nucleus of 
the amygdala; Hip, hippocampus; ic, internal capsule; LC, locus coeruleus; PB, parabrachial 
area; Po, posterior group of thalamic nuclei; Py, pyramidal tract; RVM, rostroventral 
medulla; V, ventricle; VMH, ventral medial nucleus of the hypothalamus; VPL, ventral 
posteriolateral nucleus of the thalamus; VPM; ventral posteriomedial nucleus of the thalamus. 
From Hunt and Mantyh, 2001.
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1.1.2 Gate Control theory  
The dorsal horn synapse is thought to be a point where sensory signals are modulated 
before relaying to second order, central neurons. Fundamental theories of pain from 
the 1960’s onwards have been influenced by the Gate Control theory proposed by 
Melzack and Wall (1965) (see Figure B). The Gate Control theory asserts that 
activation of non-nociceptive fibres can influence sensory impulses transmitted via 
nociceptors. Afferent nerves conduct impulses with at least two different 
characteristics (see Section 1.3 for detail): myelinated Aδ-fibres relay quickly and are 
perceived as “sharp pain”, whereas small, unmyelinated C-fibres transmit longer-term 
sensory impulses at a relative slower rate, and are perceived and reported as 
‘throbbing’ pain. Large-diameter Aβ-fibres transmit innocuous sensory stimuli, but 
via inhibitory interconnections were proposed to dampen transmission of stimuli 
originating from Aδ and C fibres (Figure B). 
The Gate Control theory has been challenged since being outlined. For 
example, most of the dorsal horn interneurons identified by Melzack and Wall as 
inhibitory are thought to be excitatory (Craig 2003) and Inui and colleagues (2006) 
demonstrated that cortical responses to noxious stimuli can be inhibited by innocuous 
tactile stimuli at the cortical level, with minimal contribution at the spinal level. 
Furthermore, the Gate Control theory did not provide explanations for long-term 
changes in synaptic activity, that can result from intense nociceptive input (Dubner 
and Ruda, 1992) and lead to activity-dependent plasticity and changes in spinal cord 
excitability. Cellular mechanisms which propose how synaptic potentiation may 
result in prolonged sensations have built upon the foundations of sensory signalling 
described by Melzack and Wall. Some of the principals behind these highly complex 
models are discussed below. 
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Figure B: Original schemes of the Gate Control theory by Melzack and Wall (1965) and 
updated by Wall (1969).  and C refer to small myelinated and unmyelinated afferents, 
respectively.  refers to large myelinated afferents. 2, 3, 4 and 5 indicate cells in the Rexed 
laminae of that number. T is an unspecified transmission cell. The arrowheads represent 
descending pathway from the brain. Black cells are inhibitory. Although inhibition is shown 
here as presynaptic, post-synaptic inhibition is also possible (Hillman and Wall, 1969; 
reviewed Wall, 1999). 
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1.1.3 Synaptic mechanisms of prolonged sensation  
Mechanistic explanations for use-dependent synaptic plasticity have been proposed to 
suggest how sensory signalling is prolonged or facilitated following injury (Li et al., 
1999). These include descriptions of ‘wind-up’ and ‘central sensitization’ (Woolf, 
1983; Wall and Woolf, 1984). Wind-up refers to the progressive increase in the 
magnitude of C-fibre evoked responses of dorsal horn neurons produced by repetitive 
activation of C-fibres (Woolf, 1996; Li et al., 1999), whereas central sensitization 
refers to enhanced excitability of dorsal horn neurons, and is characterised by 
increased spontaneous activity, enlarged receptive fields and an increase in responses 
evoked by large and small calibre primary afferent fibres (Woolf, 1996). A proposed 
model for central sensitization was outlined by Dubner and Ruda (1992). The model 
described how dynorphin, substance P (SP) and calcitonin gene-related peptide 
(CGRP) act together to enhance glutamate transmission, through the NMDA-type 
glutamate ion channel, in the dorsal horn by increasing depolarisation strength in the 
post-synaptic cell. The fundamental key was shown to be opening of the 
glutamatergic NMDA receptor, via removal of a magnesium ion (Mg2+) block (Chen 
and Huang, 1992), facilitating influx of calcium ions. 
Although the complexities are still under investigation and a number of other 
mediators including BDNF discussed below, are likely also involved, the 
development of central sensitization and wind-up may act together to increase the 
post-synaptic response to a sensory stimulus and/or prolong hyperalgesia following 
injury. Modelling central sensitization and wind-up provide key explanations for 
pathological observations noted in both humans and animals with neuropathic pain
(discussed below, Section 1.1.4), particularly ongoing pain sensations after an injury 
has healed. Indeed, cellular mechanisms implicated in learning in the hippocampus, 
the concept of long-term potentiation (LTP) (Bliss and Lømo 1973), are thought to 
have similarities to those mechanisms outlined above (Chen and Huang, 1992; 
Dubner and Ruda, 1992) involved in the formation of central sensitization (Ji et al., 
2003). Further investigation into similarities and differences between laying down 
memories and facilitated pain pathways may advance understanding of chronic pain. 
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1.1.4 – Neuropathic pain
Neuropathic pain can develop after nerve injury or as part of other diseases that 
involve damage to peripheral nerve function, such as peripheral neuropathy in 
diabetes, late-stage AIDS, or certain forms of cancer. Peripheral neuropathic pain 
manifests as spontaneous pain (stimulus-independent pain) or pain hypersensitivity 
elicited by a stimulus after damage to or alterations in sensory neurons (stimulus-
evoked pain) (Woolf and Mannion, 1999). 
Stimulus-independent activity of C-fibres is thought to be responsible for the 
persistent burning pain, which is a common characteristic of neuropathic pain in 
humans, and sensitisation of dorsal horn neurons. Similarly, spontaneous activity in 
large myelinated Afibres is thought to be related to stimulus-independent 
paresthesia and, after central sensitization, to dysesthesia and pain. 
Stimulus-evoked pain is a common component of neuropathic pain, and 
involves at least one of two key modalities: hyperalgesia and allodynia. Hyperalgesia 
is an increased response to a stimulus that would normally result in pain, and is the 
result of abnormal processing of nociceptor input. Allodynia is the sensation of pain 
elicited by a non-noxious stimulus and can be produced either by low threshold A-
fibres on an altered central nervous system, or the reduction in threshold of nociceptor 
terminals in the periphery (Woolf and Mannion, 1999; Ossipov et al., 2000). Thermal 
and mechanical allodynia are common modalities measured in behavioural models of 
nociception, outlined below in Section 1.2. These behavioural observations have 
formed the basis of our understanding into chronic pain. 
Neuropathic pain conditions are often complicated through interplay with 
non-nociceptive pathways. For example, sympathetically-maintained pain, such as 
that seen in Reflex Sympathetic Dystrophy (RSD; also known as Complex Regional 
Pain Syndrome (CRPS)-type I), is clinically classified as a neuropathic pain condition 
due to presenting features of stimulus-independent (e.g., burning, spontaneous firing) 
and stimulus-dependent pain (allodynia, hyperalgesia). However there is often no 
direct injury to a nerve. Indeed, the most common precipitating events are sprain or 
fractures, driven by inflammation (Bruehl and Chung 2007). As such, interplay
between chronic inflammation and mechanisms of neuropathic pain (Woolf and 
Mannion, 1999) may be responsible for the condition. The exact mediators behind 
any interaction are not fully understood. However, neurotrophic factors, such as nerve 
growth factor (NGF) (Ruiz et al., 2004), and cytokines within the neuropoietic family 
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such as IL6 (Ramer et al., 1998; Ramer et al., 1999) and leukaemia inhibitory factor 
(LIF) (Thompson and Majithia, 1998) can promote sprouting of sympathetic post-
ganglionic neurons in animal models. Therefore, these cytokines have the potential to 
form and/or maintain cross-talk between sympathetic and sensory pathways and their 
contribution to sympathetically-maintained pain requires further investigations. 
Interestingly, cytokine IL6 has been recorded to be increased in the cerebrospinal 
fluid of patients with CRPSI (Alexander et al., 2005) and, therefore, might be of 
particular importance in the ongoing pathology of sympathetically-maintained pain. 
By definition neuropathic pain results following nerve damage. However, 
nerve trauma, particularly in humans, often does not result in complete severing and 
neat transection of a nerve fibre bundle, but in reality leaves injured nerves 
juxtaposed with intact fibres; some of the consequences of which are now discussed. 
1.1.5 – Injured versus uninjured fibres in neuropathic hypersensitivity 
Partial injury of a nerve bundle in humans or animals results in sensory pathways 
remaining at least partly intact, and consequently sensory impulses can still be 
transmitted via these intact pathways. Indeed, uninjured C-afferents have been shown 
to be necessary for the induction and maintenance of neuropathic pain, and 
furthermore afferent inputs, presumably from injured Aβ-fibres, also contribute to the 
maintenance at an earlier stage (Jang et al., 2007). These intact fibres share the injury 
environment and also the consequences resulting from an injury, some of the 
consequences of which are shown schematically on Figure C. Collectively, 
differential regulation of receptors (such as thermoreceptor, TRPV1), ion channels 
(such as TTX resistant sodium channels), and neurotransmitters (such as SP) have 
been noted in injured vs. intact fibres (see McMahon and Priestley, 2005). Intact 
nerves will also be exposed to activated peripheral immune cells with degeneration of 
adjacent damaged fibres. Excess exposure to growth factors or injury-generated 
cytokines may result for example to the formation of sympathetic baskets, discussed
above. Other consequences include the exposure to injury mediators at peripheral 
targets, such as target-derived growth factors (e.g., NGF or glial cell-line derived 
neurotrophic factor [GDNF]). Furthermore, as intact nerves have functional axonal 
transport complexes, these target-derived mediators can be retrogradely transported 
by intact nerves to the DRG, whereby they may promote changes in gene expression. 
For example, NGF and brain-derived neurotrophic factor (BDNF) levels have been 
shown to progressively increase in the uninjured (adjacent) L4 DRG after L5 nerve 
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transection (Fukuoka et al., 2001). Whether similar mechanisms occur in humans 
following nerve injury remain unknown. 
These complex changes that take place in DRG cells in response to nerve 
injury have been shown through animal models, to play a key role in the generation of 
neuropathic pain. Animal models of nerve injury will therefore now be described 
(Section 1.2), followed by a review of the main types of DRG cells and the changes 
that may occur following nerve injury (Sections 1.3-1.5). 
Figure C: Diagram summarising the range of phenotypic changes that can occur in damaged 
and in undamaged nociceptor fibres after partial nerve injury. BDNF, brain-derived 
neurotrophic factor; DRG, dorsal root ganglion; MOR, morphine receptors; Sub P, substance 
P; Sym, sympathetic; TTXs, tetrodotoxin-sensitive voltage-gated sodium channel; TTXr, 
tetrodotoxin-resistant voltage-gated sodium channels; VR1, TRPV1 (transient receptor 
potential vanilloid 1). Taken from: McMahon and Priestley, 2005.
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1.2. Animal models of injury 
In order to investigate the physiological properties of sensory transmission associated 
with neuropathic pain, a number of animal models have been developed to model 
inflammatory or neuropathic injury. In these experimental models, it is important to 
design balanced methodology with specific controls, and to consider the limitations of 
the methods, design and materials. For example, normal distribution of some 
neurotransmitters modulating sensory action in Wistar Kyoto rats make this model 
more prone to develop neuropathic pain than Sprague-Dawley rats (Yoon et al., 
2003). Furthermore, as many models involve surgical procedures, an important 
consideration is the anaesthetic used and any effect the agent might have on 
nociception. For example, the GABAergic system forms the principal inhibitor 
network via spinal cord interneurons, and is critical in descending control (see Figure 
A). Many anaesthetic agents (such as barbiturates, e.g., pentobarbital) act via the 
GABAergic system and may inadvertently skew experimental data, especially if 
baseline or comparative measures of acute pain are recorded immediately after 
surgery. 
1.2.1 – Behavioural measures of nociception  
Animal behaviour can be used to represent characteristics reported in human 
chronic pain; specifically allodynia (pain in response to non-noxious stimuli) and 
hyperalgesia (an exaggerated pain response to a stimulus that would normal cause 
pain). Methods have been developed to measure hypersensitivity following 
inflammation or nerve injury. For example, in a model of nerve injury or foot pad 
inflammation, changes in withdrawal thresholds to mechanical stimuli is generally 
tested using different calibre Von Frey hairs presented to the dorsal surface of the 
paw. The force (in grams) at which withdrawal occurs can be compared between 
injury and control. Separately, changes in withdrawal thresholds to temperature can 
be tested by measuring footpad removal from heat lamp or cold stimulus, between 
control and injury state, which is then interpreted as peripheral hypersensitivity. 
Behavioural data, in association with histological or electrophysiological data,
provide compelling evidence for mechanisms behind sensory hypersensitivity and 
ultimately the perception of pain following inflammation or nerve injury. 
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1.2.2 – Modelling inflammatory injury
As models of inflammatory injury are not investigated herein, only a brief outline is 
provided for comparison purposes with nerve injury models. The most commonly 
used model for inflammatory injury involves subcutaneous injection of an irritant, 
such as formalin solution, complete Freund’s adjuvant (CFA), carrageenan, mustard 
oil, capsaicin, endotoxin, or similar irritant, into the foot pad or dorsal skin of an 
animal. Behavioural measures (above Section 1.2.1) can be recorded pre- and post-
injury to record the consequences to baseline sensitivity after inflammation. The skin 
territory of the footpad is innervated principally by sensory fibres in the sciatic nerve, 
and lumbar DRGs (specifically L3-L5) comprise the majority of cell bodies forming 
the sciatic nerve. Thus, following inflammation of the foot pad, extracted DRGs (see 
Section 1.3.) can be analysed for changes in expression of peptides, receptors or ion 
channels that result after local inflammatory injury of the footpad. Phenotypic 
changes in DRG cells may be correlated with behavioural measures of 
hypersensitivity, such as changes in withdrawal threshold to heat or mechanical 
stimuli, and conclusions can be drawn regarding the importance of the dynamic 
changes observed in the DRG cell body or central terminals to any hypersensitivity
recorded. Similar studies can be conducted following different types of nerve injury. 
1.2.3 – Modelling nerve injury 
Models of partial and complete nerve injury have been developed with corresponding 
loss of some, or all, nerve fibres within a nerve bundle (Figure D). The consequences 
of each type of injury are distinct, with respect to the magnitude of behavioural 
responses recorded and the neurochemical changes observed. Both partial and 
complete nerve injury models produce abnormal stimulus-evoked sensations 
(allodynia; hyperalgesia), as reported in humans with neuropathic pain, in addition to 
some signs of on-going spontaneous sensations such as guarding or limping (Kim et 
al., 1997). Direct dorsal horn communication with DRG cells is not thought to be a 
crucial factor in the development of mechanical allodynia, as decentralisation of the 
L5 DRG by complete L5 dorsal root lesion has been shown to produce profound 
mechanical hyper-sensitisation (Colburn et al., 1999). Conversely, microglia 
activation (discussed in Section 1.6) appears to be dependent upon DRG-mediated 
sensory impulses and, contrary to behavioural responses, microglia activation has
been shown to be robust only when a nerve lesion is peripheral to the cell body 
(Colburn et al., 1999). Taking these differential points into consideration, some 
models are more appropriate for different types of end point observations. 
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In the present study, the L5 spinal nerve ligation (L5 SNL) model was used to 
axotomise all fibres within the L5 DRG (Figure D). Transection of only L5 axons 
(e.g., 5–8 mm from the DRG), leaves the adjacent L4/L6 axons intact, although distal 
to the ligature both damaged and undamaged fibres are co-mingled in the sciatic 
nerve. The model enabled comparison of injured versus non-injured DRG separately 
in L5 and L4/L6 ganglia, respectively. In comparison, cutting the sciatic nerve 
transects both myelinated (larger diameter) and unmyelinated (smaller diameter) 
axons (e.g, about 50 mm from the DRG) and leads to the formation of a neuroma. 
Sciatic nerve axotomy damages the majority of axons within the L3-L5 DRG, with 
little co-mingling of injured and non-injured fibres in the periphery (Figure D). 
Furthermore, these axons are not exposed to the products of Wallerian degeneration. 
However, only approximately 50-80% of fibres in the L5 DRG would be damaged. 
Partial nerve injury models involve damaging some fibres within specific 
DRG leaving intact fibres in contact with injured fibres within the distal nerve, some 
of the consequences of which are outlined above (Section 1.1.5) and schematically in 
Figure C. As noted above partial nerve injury is thought to more closely model the 
consequences of nerve injury in humans. Furthermore, in humans and animal models, 
the most severe and long-lasting hypersensitivity results from afferent activity after 
partial nerve injury (see McMahon and Priestley, 2005). Partial nerve injury produces 
a more gradual degeneration of nerve fibres over time compared with the immediate 
neuropathy produced with complete nerve transection. Other models of partial 
neuropathy have been developed, and include the Bennett model (Bennett, 1998a; 
involving chronic constriction injury [CCI] of the sciatic nerve (Figure D), resulting 
in oedema at the ligatures and self-strangulation), the Seltzer model (1990; involving 
partial ligation of sciatic nerve) and the Gazelius model (1996; involving 
photochemical lesion of the exposed sciatic nerve). The CCI model, like the L5 SNL 
model, results in intermingling of intact and degenerated axons in the nerve stump, 
compared with a co-mingling in the same DRG of neurons with injured and uninjured 
axons for sciatic axotomy and the spared nerve injury (SNI) model. The SNI model 
will commonly involve a lesion of two of the three terminal branches of the sciatic 
nerve (tibial and common peroneal nerves) leaving the remaining sural nerve intact 
(Decosterd and Woolf 2000) (Figure D). The SNI model differs from partial nerve 
injury models as co-mingling of distal intact axons with degenerating axons is 
restricted, but there is considerable intermingling of injured and non-injured fibres of 
cell bodies within the same DRG (Decosterd and Woolf 2000). The model therefore 
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permits behavioural testing of non-injured skin territories adjacent to the denervated 
areas. 
The present study focuses on the dynamic changes that take place in 
categories of DRG cells, and behavioural observations are not conducted. Complete 
L5 SNL was considered most appropriate for these histochemical investigations to 
facilitate comparison of injured versus non-injured DRG. Accordingly, histochemical 
classification of DRG cells is an important facet to the work carried out in this thesis, 
and will be discussed in detail in the following sections (Section 1.3-1.5). 
Figure D: Diagrammatic representation of nerve injury models. L4, L5 and L6 DRG fibres 
project axons into the sciatic nerve. Spinal nerve ligation (SNL) involves complete transection 
of one or more spinal nerves (L6 and L5 as shown). For example, SNL transects only L5 
axons 5-8 mm from the DRG, leaving intact L4 axons distally within bundles together with 
degenerating axons. Peripheral nerve ligation (PNL) involves lesion of the sciatic nerve, and 
both myelinated (larger diameter) and unmyelinated (smaller diameter) axons about 50 mm 
from the DRG leading to the formation of a neuroma. These axons are not exposed to the 
products of Wallerian degeneration. Spared nerve injury (SNI) model generally involves a 
lesion of two of the three terminal branches of the sciatic nerve (tibial and common peroneal 
nerves) leaving the remaining sural nerve intact. Chronic constriction injury (CCI) involves 
constriction of the sciatic nerve. Taken from Ueda and Rashid 2003. 
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1.3. Immunohistochemical classification of dorsal root ganglia
The majority of the skin’s surface and most muscles/joints are supplied by primary 
sensory neurons whose cell bodies are located in the DRG, laterally located to the 
spinal cord. DRG neurons do not possess dendrites but have an axon that divides into 
two branches: a peripheral branch having receptor, and possibly also effector, 
properties; and a central branch, which synapses with second order neurons within the 
spinal cord. 
DRG cells can be characterised according to their physiology, anatomy or 
neurochemistry. Broad distinction can be made based on size of cells. Myelinated, 
A/A-fibres have high conduction velocity (30-120 m.s-1) and are especially 
identified using antibodies against phosphorylated, heavy neurofilament (NF200). 
These fibres comprise approximately 30-40% of lumbar DRG cells (Priestley et al., 
2002) and are generally involved in conducting innocuous mechanosensitive
information (Lawson and Waddell, 1991; Lawson 2002). A-fibres can become 
involved in neuropathic pain following injury (Neumann et al., 1996) including in 
humans (Gibbs et al., 2008), and may contribute to allodynia as discussed above 
(Section 1.1.5) or e.g., involving release of SP (Malcangio et al., 2000).
This project used the classification of DRG cells involved in nociception 
according to three neurochemical categories (Figure E) (see: Priestley et al., 2002). 
(1) thinly-myelinated, peptidergic A fibres: have medium diameter (area: 
800–2400 μm2 [~32-54m diameter]), transmit impulses at 2.5-30 m.s-1, and express 
peptides (CGRP) in terminals.
(2) unmyelinated, peptidergic C-fibres: have small diameter (area <800 m2
[~20-31.9m diameter]), transmit impulses at 0.5-2.5 m.s-1, and express peptides 
(CGRP/SP) in their terminals. 
(3) unmyelinated, non-peptidergic C-fibres: have small diameter (area ≤800 
m2 [20-32m diameter]), and are identifiable via lectin marker Griffonia 
simplicifolia IB4. 
The majority of small diameter unmyelinated C-fibres are polymodal however 
distinct populations are thought to exist. For example, C-fibres have been shown to 
include populations of thermoreceptors specifically adapted to respond to given 
temperature ranges (discussed by Tominaga and Caterina, 2004). Another population 
of C-fibres is exclusively chemosensitive, and a further population is ‘silent’ and do 
not respond to mechanical or thermal stimuli under normal circumstances (Lynn 
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1991). Furthermore, a small population of Mrgpr-expressing cells might mediate light 
touch (Liu et al., 2007). This specific ability of sensory nociceptors to respond to 
chemical, thermal or mechanical stimuli is determined by expression of ion channels 
and receptors. Electrophysiological studies have demonstrated that most C-fiber 
nociceptors are polymodal, responding to multiple stimuli, including temperature, 
pressure, and other mediators (e.g., 5HT, H+, histamine, prostaglandins) produced 
with injury. Nevertheless, stimuli are perceived as distinct and it has correspondingly 
been proposed that discrimination among these modalities occurs at spinal or 
supraspinal levels of processing (Cavanaugh et al., 2009). Indeed, recent evidence 
suggests that behavioral discrimination between different pain modalities can occur at 
the earliest stages of sensory processing (Cavanaugh et al., 2009), highlighting the 
importance of a thorough understanding of the differences that exist between 
categories of nociceptor. This includes understanding of the specific regulation by 
growth factors (Section 1.3.1), and the key characteristics between the two 
populations of unmyelinated C-fibers: peptidergic (Section 1.4) and non-peptidergic 
(Section 1.5). 
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Figure E: Pie chart summarising the main neurochemical populations of DRG cells. 
Nociceptors comprise medium-diameter CGRP cells (brown), small-diameter CGRP cells 
(blue) and small-diameter IB4 cells (green). An overlap between CGRP and IB4 cells is 
shown in turquoise. Non-nociceptive cells can be identified by NF200, represent 30% of DRG 
cells (red). Other characteristic immunohistochemical markers are given in coloured boxes. 
Arrows around the edge of the figure represent receptor components for neurotrophic factors 
expressed by different populations of cells; trkA for NGF-responsive; GFR1, GFR2, 
GFR3 for GDNF-responsive; trkC for neurotrophin 3 (NT3) responsive cells. Taken from 
Priestley et al., 2002.
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1.3.1 – Termination pattern and growth factor regulation of DRG cells
All three categories of nociceptive DRG cell are regulated by growth factors, and 
correspondingly express given receptor components (Figures E, Figure F).
Furthermore, detailed observations of fiber termination patterns within the dorsal 
horn have shown discrete termination patterns (Figure F), which has helped to 
further subcategories these cells. In the uninjured state, medium diameter, peptide-
expressing DRG cells, which have finely myelinated axons, respond to NGF and 
neurotrophin 3 (NT3) and innervate predominantly laminae I and III/IV. In 
comparison, small-diameter, peptide-expressing (CGRP) cells (discussed in 
Section 1.4) respond to NGF via trkA and innervate predominantly lamina I and outer 
lamina II. Unmyelinated, non-peptidergic C-fibres (discussed in Section 1.5) respond 
to GDNF via expressed GFR and predominately innervate the inner part of lamina II
(Molliver et al., 1995). The functional relevance of this termination pattern is unclear, 
but might suggest these two classes of fibres transmit different modalities of sensory 
information or target different second order neurons (see Snider and McMahon 1998; 
Braz et al 2005; Cavanaugh et al., 2009).
There is overlap of approximately 10% (shown by brown section on 
Figure E) between neurons expressing CGRP and NF200 and this likely represents 
the population of high-threshold, type-I thermoreceptors (Caterina et al., 1999); this 
subclass also express the high heat-threshold ion channel, TRPV2, and are primarily 
medium-diameter and some express receptor components for NT3 e.g., trkC (Tamura 
et al., 2005), in addition or instead of receptor components for NGF (trkA) or GDNF 
(GFRGFRGFR). 
Specific regulation by growth factors, when considered in association with 
expression of immunohistochemical markers and/or peptides, and the specific 
termination pattern in the dorsal horn, provides compelling evidence for these distinct 
populations of nociceptors. However, these relatively exclusive categories described 
in the uninjured state, are influenced markedly by factors generated with injury and 
the marked plasticity which occurs is outlined below. 
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Figure F: Schematic diagram showing three main populations of nociceptors and illustrating 
their differential expression of receptors for, and regulation by, neurotrophic factors: (1) small 
diameter IB4 cells (green) are polymodal nociceptors (express TRPV1) and respond to GDNF 
via GFR, and predominantly innervate lamina II (inner) in a region sandwiched between the 
terminal zone of peptidergic C-fibres and a zone of PKC interneurons; (2) small-diameter, 
peptide-expressing (CGRP, substance P) cells (blue) are polymodal nociceptors (express 
TRPV1) respond to NGF via trkA and innervate predominantly lamina I and lamina II (outer)
and their targets include NK1-expressing projection neurons; and (3) medium diameter 
peptide-expressing (CGRP) cells (red) are high-threshold mechanoreceptors and express 
TRPV2, have finely myelinated axons, and respond to NGF (via trkA) and neurotrophin 3 
(NT3) (via trkC) and innervate predominantly laminae I and III/IV. Brain-derived 
neurotrophic factor (BDNF) can be expressed by cells that respond to NGF (myelinated (red) 
and unmyelinated (blue) peptide-containing cells) (Adapted from McMahon and Priestley 
2005; Priestley, 2008).
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1.3.2 – Plasticity within DRG categories 
The phenotypic characteristic of DRG cells is influenced by the induction of tissue-
or nerve- damage (among others Dubner and Ruda, 1992). This ‘plasticity’1 generates 
marked heterogeneity within both injured and spared afferent fibres; some of the 
changes are outlined schematically above in Figure C (McMahon and Priestley, 
2005). For example, there are marked differences between the changes in 
transmitters, receptors, and ion channels seen in spared and injured afferents after 
injury. Key examples would be the loss of SP in injured afferents compared with 
spared in a partial nerve injury, or the upregulation of galanin in damaged (L5) vs. 
spared (L4) afferents following L5 SNL. Further still, there are different changes seen 
in C-fibres to that of larger-diameter fibres (McMahon and Priestley, 2005). 
Evidence suggests phenotypic plasticity is regulated by an array of target- and 
injury-derived growth factors, including neurotrophic factors, especially NGF and 
GDNF for peptidergic and non-peptidergic fibres (see Sections 1.4 and 1.5), 
respectively, and injury-related cytokines such as TNF and IL6 (discussed in more 
depth in Section 1.7). Ongoing hypersensitivity following nerve injury has been 
linked to DRG plasticity, and especially to changes in neuropeptide expression (Shi et 
al., 1999). Therefore even subtle changes in peptide expression in nociceptors 
following injury may be of importance to nociception. 
Indeed, the differential categorisation of peptidergic and non-peptidergic 
nociceptors following nerve injury is complicated by the down-regulation of peptides 
from peptidergic cells expressed in the non-injured state. These two classes of small-
diameter nociceptor are now considered in more detail. 
                                                  
1 Plasticity is not a formal definition and is often taken with different meaning by different authors. 
Plasticity herein refers to long-term changes in nociceptor phenotype with injury.
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1.4. Nociceptors: Peptidergic, small diameter DRG cells 
Small diameter peptidergic (CGRP-containing) DRG cells universally express the 
thermosensitive receptor, TRPV1 (transient receptor potential vanilloid subfamily 
member 1), and are regulated by NGF via trkA receptors (Averill et al., 1995). 
1.4.1 NGF regulation of peptidergic DRG cells
During embryonic development and early post-natal life, most DRG neurons (70-
80%) and virtually all nociceptors (<26m diameter) express the high-affinity NGF 
receptor, trkA (Molliver and Snider, 1997). However during post-natal maturation 
approximately 50% of these cells down-regulate trkA and thus lose their sensitivity to 
NGF. Retention or down-regulation of trkA likely distinguishes the peptidergic- and 
non-peptidergic subclasses (Molliver and Snider, 1997) (see above Figure E). 
Notably, these changes occur after most neurons lose their dependence on NGF for 
survival (Lewin et al., 1992), indicating a role for NGF-trkA beyond survival and 
development. 
In the adult animal, NGF acting via trkA switches from primarily a 
survival/growth factor to being a critical molecule involved in sensitisation of 
peptidergic nociceptors. NGF is thought to trigger hypersensitivity in three principal 
ways, and involves both peripheral and central (NMDA-dependent) mechanisms of 
action (Lewin et al., 1994). Firstly, NGF causes direct degranulation of mast cells 
with inflammatory injury (Leon et al., 1994), and the release of further NGF stored in 
mast cells. Secondly, via indirect sensitization of sensory neurons, such as by post-
translational modification of the ion channel, TRPV1 (Shu and Mendell 1999) via 
p38 MAPK and leading to a lowering of the activation threshold to heat stimuli (Ji et 
al., 2002); and indirect modulation of expression and/or intracellular transport of 
mediators involved in nociception. Of these, the first two mechanisms are proposed to 
be important for rapid onset pain and transient hypersensitivity while the third 
mechanism is considered to be important in ongoing hypersensitivity and in the 
regulation of late-onset mechanical hyperalgesia. In this role, NGF signalling via trkA 
can regulate a host of down-stream target molecules, including neurotransmitters, 
(e.g., SP/CGRP; Lindsay and Harmar 1989; Malcangio et al., 1997), receptors (e.g., 
TRPV1; Shu and Mendell 1999), and ion channels (e.g., NaV1.8; Kerr et al., 2001a), 
involved in driving acute and chronic hypersensitivity. For example, NGF can 
increase BDNF within peptidergic cells (Apfel et al., 1996) to the extent that almost 
90% of trkA cells contain BDNF mRNA after intrathecal NGF treatment, and 80-
90% of BDNF-expressing cells express trkA (Michael et al., 1997). BDNF is
expressed in small- and medium-sized neurons, and is released on pre-synaptic 
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stimulation (Lever et al., 2001). Upon release, BDNF acts as a central modulator, 
acting via post-synaptic trkB receptors. BDNF-trkB binding switches on intracellular 
signalling protein kinases which may lead to phosphorylation of glutamate receptors. 
This NGF-BDNF interaction has been implicated as an important mechanisms 
resulting in prolonged sensitization of C-fibres, via an increased likelihood of central 
sensitization (Michael et al., 1997; Kerr et al., 1999; Fukuoka et al., 2001). 
4.2 NGF regulation of peptidergic DRG cells following nerve injury 
The methods above via which NGF has been proposed to contribute to 
hypersensitivity have their foundations from inflammatory injury, as NGF is 
upregulated e.g., from mast cells as a result of inflammation (see McMahon 1996). 
Establishing a role for NGF contributing to nociception following nerve injury has 
proven more complex, as with nerve injury, the dramatic loss of peptides from 
peptidergic fibres e.g., SP from nerve terminals, is linked to a loss of the target-
derived NGF. Accordingly, supplementing NGF prevents the loss of SP mRNA 
(Lindsay and Harman, 1989) and protein (Fitzgerald et al., 1985; Doughty et al., 
1991; Wong and Oblinger 1991). Nevertheless, peripheral neuropathic pain has been 
correlated at the injury site with elevated NGF levels (Herzberg et al., 1997; Li et al., 
2003), and direct administration of NGF into the sciatic nerve produces hyperalgesia 
with endoneurial sprouting (Ruiz et al., 2004). The source of NGF is complicated by 
glia and non-neuronal cells, which start expressing NGF following nerve injury (see 
Section 1.6). This supply is insufficient to prevent histological changes that occur in 
damaged fibres and DRG with peripheral nerve injury (Heumann et al., 1987; 
Priestley et al., 2002) but these cells provides a source of NGF which may contribute 
to the role a of NGF in nociception following nerve injury. 
The intrinsic link of NGF-trkA pathway to hypersensitivity after both 
inflammation and nerve-injury has lead to development of inhibitors as analgesic 
agents. Indeed, anti-NGF monoclonal antibodies are in clinical development for 
osteoarthritis, bone pain, back pain and post-herpetic neuralgia (see Hefti et al., 2006) 
conditions with inflammatory (osteoarthritis, back pain) and neuropathic origins 
(bone pain, post-herpetic neuralgia). This wide application underscores the 
importance of NGF and peptidergic nociceptors in the pathophysiology of chronic 
pain. The presence of sensory peptides (CGRP/SP) in afferent terminals of 
peptidergic DRG cells historically gave these fibres a clear role in nociception. 
Research focusing on small-diameter non-peptidergic DRG has now outlined some 
unique characteristics and through these properties a role for non-peptidergic cells in 
nociception particularly following nerve injury, has been described. 
30
1.5. Nociceptors: Non-peptidergic, small diameter IB4-positive DRG 
cells
Non-peptidergic DRG cells exhibit some unique properties compared with 
peptidergic DRG cells, despite both having small diameter and lacking myelin. In 
addition to regulation by GDNF not NGF (see above Figure E, Figure F) and a 
discrete termination pattern in the dorsal horn (see above Figure F), non-peptidergic, 
IB4 cells generally (>90%) innervate dermis and epidermis, including hair follicles, 
and generally do not form perivascular endings as found with peptidergic fibres 
(Stucky and Lewin, 1999). Furthermore, IB4-cells do not innervate bone compared 
with peptidergic cells (as depicted in Figure F). 
In addition to IB4, non-peptidergic cells can be uniquely identified by 
fluoride-resistant acid phosphatase (FRAP) or Mrgprd genes (Zylka et al., 2005). 
However, it has been the research demonstrating their distinct electrophysiological 
properties, regulation by GDNF, and the expression of TRPV1 and P2X3 which has 
outlined a role in nociception. 
1.5.1. Immunohistochemical characteristics of non-peptidergic fibres: P2X3 and 
TRPV1  
Non-peptidergic DRG cells uniquely express a purinergic receptor, P2X3, giving 
them sensitivity to ATP (Bleehen and Keele, 1977). ATP is present in all cells but its 
extracellular concentration increases when cells are lysed/damaged. ATP acts via 
P2X ion channels and P2Y G-protein coupled receptors (GPCRs), with P2X3 being 
the subtype expressed on IB4 cells (Bradbury et al., 1998; Novakovic et al., 1999). 
Local sensitization to ATP may involve an interaction with TRPV1 receptors
(Tominaga et al., 2001). More specific to non-peptidergic cells, ATP may be to act on 
presynaptic terminals to facilitate glutamate transmission through the dorsal horn, or 
ATP might also be released post-synaptically and contribute towards an increase in 
second order signalling (Wirkner et al., 2007). ATP is also a co-transmitter with 
noradrenaline from sympathetic fibres, and is likely a key contributor in sympathetic-
mediated pain (see Section 1.1.4). Indeed, it is conceivable that as sympathetic nerves 
can sprout into DRG after nerve injury (Ramer and Bisby, 1997), they may provide a 
source of ATP that locally activates P2X3 receptors on IB4 cells.
IB4-positive and IB4-negative cells have different electrophysiological and 
thermosensitive properties, possibly indicating they relay separate aspects of heat 
sensitivity (Stucky and Lewin, 1999). Indeed, expression of the heat-sensitive ion 
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channel, TRPV1, is associated with nociceptive peripheral sensory neurons of both 
peptidergic and non-peptidergic subtypes. TRPV1 is now known to be also expressed, 
albeit at lower levels, in the spinal cord, brain and a wide-range of non-neuronal cells 
(Gunthorpe and Szallasi, 2008), and, in addition to heat ≥43°C, a wide variety of 
exogenous and endogenous stimuli are TRPV1 agonists, including low pH, 
anandamide, N-arachidonoyl-dopamine, and capsaicin. The majority of these agonists 
are generated with the inflammatory response and accordingly much research to 
define the role of TRPV1 receptors on sensory neurons has been conducted using 
inflammatory models. 
The proportion of IB4 cells responding to and/or expressing TRPV1 has been 
disputed (Amaya et al 2003; Amaya et al 2004; Dirajlal et al 2003; Liu et al 2004; 
Breese et al 2005). In one study using naïve whole cell recordings from isolated 
mouse DRG cells, twice the number of IB4-negative cells responded to TRPV1
agonist, capsaicin, when compared with IB4-positive cells, the recorded current being 
4-times larger from IB4-positive cells (Dirajlal et al., 2003). However, a patch clamp 
study of isolated rat DRG cells showed that more IB4 cells respond to capsaicin than 
IB4-negative cells, and also had larger currents (Liu et al., 2004). These large currents 
were sensitive to the TRPV1 antagonist, capsazepine. Species variation or variation in 
recording techniques might well account for some discrepancy. 
Amaya et al., (2003) demonstrate an increased expression of TRPV1 in small 
and medium-diameter DRG cells with inflammation. The same group later (Amaya et 
al., 2004) classified these cells as both IB4-positive and -negative, and demonstrated 
the dependence of this TRPV1 upregulation after inflammation, on both NGF (in 
peptidergic, IB4-negative cells) and GDNF (in non-peptidergic, IB4-positive cells). 
This dual regulation of TRPV1 after inflammation seems to suggest that IB4 cells 
have the potential to respond to TRPV1 stimuli and contribute to formation of 
thermal hyperalgesia following injury via TRPV1 upregulation (Amaya et al., 2004).
Separately, Breese et al., (2005) used intraplantar CFA to induce peripheral 
inflammation and recorded subsequent sensitisation of IB4-positive DRG fibres, but 
not IB4-negative fibres, to capsaicin and protons. No sensitisation of either 
population occurred in TRPV1 knockout animals. The group concluded that increased 
responsiveness of IB4 cells was due to novel TRPV1 expression in IB4 cells. The 
group also suggested that TRPV1 function was ‘maximal’ in trkA-positive (i.e., 
peptidergic) cells in the basal/acute inflammatory state. However, this lack of 
sensitisation in peptidergic cells to TRPV1 stimuli goes against the bulk of literature 
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regarding peptidergic cells and their importance in peripheral sensitisation following
inflammation e.g., by TRPV1 phosphorylation (Vellani et al., 2001), leading to, for 
example, activation of receptors at body temperature (Tominaga et al., 2001; Ji et al., 
2002).
1.5.2 – Glial cell-line derived neurotrophic factor (GDNF) and its influence on 
non-peptidergic DRG cells
Another defining characteristic of non-peptidergic nociceptors is their regulation and 
dependence on GDNF (Molliver and Snider, 1997) via expressed GDNF-receptor 
components (Bennett et al., 1998a) (see above Figure E, Figure F). GDNF is 
structurally unrelated to neurotrophins such as NGF, but is related to other members 
of the GDNF family, neurturin, persephin and artemin. All share the common 
receptor tyrosine kinase RET (Sariola and Saarma, 2003). The endogenous role of 
GDNF is complex, and GDNF can signal independently of RET (Poteryaev et al., 
1999), although this is not considered further. At least 60% of adult DRG cells 
respond to GDNF via expressed receptor components, notably including the majority 
of small diameter, non-peptidergic cells (Molliver and Snider, 1997) (see above 
Figure E, Figure F). 
GDNF signals principally via a two-component receptor complex that consists 
of a glycosyl phosphatidylinositol-anchored co-receptor (GFRα-1) or soluble GFR1, 
and the essential tyrosine kinase, RET (Durbec et al., 1996) (Figure G). A dimer of 
GDNF brings together two GFR1 molecules, from pre-assembled GFR1-c-RET 
complex (Eketjall et al., 1999). c-RET is then thought to be recruited to a lipid raft. 
Soluble GFR1 mobilises c-RET to these lipid rafts by a different mechanism 
compared with that seen for the anchored GFR1, and c-RET interacts with different 
proteins outside the lipid rafts (Saarma, 2001) (Figure G). Ret then activates several 
intracellular signalling cascades, which can regulate cell survival, differentiation, 
proliferation, migration, chemotaxis, branching morphogenesis, neurite outgrowth 
and synaptic plasticity (Sariola and Saarma, 2003). 
In lumbar DRG cells, virtually all IB4-labelled cells express RET mRNA, and 
the majority of these non-peptidergic cells (79%) also express GFR-1, GFR-2, or 
GFR-1 plus GFR-2 (Bennett et al., 1998a), whereas GFR3 is expressed by some 
peptidergic DRG, which may also expresses trkA (see above Figure E). GFR is 
the preferred receptor for GDNF (Airaksinen and Saarma, 2002) (Figure G). 
Changes in the proportion of DRG cells expressing GDNF receptor 
components have been reported after nerve injury, such as following sciatic axotomy 
(Bennett et al., 2000) or CCI (Dong et al., 2005). For example, in one study by 
Bennett et al., (2000) two weeks after sciatic axotomy the expression of GFRα-2 was 
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markedly reduced from ~32% before injury to 12% of sciatic afferents following 
injury. In contrast, the proportion of sciatic afferents that expressed GFRα-1 increased 
(from ~41% to 66% of sciatic afferents), and correspondingly virtually all large-
diameter afferents would have the ability to respond to GDNF (Bennett et al., 2000). 
Expression of GFRα-3 also increased following sciatic nerve injury (from ~43% to 
66% of sciatic afferents), and importantly this occurred predominantly in small-
diameter afferents. Infusion of GDNF at least partially prevented these changes, and 
the loss of GFR2 was completely counteracted (Bennett et al., 2000). 
The physiological role of GDNF, and accordingly an importance for non-
peptidergic fibres in nociception, is suggested by evidence that intrathecal GDNF can 
prevent and reverse (2 days after axotomy) both mechanical and thermal 
hypersensitivity following nerve injury (Boucher et al., 2000). Notably, GDNF did 
not change the nociceptive withdrawal threshold when administered to naïve animals, 
either intrathecally (12g/day) or via intraplantar administration (0.1-10g) (Boucher 
et al., 2000). In this study by Boucher et al., (2000), control experiments using NT3 
or NGF (given intrathecally) failed to prevent or reverse hypersensitivity using the 
same experimental models of neuropathic injury (sciatic nerve ligation or L5 SNL) as 
used with GDNF. Furthermore, their behavioural observations were supported by 
physiological data which showed that intrathecal GDNF prevented formation of 
ectopic discharge. As discussed above (Section 1.1.4) spontaneous activity such as 
ectopic discharge which typically manifests as an afferent barrage from myelinated 
neurons after nerve injury in animals, is a clinical characteristic of neuropathic pain in 
humans. Indeed, the rate and strength of the afferent barrage was reduced with GDNF 
(measuring from strands of L4/L5) and these cells were classified as mostly ‘low 
threshold’ mechanoreceptors (A/A fibres) (Boucher et al., 2000). In contrast to data 
whereby injection of NGF causes ipsilateral hind paw behavioural hypersensitivity, 
GDNF failed to change nociceptive behaviour in uninjured animals (Boucher et al., 
2000). However, more recent studies have demonstrated that hind paw injection of 
GDNF (0.2μg) produced ipsilateral thermal hyperalgesia (Malin et al., 2006). This 
study also indicated a role for other members of the GDNF-family (artemin, 
neurturin) in nociception. 
Although some evidence is conflicting observations demonstrating that 
GDNF may influence peripheral behavioural hypersensitivity following nerve injury, 
indirectly supporting a role for non-peptidergic fibres in transmission of nociception 
following nerve injury. 
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Figure G: Homodimeric glial cell line-derived neurotrophic factor (GDNF)-family 
ligands activate RET tyrosine kinase (TK) by first binding their cognate GDNF-
family receptor-α (GFRα) receptors. Arrows indicate the preferred ligand–receptor 
interactions. GFR proteins are attached to the plasma membrane by a glycosyl 
phosphatidylinositol (GPI) anchor and are predicted to have three globular cysteine-
rich domains (1,2,3) (except for GFRα4, which has only two), joined together by less 
conserved adaptor sequences. The GDNF family of ligands bind mainly to the second 
domain of GFR receptors, which is also crucial for RET binding. Although the 
extracellular domain of RET interacts with all four GFRα complexes, the regions of 
RET that are involved in these interactions have not been delineated. Binding of Ca2+ 
ions to one of the four extracellular cadherin-like domains of RET is required for its 
activation by this family of ligands. ARTN, artemin; NRTN, neurturin; PSPN, 
persephin. Taken from Airaksinen and Saarma, 2002. 
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1.5.3. –IB4 cells contribute to nociception following nerve injury 
After nerve injury, non-peptidergic DRG rapidly down regulate the IB4-marker 
(Bennett et al., 1998a; see Priestley et al., 2002). This is likely due to loss of alpha-D-
galactose residues with injury, to which IB4 binds, as using an alternative marker 
(P2X3) consistent expression has been reported (Averill et al., 2002). The conclusion 
that non-peptidergic cells do not die with nerve injury is further supported by 
evidence that IB4-binding returns in a similar proportion of DRG cells, 20-weeks 
after spinal nerve ligation (Hammond et al., 2004). However, evidence has also been 
presented for a significant decrease in the density of IB4-labeled boutons, ipsilateral 
to the lesion following CCI (Bailey et al., 2006). In particular, morphological changes 
in the nociceptive C-fiber input of the rat dorsal horn were restricted to the non-
peptidergic sub-population of DRG cells, and no changes were reported in the 
peptidergic population (Bailey et al., 2006). Although this could suggest a limited 
role for IB4 cells following nerve injury, these changes did not correlate with the 
time-course of the allodynia. Indeed, more recent evidence demonstrates a distinct 
role for IB4-cells in specific modalities of nociception, discussed below (Cavanaugh 
et al., 2009; Liu et al., 2007). 
Other evidence for a role of IB4 cells in nociception includes experiments 
targeting the P2X3 receptor. For example, using antisense oligonucleotides to down-
regulate P2X3 receptors following partial nerve injury (Seltzer model), the time 
course of the reversal of hyperalgesia is consistent with down-regulation of P2X3 
receptor protein and function (Barclay et al., 2002). 
Supporting a distinct role for IB4-cells in specific modalities of nociception, 
genetic ablation of Mrgprd-expressing sensory neurons (i.e., non-peptidergic cells) 
reduces behavioural sensitivity to noxious mechanical stimuli, but not to heat or cold 
stimuli (Cavanaugh et al., 2009). Conversely, the same group showed that 
pharmacological ablation of the central branches of TRPV1+ nociceptors (see above 
Figure E, both small diameter peptidergic and non-peptidergic DRG cells),
selectively ablates sensations to noxious heat. Combined elimination of both 
populations resulted in an ‘additive phenotype’ but without additional behavioural
deficits. This ‘double-dissociation’ was concluded to rule out a redundant 
contribution of these populations to heat and mechanical pain sensitivity, but to 
suggest that the brain can distinguish different noxious stimulus modalities from the 
earliest stages of sensory processing (Cavanaugh et al., 2009). 
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Other evidence supporting a key function for non-peptidergic fibres in 
nociception after injury, involves selectively destroying IB4-binding cells with 
saporin-conjugated IB4 (Vulchanova et al., 2001; Tarpley et al., 2004). However, 
these studies might need to be interpreted cautiously. Vulchanova et al., (2001) used 
intrasciatic injection of conjugated IB4-saporin, to cause permanent and selective loss 
of IB4-binding neurons in DRG, spinal cord, and skin from treated animals. 
Furthermore, hind paw withdrawal threshold to mechanical and thermal stimuli were 
elevated 7-10 days after injection of IB4-saporin conjugate. However, 21 days post-
treatment, nociceptive thresholds returned to baseline levels (Vulchanova et al., 
2001). The same group later (Tarpley et al., 2004) used intrasciatic IB4-saporin 
conjugate (or IB4, saporin, IB4 + saporin, or saline as control) to further define the 
contribution of IB4 cells after nerve injury. These investigations outline that the 
saporin toxin is targeted to selectively destroy IB4 neurons, as the conjugate binds, is 
internalised, and transported to the DRG, where it kills the cells by interfering with 
protein synthesis. Although this method should specifically target IB4-expressing 
cells, and therefore peptidergic cells should remain unaltered, CGRP staining was 
reduced by one-third, suggesting widespread loss of peptidergic C-fibres (Tarpley et 
al., 2004). Further still, if the saporin conjugate created a ‘damaged’ environment, 
sensory signalling may be altered as a result of the damaged environment. 
Vulchanova et al., (2001) discuss a potential effect of the massive 
demyelination caused by injection of the saporin conjugate, which is mentioned to 
cause muscle atrophy without affecting withdrawal responses (though ‘curling’ of the 
foot was reported). Conduction velocity will be lower in demyelinated fibres, 
including thinly myelinated nociceptors. However, as recovery of hind paw 
withdrawal threshold was not accompanied by recovery of myelin basic protein 
immunoreactivity, the authors conclude that demyelination was not a factor in the 
reduction in pain behaviour (Vulchanova et al., 2001). Nevertheless, the environment 
produced with injection of the saporin toxin may also alter the ability of invading 
immune cells to enter, or become activated. Similarly, any changes the toxin-induced 
environment and subsequent demyelination causes in the spinal cord, such as 
sprouting and central sensitisation, will affect behaviour hyperalgesia/allodynia. 
These are all factors involved in nerve injury and neuropathic pain, and there is 
potential for results derived from these studies to be misleading. Thus, these data 
should be considered in the light of their limitations.
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One needs to additionally consider that IB4-saporin conjugate may be taken 
up by other cells that express IB4 surface marker, such as microglia and other non-
neuronal cells. Thus, other IB4-expressing cells may be also damaged or killed by the 
saporin conjugate. Indeed microglia may contribute themselves to nociception (as 
discussed next in Section 1.6), and therefore any loss of nociception could be due to 
their absence in this model rather than absence of IB4 cells. 
The potential role of non-neuronal/microglia cells, now thought a critical 
factor in the generation of sensory hypersensitivity after nerve injury (Section 1.6.), 
was not discussed by Tarpley et al., (2004), but they do acknowledge that a non-
specific toxicity of saporin cannot be ruled out as influencing the behavioural results 
obtained.
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1.6. Non-neuronal cells and nociception
Glial cells were historically viewed as housekeeping cells, which maintain the 
neuronal environment whilst offering nourishment and support to nerve fibres. This 
view has more recently been expanded. In 1991, Garrison et al., demonstrated that the 
decrease in mean foot withdrawal latency to radiant heat associated with peripheral 
nerve damage was associated with ‘activation’ of glia; ‘activation’ describing a 
change in cell-surface phenotype and morphology when viewed under a microscope. 
Activated glia were later shown to extensively infiltrate the injured DRG cells after 
peripheral nerve injury (Lu and Richardson, 1993) and their role in injury was 
suggested to be more important than clearing axonal debris during Wallerian 
degeneration. 
There are distinct populations of glia with different embryonic origins and 
responses, and discussion of all in detail is outside the scope of this project. Immune 
cells, specifically macrophages, and their influence on sensory transmission after 
injury will also be outlined. In the acute response, immune cells are thought to remain 
as ‘silent bystanders’ (see Marchand et al., 2005) and only when an injury is 
persistent do non-neuronal cells contribute to the injury response. 
1.6.1 – Immune cells 
Peripheral nerves have an immune privilege owing to the restricted access of cells and 
molecules originating from the immune system. This protection from immune damage 
is particularly important for preservation of the central nervous system (CNS), as 
mature brain cells are terminally differentiated and not replaced after death (Wong 
and Sternberg 2000). The ‘privilege’ is maintained by a blood-brain and blood-nerve 
barrier. Nerve injury dissolves this barrier, leaving the nerve sheath susceptible to 
invasion by blood-borne immune cells. 
Mast cell are immediately degranulated on tissue integrity being breached, 
resulting in release of various inflammatory mediators (e.g., NGF, nitric oxide, PGE2, 
IL1, TNF, bradykinin, histamine, etc.), which act to directly simulate or sensitise 
polymodal C-fibre terminals. The importance of mast cell degranulation initiating the 
injury cascade can be demonstrated through stabilisation of mast cells (using for 
example, sodium chromoglycate), which results in decreased recruitment of 
neutrophils and monocytes (macrophages) to the injury site (Zuo et al., 2003). 
Neutrophils are the first immune cell-type to infiltrate inflamed tissue from the blood, 
and subsequently produce/release cytokines, chemokines and also opioid peptides 
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(see Hunt and Mantyh, 2001). Neutrophil concentration peaks at 24 hours after the 
initial trauma, and evidence suggests NGF-produced hyperalgesia is dependent on 
neutrophil infiltration (Bennett et al., 1998b). To demonstrate their importance, 
depleting tissue neutrophils at the time of tissue injury decreases pain but cannot 
reverse established symptoms (Perkins and Tracey, 2000), supporting a primary role 
in acute rather than chronic pain. 
Following neutrophil infiltration, monocytes are recruited by chemotaxis from 
the blood, and on entering damaged tissues become macrophages.
1.6.2. - Macrophages
With activation, blood-borne monocytes/macrophages quickly invade the damaged 
area and, in addition to a small population of resident macrophages, express surface 
markers following injury (Coyle, 1998). Activated macrophages (resident or 
recruited) release inflammatory mediators similar to other immune cells into the 
injury environment for example including nitric oxide, NGF, prostanoids and 
cytokines. One critical role for macrophages is in phagocytosis of necrotic cell debris 
following injury. However, data also suggest that circulating monocytes are important 
for generating and maintaining hyperalgesia, especially following nerve injury (Liu et 
al., 2000) as mentioned above, when the blood-nerve barrier is broken down. 
Indeed, evidence discussed below supports a temporal correlation between 
invasion of blood-borne macrophages and development of mechanical and thermal 
hyperalgesia following nerve injury. 
1.6.3 Macrophages and nociception following nerve injury
Following nerve injury, macrophages are the principal inflammatory cells that invade 
from the blood into the injury environment. Surface antigens, such as ED1, OX6 or 
OX42, can be used to detect macrophages in their activated state. Animal models 
have been developed that remove and/or inactivate macrophages and these have 
underscored an importance for macrophages in neuropathic hyperalgesia, although 
some data are contradictory. For example, depleting macrophages with liposome-
encapsulated clodronate, decreased macrophage infiltration into the injured nerve and 
alleviated thermal hyperalgesia (Liu et al., 2000). Rutkowski et al., (2000) failed to 
duplicate this decrease in pain hypersensitivity (using Kim and Chung (1992) model 
of mononeuropathy) with both systemic and perineural administration of liposome-
encapsulated clodronate and CNI-1493 (which inhibits L-arginine transport in 
macrophages, preventing activation). Rutkowski et al., (2000) also supplied activated 
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and non-activated macrophages exogenously, injecting 250l (1M concentration) 
over the exposed nerve (perineurally). The authors conclude that peripheral 
macrophages and axonal transport play a ‘limited’ role in formation of neuropathic 
pain following injury (Rutkowski et al., 2000). 
Marchand et al., (2005) discuss this lack of effect reported by Rutkowski et 
al., (2002) and conclude that it was due to the supply of macrophages exogenously, 
resulting in the cells not being physiologically recruited and programmed sufficiently 
to perform a specific role in pain processing (macrophages were activated in vitro
with interferon-. 
The role of cytokines, in particular neuropoietic cytokines in regulation of 
different classes of nociceptor following nerve injury is a key component of this 
thesis. Accordingly, evidence discussing a source of these cytokines is relevant, 
particularly when correlated with nociception following nerve injury. 
Ma and Quirion (2005) investigated peripheral activation of macrophages in 
vitro (both in normal and injured DRG) and in vivo after nerve injury, and especially 
the relationship between macrophage activation (shown using surface marker ED1) 
and IL6- and/or prostaglandin E2 (PGE2) expression. Prostanoid, and especially 
PGE2, are pivotal inflammatory components and inhibiting their production with 
NSAIDs has been the foundation for acute pain management for decades. Prostanoids 
also facilitate release of neuropeptides from nerve terminals (Martin et al., 1987), 
such as SP and CGRP and the prostanoid receptor, EP1, has been shown to increase 
in sensory neurons after injury. Noteworthy here, macrophage infiltration preceded an 
increased COX-2 expression by macrophages (Durrenberger et al., 2006). 
Specifically, Ma and Quirion (2005) demonstrated in vivo using a model of 
partial sciatic nerve injury that IL6 is co-expressed by macrophages, and IL6-
immunoreactivity co-expressed with ED1 and with PGE2 (Figure H). Further, using 
in vitro cultures from the injured nerve, ED1, COX2, and IL6 immunoreactivity were
co-expressed. The authors also showed evidence that both IL6 and PGE2 expression 
was inhibited by indomethacin, suggesting a COX-dependent mechanism 
(indomethacin being a non-specific COX inhibitor). Also, inhibiting PGE2 (with 
indomethacin) or activity (via prostanoid receptor antagonists), or blocking other key 
transduction pathways (such as PKC, and/or PKA) did not prevent IL6 production 
(Ma and Quirion, 2005), suggesting independence of this inflammatory response. 
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Further evidence for a role of cytokines produced by macrophages in 
nociception following nerve injury has been presented by Cui et al., (2000). Cui and 
colleagues used three models of partial nerve injury and L5 transection, to show a 
“clear correlation” between the increase of ED1-positive cells (macrophages), of IL6 
and of TNF and the degree of allodynia at 14 days after injury. The extent of 
peripheral nerve degeneration was not consistent with degree of ED1 (macrophage) 
infiltration and the consequent allodynia following partial nerve injury; accordingly, 
following partial nerve injury, animals showed more allodynia, with high infiltration 
of macrophages, but less nerve degeneration. The paper concluded that macrophages 
do not correlate directly with the degree of nerve degeneration following injury but 
do correlate with the degree of allodynia shown (Cui et al., 2000). Interpreting these 
data suggests the potential to modulate macrophage-generated allodynia after nerve 
injury without affecting the regeneration capacity of the nerve.
When considered together, these papers allude to an interesting role for IL6 
and macrophages, involving the inflammatory mediator, PGE2 (Cui et al., 2000; Ma 
and Quirion, 2005), whereby IL6 and PGE2 are increased after nerve injury in ED1-
positive cells. IL6 is a member of the neuropoietic family of cytokines, a family 
involved early in the injury response following both inflammation and nerve injury. 
Accordingly, literature regarding these cytokines and their effects on DRG cells will 
now be reviewed in Section 1.7. 
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Figure H: Colour confocal photographs showing the co-localisation of IL-6 with ED1 (a–c) IL6 with 
COX2 (d–f) in infiltrating macrophages in injured nerve of partial sciatic nerve ligation (1 week). In 
injured nerve, IL-6 (a, green) and macrophage marker ED1 (b, red) were co-expressed in the same cells 
(c, yellow). Similarly, in injured nerve, IL-6 (d, green) and COX2 (e, red) were coexpressed in the same 
cells (f, yellow). Scale bar = 20m. Taken from Ma and Quirion, 2005.  
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1.7. Cytokines 
Cytokines are small regulatory signalling molecules produced and released by various 
cells, including inflammatory cells, neurons and some non-neuronal cells. They have 
specific actions on cell growth, cell-cell communication, and examples include 
growth factors (e.g., TGF), interleukins (e.g., IL6, IL1) and chemokines (e.g., CCL2, 
MCP-1, and RANTES). Cytokines are produced on demand, act over small distances 
with very high efficacy and are present in vivo at pg.mL-1 to ng.mL-1 concentrations 
(see Sommer and Kress, 2004). Synergism occurs between different cytokines and 
most families operate with significant redundancy. As such, it is often difficult to 
investigate the influence of a single member of one family of cytokines, without 
accounting for other members of the cytokine family. The development of specific 
inhibitors has naturally aided investigations. 
Many cytokine families exist and discussion of these in depth is outside the 
focus of the present thesis. Instead, key examples relating to neuropathic pain are 
discussed. As cytokines often initiate cascades, some specific cytokines are especially 
important being at the top of an amplification cascade. For example, TNF and IL1
are often produced early in the injury response from a variety of cells including mast 
cells or macrophages, and inhibiting TNF or IL1 prevents formation of other 
inflammatory mediators.
Another family of cytokines involved early in the injury response are the 
neuropoietic cytokines, which includes IL6 and LIF, and additionally cardiotrophin-1 
(CT1), IL11, oncostatin-M (OSM) and ciliary neurotrophic factor (CNTF). Of note, 
receptor components for these cytokines are thought to be expressed by small 
diameter nociceptors (Qui et al., 1997; discussed by Priestley 2008), in particular by
non-peptidergic DRG cells that are also regulated by GDNF (see above Figure E, 
Figure F). 
1.7.1 – Neuropoietic cytokines and their receptor components
Neuropoietic cytokines collectively signal via the gp130-pathway and co-receptors, 
such as LIFR and IL6R/soluble IL6R (sIL6R2) (see Taga and Kishimoto, 1997, and 
references therein) (Figure I). Within the cytokine family there is considerable 
pluripotency and redundancy. The membrane-spanning subunit, gp130 is ubiquitously 
expressed (Gardiner et al., 2002) and comprises an extracellular region with 6-
                                                  
2 Also termed gp80
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fibronectin domains (Figure I). The gp130 unit itself has no inherent tyrosine kinase 
activity or cytokine binding capacity, and cellular responsiveness to the neuropoietic
cytokines is determined by association with specific co-receptors. Specifically, IL6, 
IL11 and CNTF first bind to soluble or membrane-bound receptor subunits,
required to form the high-affinity receptor complexes. However, IL6 and IL11 trigger 
homodimerisation of two gp130 molecules in association with the α-receptor subunit, 
whereas CNTF-CNTFα-R forms a heterodimeric complex of gp130 plus the LIF co-
receptor, LIFR (also termed gp90). LIF binds to heterodimers involving the LIF co-
receptor, LIFR, and gp130. In addition, OSM forms a heterodimeric complex of 
gp130 plus OSMR, whereas CT1 uses gp130-LIFβR heterodimeric complex, 
although CT1 might involve an additional co-receptor component currently undefined 
(see Bauer et al., 2007; Gearing et al., 1991; Gearing et al., 1992) (Figure IA). 
Dimerisation results in activation of JAK-STAT pathway and MAPK, and tyrosine 
phosphorylation of STAT3 (at tyr705) (Schweizer et al., 2002). Tyrosine-
phosphorylated STAT3 (p-STAT3) is translocated to the nucleus where it is serine 
phosphorylated (ser727). In the nucleus, p-STAT3 activates a number of transcription 
factors, including c-mym, c-myb, junB, IRF1, erg-1, bcl-1; shown schematically in 
Figure IB (Taga and Kishimoto, 1997). 
Relatively few studies have examined the particular DRG cell types affected 
by the neuropoietic cytokines, or the expression of their co-receptors by DRG 
neurons. As discussed below, strong candidates are small diameter non-peptidergic
cells (Priestley 2008). The gp130 signalling component is expressed by all DRG 
neurons (Mizuno et al., 1997; Gardiner et al., 2002). gp130 mRNA is low in intact 
nerves but rapidly increase 2-21 days following nerve transection (Ito et al., 1998), 
although gp130 levels at the DRG are reportedly unaffected by axotomy (Gardiner et 
al., 2002). The temporal expression pattern of LIF and IL6 and their respective 
receptor components have been shown to be distinct in the naïve animal, and 
particularly after nerve injury (see below, Figure J) suggesting that each cytokine 
plays a unique role following nerve injury. 
45
Figure I: Neuropoietic cytokine receptor complexes. (A) Various combinations of receptor 
subunits and signalling pathways are used by different members of the neuropoietic cytokine 
family. gp130 homodimers associate with specific interleukin (IL) receptors such as the IL6
receptor (IL-6R) to mediate the actions of IL6. Leukaemia inhibitory factor (LIF) binds to 
heterodimers of LIF receptor (LIFR) and gp130. LIFR–gp130 heterodimers can also associate 
with other receptor subunits to bind ciliary neurotrophic factor (CNTF) and cardiotrophin 1 
(CT-1). The oncostatin M receptor (OSMR) forms heterodimers with gp130 to bind 
oncostatin M (OSM). The signal-transducing subunit gp130 is found in all complexes, and is 
responsible for the intracellular activation of the Janus-activated kinase–signal transducer and 
activator of transcription (JAK–STAT) and the mitogen-activated protein kinase (MAPK) 
pathways. Figure from Bauer et al., (2007). (B) Cytoplasmic protein tyrosine kinases in the 
JAK family (JAK1, JAK2, TYK2) are associated with the membrane-portion of the gp130 
complex. Tyrosine residues in the gp130 region are phosphorylated and STAT3 is recruited. 
Other transcription factors, such as NF-IL6, are activated after gp130-stimulation through 
MAPK. Blank ovals represent an unidentified serine-threonine kinase pathway. White thick 
bars in the cytoplasmic region of the gp130 represent conserved motifs. P-T tyrosine 
phosphorylation; P-S, serine phosphorylation; (P), phosphorylation; Taken from Taga and 
Kishimoto, 1997.
A
B
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1.7.2 – LIF and LIFR are upregulated after nerve injury 
Both intact and injured sensory neurons express receptor components for LIF, 
including LIFR and gp130 (Mizuno et al., 1997; Qiu et al., 1997; Scott et al., 2000). 
In the adult nervous system LIF is normally undetectable (Yamamori, 1991) but is 
induced at the site of peripheral nerve axotomy (Banner and Patterson, 1994). Indeed, 
LIF mRNA has been shown to increase 10-fold rapidly following nerve transection, 
before gradually returning to normal 4-week post-injury (Ito et al., 1998) (Figure J). 
LIF is retrogradely transported and accumulates within the DRG in small diameter, 
nociceptive-specific neurons (Thompson et al., 1997). In this study, the majority of 
LIF-accumulating neurons (81%) were demonstrated to be immunopositive for CGRP 
(peptidergic), whereas 34% were immunopositive for IB4 and 62% were 
immunopositive for trkA (Thompson et al., 1997). 
LIFR mRNA is high in intact nerves and mRNA decreases slightly 
following nerve injury (Banner and Patterson, 1994; Ito et al., 1998) (Figure J). 
However, mRNA levels have been shown to return to normal within 14 days (Ito et 
al., 1998). More recent evidence demonstrated that the intracellular location of LIFR
alters following nerve injury (Gardiner et al., 2002). Specifically, LIFR was
expressed in vesicle-like structures in the cytoplasm of a subset of nociceptive 
sensory neurons following nerve injury. Furthermore, LIFR was co-expressed in this 
intracellular compartment with gp130, suggesting a potential responsiveness of 
injured sensory neurons to LIF and to other members of the neuropoietic family of 
cytokines (Gardiner et al., 2002).
Following injury to the mature nervous system LIF acts as an important 
phenotypic specifying factor (see Zigmond et al., 1996). Indeed, an increase in LIF 
mRNA expression in the adult DRG has been shown as consistent in time course and 
magnitude with the changes in neuropeptide expression found in the ganglia after 
injury (Banner and Patterson 1994). More specifically, LIF can promote upregulation 
of proteins at the DRG when applied in vitro, including VIP, SP, substance K and 
galanin (Corness et al., 1998; Rao et al., 1993; Zigmond et al., 1996; Sun and 
Zigmond, 1996), and in vivo including galanin (Thompson et al., 1998). However, 
changes in the levels of cytokines including LIF are thought to be insufficient to 
account for the complete repertoire of neuropeptide phenotypic changes associated 
with peripheral nerve injury (Thompson et al., 1998). This observation suggests other 
factors are involved. 
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The dramatic rise in LIF mRNA after nerve injury (Ito et al., 1998) suggests 
LIF is involved in the response to nerve damage immediately following injury. 
Indeed, LIF has been shown to act as an injury-induced conditioning factor, capable 
of mediating the elongation phase of sensory neuron regeneration in vitro (Cafferty et 
al., 2001). Therefore, LIF is thought to be essential for normal regeneration of injured 
sensory neurons in vivo, a function that may overlap with the proposed role in 
wounding or infection in several nonneural tissues (discussed by Ebadi et al., 1997). 
Through direct comparison between members of the neuropoietic family, specific 
roles and consequences of these cytokines following nerve injury can be 
demonstrated, and IL6 is now discussed.
1.7.3 – IL6 and IL6R are upregulated after nerve injury
LIF and IL6 have a broad range of actions that in many cases parallel one another, 
although LIF and IL6 have been suggested to be structurally unrelated (Gearing, 
1989). Nerve injury evokes increased levels of IL6 mRNA and protein in injured 
nerves (Figure J) (Bourde et al., 1996; Cui et al., 2000; Grothe et al., 2000; Ito et al., 
1998; Reichert et al., 1996; Zhong and Heumann, 1995), in lumbar DRG (Murphy et 
al., 1995; Saab et al., 2009) and in Schwann cells at the site of injury (Bolin et al., 
1995; Grothe et al., 2000). IL6 mRNA and IL6R mRNA are also found in vascular 
endothelial cells and Schwann cells of the intact sciatic nerve at very low levels (Ito 
et al., 1998). Of the non-neuronal cells that reside in intact and injured nerves, 
macrophages and fibroblasts have been shown to be the major contributors to IL6 
production (Reichert et al., 1996). Furthermore, IL6 mRNA/protein and its receptor 
transduction components, IL6αR, are expressed by activated central microglia (Van 
Wagoner and Benveniste, 1999). As outlined above, IL6 signals via specific binding 
to cell surface receptor, gp130, but for signal transduction to occur, IL6-IL6R 
complex associates with two gp130 molecules (Hirano et al., 1994; Mullberg et al., 
1999). Thus, IL6 is completely dependent on the presence of both receptor 
components for physiological activity. 
Upregulation of IL6 following nerve injury is transient, peaking at 2-days 
follow sciatic nerve injury (Ito et al., 1998). At the DRG, IL6 mRNA is upregulated 
after different types of nerve injury, including axotomy (Murphy et al., 1995), CCI 
(Murphy et al., 1999b), spinal nerve cryoneurolysis or spinal nerve tight ligation 
(Arruda et al., 1998), nerve crush and spinal nerve root transection (Murphy et al., 
1999a). With axotomy, IL6 mRNA is localised within large and medium-sized 
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axotomised neurons (Murphy et al., 1995). This contrasts LIF accumulating within 
the DRG in small diameter, nociceptive-specific neurons (Thompson et al., 1997). 
Mirroring the expression profile of IL6, the IL6R increases rapidly following sciatic 
nerve injury to 8-fold of control levels (Figure J) in distal portion of the sciatic nerve.
Interestingly, IL6 has been shown to promote upregulation of gp130 mRNA 
(Geisterfer and Gauldie 1996), highlighting one potentially important interplay 
between signalling components within this family.
Figure J. Temporal expression characteristics of (A) LIF, (B) IL6, (C) LIFR and 
(D) IL6R, in the distal portions of the sciatic nerve after transection. The results are 
expressed as a ratio to cyclophilin as the internal steady-state control. Each time point 
represents the mean determination from four to six samples, and one sample contains 
eight to nine mouse sciatic nerves, each assayed at least twice, ±S.E.M. Adapted from 
Ito et al., (1998). 
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1.7.4. IL6 has a role in nociception following nerve injury 
Demonstrating a role for IL6 in nociception, direct administration of IL6 alters the 
peripheral response to thermal or mechanical stimuli in animals. For example, 
intraplantar injection of 1ng IL6 resulted in rapid peripheral thermal hyperalgesia and 
tactile allodynia (Ferreira et al., 1997), which can be inhibited by the anti-
inflammatory agent, dexamethasone. Furthermore, exogenous administration of IL6 
(200ng in combination with sIL6-R) has been shown to directly sensitise nociceptors 
in the skin to heat (Obreja et al., 2002).
Linking this sensitisation with IL6 to hypersensitivity following nerve injury, 
Cui et al., (2000) found a correlation between post-operative allodynia and the 
number of IL6-positive cells in the sciatic nerve, measured 14-days after injury. Sham 
rats had the smallest number of IL6-upregulated cells, as might be expected if a 
correlation between IL6 and injury exists. The authors correlated the inflammatory 
response with tactile hypersensitivity after different models of peripheral nerve 
injury, and closely linked inflammatory cytokines, including IL6 and TNF, and also 
monocytes/macrophages to allodynia (Cui et al., 2000). 
Data have conversely been presented for an anti-nociceptive role for IL6. 
Flatters et al., (2004) demonstrated that intraplantar administration of IL6 (0.01-1 g) 
elicited ipsilateral behavioural thermal hypoalgesia in hind paw of naïve rats. These 
higher concentrations of IL6 (0.01-1µg) used by Flatters et al., (2004) incorporated 
the concentration used by Obreja et al., (2002) (IL6 200 nM), who contrary showed 
that in combination with the soluble receptor (IL6R), IL6 evoked peripheral 
sensitisation to heat in naïve animals (Obreja et al., 2002). As discussed above, the 
specificity of IL6 is dependent on the presence of the soluble receptor subunit, and 
low expression of the IL6R may account towards the discrepancy in results using 
naïve animals. Flatters et al., (2004) also described how peripheral administration of 
IL6 was anti-nociceptive in different experimental settings; producing a significant 
inhibition of heat responses of nociceptors in vitro, spinal neuronal responses in vivo, 
in addition to anti-nociceptive in hind paw of naïve rats (Flatters et al., 2004). 
Specifically, peripheral administration of IL6 (40-100ng) markedly inhibited all 
naturally evoked neuronal responses in naïve rats, yet only neuronal responses to heat 
in neuropathic rats, and not mechanical neuronal responses. Notably, the inhibitory 
effects of IL6 seen using electrophysiology were completely in accordance with the 
behavioural effects of IL6 (Flatters et al., 2004). These data suggest that IL6 inhibits 
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normal peripheral nociceptive transmission, yet such anti-nociceptive effects are 
attenuated following nerve injury in a modality-specific manner. 
The contradicting evidence for the role of IL6 in nociception has been 
investigated further through neutralising IL6 with specific antibodies, or through gene 
manipulation studies. For example, Arruda et al., (2000) investigated a role of spinal 
IL6, and demonstrated that inhibiting IL6 with intrathecal IL6 IgG can decrease 
mechanical allodynia associated with peripheral nerve injury (Arruda et al., 2000), 
taken to suggest that IL6 might be pro-nociceptive in this context. However, a 
differential effect was noted between high and low concentrations of IL6 IgG. 
Specifically, 0.01-0.001µg of goat or rat IL6 IgG significantly attenuated mechanical 
allodynia, but higher doses of IL6 IgG (0.08-0.008 µg) did not (Arruda et al., 2000). 
Evidence from genetic studies have likewise been contradictory for a role of 
IL6 being anti- or pro-nociceptive. Xu et al., (1997) used IL6 knockout animals and 
reported increased autonomy in female IL6 knockout animals compared with wild-
type controls. Conversely, Murphy et al., (1999a) used IL6 knockout animals and 
reported no significant difference with respect to mechanical withdrawal threshold
when compared with wild-type controls. Furthermore, the IL6 knockout animals did 
not develop thermal or mechanical hyperalgesia within 14 days of CCI (Murphy et 
al., 1999a). Knockout animals have shown deficient microglia activation (Klein et al., 
1997), and therefore the interpretation of data from genetic animals should be 
interpreted in light of this observation.
1.7.5. Consequences of IL6 upregulation following nerve injury 
After nerve injury, IL6 upregulation has been linked to phenotypic changes in 
primary nociceptors and sprouting of postganglion fibres (Ramer et al., 1998; Ramer 
et al., 1999). Exogenous IL6 can increase galanin mRNA in small and medium sized 
DRG neurons and endogenous IL6 may contribute to the increase in galanin 
immunoreactivity in the dorsal horn and dorsal column nuclei after nerve injury 
(Murphy et al., 1999b). Conversely, induction of galanin mRNA was not shown to 
significantly increase using IL6 knockout (null mutation) animals following CCI 
compared with wild-type animals (Murphy et al., 1999b). This may suggest that IL6 
is not the only factor that can regulate galanin expression following nerve injury, 
although the limitations to using knockout animals should also be accounted for. 
Indeed, LIF may compensate for the loss of IL6 to induce galanin expression, as 
outlined above, LIF can upregulate galanin in vitro and in vivo (Sun et al., 1996; 
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Thompson et al., 1998). Furthermore, the loss of target-derived NGF that occurs after 
nerve injury also likely contributes to the upregulation of galanin with injury 
(Shadiack et al., 2001). Nevertheless, full induction of galanin in the central 
projections of DRG neurons has been reported to be dependent on the presence of 
endogenous IL6 (Murphy et al., 1999b). The small diameter cells which express 
galanin in the presence of IL6 have not been fully defined, however receptor 
components for gp130 cytokines are thought to be expressed by some non-peptidergic
DRG cells (see Priestley 2008). 
In addition to a putative role in nociception, IL6 has been shown to have other 
important functions as a regulator of neuronal survival and differentiation in the 
central and peripheral nervous system following injury (Gadient and Otten, 1996). 
For example, IL6 can promote survival of embryonic sensory neurons (Thier et al., 
1999) and sympathetic neurons can produce and respond to IL6 in the presence of the 
sufficient amounts of the IL6αR (März et al., 1998). IL6 also induces neurite 
extension and neuronal differentiation and, in combination with its receptor, IL6 
increases neuronal survival (Satoh et al., 1988). Accordingly, axonal regeneration is 
attenuated in IL6 knockout animals (Zhong and Heumann, 1995), and anti-IL6R 
retards the regeneration of axotomised nerves (Hirota et al, 1996). These studies 
indicate a positive effect of IL6 on regeneration following nerve injury and these 
additional functions produce variables that should be taken into account when 
considering the consequences of IL6 in nociception following nerve injury.  
Other evidence for a key role of IL6 in regeneration following nerve injury 
has been demonstrated using genetic studies. For example, preconditioning injury of 
the sciatic nerve in IL6 knockout mice resulted in the total failure in regeneration of 
dorsal column axons and a lack of GAP43 upregulation (Cafferty et al., 2004). 
GAP43 is expressed by developing and regenerating neurons, and to a lesser extent, 
by reactive glial cells. In wild type mice, a conditioning injury to the sciatic nerve 
before bilateral dorsal column crush resulted in regeneration of dorsal column axons 
up to, and beyond the injury site (Cafferty et al., 2004). As mentioned above 
(Section 1.1.4), IL6 and LIF are two mediators that have been linked to the formation 
of sympathetic baskets following nerve injury (Ramer et al., 1998, 1999), a 
pathological mechanism linked to neuropathic pain and in particular, sympathetic-
mediated pain. Furthermore, IL6 can induce peptide expression in sympathetic 
neurons (März et al., 1998) in addition to sensory neurons. These additional 
characteristics of the IL6 response may influence nociceptive thermal and mechanical 
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allodynia/hyperalgesia following nerve injury. Indeed, these additional characteristics
of IL6 following nerve injury may account for some of the discrepancy in behavioural 
responses of hypersensitivity, particularly as IL6 may have different effects 
depending on the time-course of an injury, as regeneration progresses.  
Interestingly, with evidence emerging for a role of IL6 in memory formation 
in the hippocampus (Balschun et al., 2004), a mechanism similar to that underlying 
central sensitization involving NMDA receptors (Li et al., 1999; Woolf, 1996), there 
exists a potential link for IL6 underlying central sensitization in the spinal cord. 
As discussed, IL6 and other gp130 cytokines can influence the expression of 
neuropeptides following nerve injury, a key example being galanin, and literature 
regarding neuropeptides will now be reviewed. 
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1.8. Neuropeptides
Neuropeptides are small, biologically-active neurotransmitter proteins found in 
neuronal tissue. Key examples involved in sensory signalling include SP and CGRP, 
located in small diameter unmyelinated peptidergic fibres, as discussed in 
Section 1.3. Other neuropeptides (galanin, enkephalin, dynorphin, cholecystokinin, 
neuropeptide Y [NPY]) are synthesised and packaged in nociceptors, and often have 
direct effects on postsynaptic cells, acting via their respective receptors. This project 
focuses on galanin. Galanin and its receptors are expressed in selective DRG neurons 
and in the spinal cord (Zhang et al., 1995a; Villar et al., 1989, 1991; Landry et al., 
2005). Furthermore after nerve injury galanin expression increases rapidly as 
discussed in below. 
1.8.1 – Galanin
Galanin is a 29 (rat) / 30 (human) amino acid peptide, first identified from porcine 
intestine (Tatemoto et al., 1983). Galanin is widely distributed in both the central and 
peripheral nervous systems as well as in the endocrine system (reviewed by Hökfelt, 
2005). Galanin may act to modulate the release and postsynaptic action of 
neurotransmitters, including acetylcholine, serotonin and dopamine. Galanin co-exists 
with other neuropeptides, like neuropeptide Y (NPY), SP and vasoactive intestinal 
peptide (VIP), and has been shown to likewise modulate their activity. 
In naïve animals, galanin shows low expression in DRG (~5% L4/L5 DRG 
Villar et al., 1989) but protein and mRNA are rapidly upregulated with nerve injury, 
in rodents and monkeys (see: Zhang et al., 1993; Zhang et al., 1998), discussed in 
detail below (Section 1.8.4). There is evidence from ultra-structure and confocal 
microscopy that galanin expression may be higher (up to 90% of all DRG) in the 
naïve animal, but that detection via conventional light microscopy is insufficient to 
show widespread expression before injury (Zhang et al., 1993). 
1.8.2. – Electrophysiology of galanin in sensory signalling
Early studies of the physiological activity of galanin suggested galanin was an 
inhibitory peptide. For example, using an isolated spinal cord-peripheral nerve 
preparation, developed to record spinal reflexes from a lumbar ventral root in 
response to stimulation of the ipsilateral saphenous or obturator nerve (Nussbaumer et 
al., 1989), exogenous galanin (1-2 M) inhibited the slow ventral root potential 
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evoked by saphenous nerve stimulation. For comparison, CGRP potentiated the slow 
ventral root potential (Nussbaumer et al., 1989). 
Later evidence from Wiesenfeld-Hallin and colleagues (e.g.: Wiesenfeld-Hallin et al., 
1988; Wiesenfeld-Hallin et al., 1989; Wiesenfeld-Hallin et al., 1990; Xu et al., 1990)
using the nocifensive flexor reflex (originally developed by Woolf and Wall, 1986) 
demonstrated that different concentrations of intrathecal galanin resulted in different 
responses. Low dose of galanin (10 ng) caused facilitation of the nocifensive reflex
(Wiesenfeld-Hallin et al., 1988). This is in line with other data of low-dose galanin 
(0.1 and 1 nmol) decreasing the mechanical nociceptive threshold of the rat hind paw 
(Kuraishi et al., 1991). As endogenous galanin expression is relatively low, one might 
consider this intrathecal low concentration (10 ng) as representative of galanin 
activity in the non-injured state. However, intrathecal galanin (0.1 and 1 nmol, but not 
0.01 nmol) decreased the mechanical nociceptive threshold of the non-inflamed hind 
paw with no effect on thermal nociception (Kuraishi et al., 1991). In addition, 
intrathecal antiserum against galanin was separately shown to reverse the decreased
nociceptive threshold for mechanical, but not thermal, stimulation of carrageen 
inflammation, but shown no effect on the nociceptive threshold of the non-inflamed 
hind paw. These data were taken to suggest that galanin present in the dorsal horn is 
involved in the facilitation of mechanical, but not thermal, nociceptive transmission 
(Kuraishi et al., 1991).
A medium dose (100ng/1g) of galanin resulted in a biphasic reflex response, 
although predominantly inhibitory (Wiesenfeld-Hallin et al., 1989). However, a 
higher dose (10g) of galanin primarily caused inhibition of the nocifensive flexor 
reflex (Xu et al., 1990). The high dose also blocked facilitation of the nocifensive 
reflex by SP and CGRP, but potentiated the analgesic action of morphine (in a 
naloxone-sensitive manner) (Wiesenfeld-Hallin et al., 1990). Data from this latter 
paper also demonstrated that the high dose galanin (10µg) facilitated the analgesic 
action of morphine, particularly in combination with a cholecystokinin-type2 (CCK2) 
receptor antagonist (Wiesenfeld-Hallin et al., 1990). Separately, Flatters et al., (2002) 
demonstrated even higher concentration of galanin (50g) inhibited ventral root 
potential. However, a lower dose of galanin was insufficient to inhibit activity after 
injury, potentially indicating a switch from a normal to a facilitated inhibitory state 
could occur after nerve injury. This ‘switch’ may need to be accounted for as the 
nocifensive reflex data were recorded from non-injured animals. 
55
Collectively the dual role for galanin in inhibiting and facilitating nociception 
has been rationalised by action of galanin on different subtypes of GPCRs (GALR1, 
GALR2, GALR3), which are differentially coupled to effector molecules and are 
located on pre- and post-synaptic membranes, as outlined below.
1.8.3 – Galanin receptors: expression, location and regulation after nerve injury 
The different electrophysiology responses recorded in response to galanin can now be 
explained through three subtypes of galanin receptors, and their physiological 
location. Galanin binds to three GPCRs, GALR1-GALR3. These high-density galanin 
binding sites have been detected especially in lamina I/II (Zhang et al., 1993); the 
area of spinal cord where nociceptors terminate (see Section 1.3). Each receptor 
subtype has a high sequence homology between different species, however in vitro
studies using specific agonists/antagonist combinations have demonstrated that 
galanin has shown both inhibitory and excitatory actions on these different receptor 
subtypes (see Barreda-Gómez et al., 2005; Jimenez-Andrade et al., 2004; Hökfelt, 
2005; Landry et al., 2006) (Figure K, Figure L). 
GALR1 has been localised mainly in the hypothalamus, the hippocampus and 
the spinal cord (see Barreda-Gómez et al., 2005), and molecular studies have 
demonstrated the receptor is coupled negatively to adenyl cyclase through Gi/Go 
proteins (Wang et al., 1998) (Figure K). GALR1 has been located on pre- and post-
synaptic membranes, whereas GALR2 is located mainly on the pre-synaptic 
membrane (Figure K). Further, galanin receptors are likely co-expressed on the same 
cell, making the resulting action of galanin complex (Figure L). Specifically, GALR1 
has been located on >20% of L4/L5 DRG cells, primarily medium- to large diameter 
(Xu et al., 1996) and mostly those expressing CGRP (peptidergic cells). Post-synaptic 
GALR1 is also expressed on excitatory glutamatergic dorsal horn interneurons 
(Zhang et al., 1998), where activation has been proposed to decrease the inhibitory 
tone in the superficial dorsal horn, which via inhibitory interconnections, may lead to 
anti-nociception (Landry et al., 2006). 
GALR2 has been cloned from the rat DRG, and the rat hypothalamus, human 
placenta, and from mouse brain. GALR2 is specifically activated by galanin agonists, 
e.g., galanin(2-29) and [D-Trp2]-galanin, and has been shown to couple to inositol 
phospholipid hydrolysis, resulting in an increase in intracellular calcium (Wang et al., 
1998) (Figure K). GALR2 is primarily located on pre-synaptic membranes on small 
and medium diameter DRG cells (O’Donnell et al., 1999). Interestingly, mice 
deficient for GALR2 show impaired pain-like behaviour, in addition to decreased 
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neurite outgrowth from adult sensory neurons (Hobson et al., 2006; Shi et al., 2006). 
GALR3 has been cloned from rat hypothalamus and is localised mainly in heart, 
spleen and testis. The galanin agonist, galanin(2-29), binds GALR3. Molecular 
studies have thus shown that GALR3 couples to Gi/Go proteins and mediates opening 
of G-protein-coupled inward-rectifying potassium channels, and a decrease in 
intracellular calcium (Smith et al., 1998) (Figure K). Less is known about the 
location of GALR3 due to the historical lack of specific agonist/antagonists, although 
a specific antagonist has now been described (Swanson et al., 2005). 
Figure K: Schematic diagram showing galanin receptor coupling to second messenger 
cascades, on pre- and post-synaptic membranes in normal state. See text for more details. 
Ca++, calcium ions; cAMP, cyclic-AMP; DAG, diacylglycerol; GAL1, GAL2, GAL3, galanin 
receptors (subtypes 1-3); Gi, Gi/Go, Gq11, G-protein coupled receptors; PLC, phospholipase C; 
PKC, protein kinase C. Dashed arrow, transduction step. 
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As different receptor locations have been demonstrated, an important consideration 
when interpreting data using intrathecal administration, such as those discussed above 
with the nocifensive reflex experiments, is that when an agent, such as galanin or 
galanin agonist/antagonist is given exogenously it will first reach and act on receptors 
in the subarachnoid space (i.e., GALR2), whereas endogenously, galanin will initially 
act on dorsal horn neurons (i.e., GALR1). Therefore, data collected using intrathecal 
galanin (or respective agonist) may be misrepresentative of the endogenous response 
(discussed further by Liu and Hökfelt, 2002). 
Galanin receptors are differentially regulated with nerve injury (Figure L), 
and in particular post-synaptic GALR1 are upregulated, whereas pre-synaptic GALR1
and post-synaptic GALR2 have been shown to be down-regulated (Kar and Quirion, 
1994; Zhang et al., 1998). When considered in addition with the upregulation of 
galanin protein after nerve injury (see below, Section 1.8.4), GALR1 may contribute 
to inhibition of glutamate-induced excitation of primary afferent neurons, being 
negatively coupled to adenyl cyclase, and results in decreased cAMP and reduction of 
intracellular calcium in the presynaptic terminal (Figure K), reducing the likelihood 
of synaptic release of pre-synaptic mediator. As GALR2 receptors are down 
regulated, presynaptic effects of galanin on primary afferent neurons, resulting in an 
increase in intracellular calcium (Figure K) and increased likelihood of presynaptic 
mediator release may therefore be less important following nerve injury. As a result, 
the end result of galanin activity following nerve injury with respect to propagation of 
messages through the dorsal horn synapse to higher centres, will differ from that seen 
in the uninjured state (Figure L), and is discussed in more detail below. 
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Figure L: Schematic illustration of possible roles of galanin in the superficial laminae of the 
dorsal horn of (a): normal, (b) after peripheral nerve injury, or (c) after inflammation. (a) 
Primary afferents (PAs), C-fibres from small DRG cells innervate small interneurons (DH2) 
and dendrites of large projection neurones (PNs). DH2 neurones have galanin GAL1 receptors 
(dark red) and are possibly glutamatergic. PAs contain low levels of galanin; high levels SP 
and CGRP, and glutamate, express GAL2 receptors (green), and probably also GAL1 
receptors (orange). GABAergic interneuron (DH1) expresses galanin, enkephalin and 
sometimes neuropeptide Y (NPY). Taken from: Liu and Hökfelt, 2002. 
59
1.8.4 - Galanin is upregulated after nerve injury 
Galanin expression increases rapidly following nerve injury and protein expression 
remains elevated for up to 50 days post injury (Brecht et al., 1997). For example 
galanin increased from <5% to at least 40%-50% of DRG cells in rats after sciatic 
nerve axotomy (Zhang et al., 1995a; Villar et al., 1991). Interestingly, an increase in 
galanin immunoreactivity after nerve injury is unique among peptides in monkeys 
(Zhang et al., 1993). This corresponds to over 100-fold increase of galanin 
immunoreactivity in DRG (Hökfelt et al., 1987; Villar et al., 1989), and high 
expression is also reported in dorsal horn lamina II and in spinal interneurons. 
Galanin upregulation in the dorsal horn is modest compared with the DRG, which 
may be due to low anterograde transport of galanin to the dorsal horn (Wynick et al., 
2001) and/or increased synaptic release with injury (shown by Colvin et al., 1997). 
Galanin immunoreactivity has been detected in both motor and sympathetic 
neurons following nerve injury, and also in the dorsal columns (Ma and Bisby, 1999; 
Shi et al., 1999). For example, Ma and Bisby (1999) reported after partial nerve injury 
that galanin is upregulated in lamina III-V of the spinal cord, areas containing fibre 
terminals conventionally associated with innocuous stimuli (Ma and Bisby, 1999). 
Shi and colleagues (1999) failed to duplicate these findings. Galanin was not 
upregulated in deeper laminae (III-V) of the spinal cord, being confined to 
nociceptive (lamina I and II) areas, and Shi et al., (1999) found little increase in the 
nerve terminals. The contradiction could be due to differences in staining protocols or 
other methodological processes. Data by Shi et al., (1999) are now supported by a 
study by Coronel et al., (2008) who demonstrated that medium and strong ligatures of 
the lumbar L4 or L5 DRG induced a marked ipsilateral increase in galanin-like 
immunoreactivity in laminae I-II. This study used different degrees of nerve ligation, 
whereby the nerve was ligated and reduced to 10-30, 40-80 or 90% of its original 
diameter corresponding to light, medium or strong single-ligature. Galanin expression 
in DRGs and spinal cord was differentially regulated by the different degrees of nerve 
constriction (Coronel et al., 2008). Behavioural observations were not directly 
correlated with the immunohistochemical data in this study by Coronel and 
colleagues (2008) however Shi et al., (1999) inversely correlated galanin expression 
with degree of allodynia. Below in Section 1.8.6 some of the consequences to 
nociception and repair of galanin upregulation following nerve injury are discussed. 
Studies have shown that galanin is principally expressed in small diameter, 
peptidergic DRG in a basal state (Villar et al., 1989; Villar et al., 1991). In accord, 
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galanin is expressed primarily in peptidergic DRG 24 hours after sciatic nerve injury 
(Villar et al., 1989; Yoon et al., 2003), and therefore galanin expression in non-
peptidergic DRG is minimal. This seems unusual as non-peptidergic cells represent a 
significant population of DRG cells, which are most likely nociceptive (above, 
Section 1.5) and with galanin implicated in nociception following injury (below, 
Section 1.8.5), co-expression and/or upregulation of galanin in these cells clearly 
needs examining over the time-course of galanin upregulation observed. However, 
galanin expression might not be expected in non-peptidergic DRG cells as by 
definition, they do not express peptides in the normal state (Priestley et al., 2002). 
Expression of peptides in these cells would therefore be noteworthy, particularly
given the role of galanin in nociception following nerve injury. 
1.8.5 - Galanin has a role in nociception following nerve injury 
The role of galanin release in the naïve state may be modulatory, due to release with 
other excitatory neuropeptides and glutamate having a strong and dominant 
stimulatory activity on second order neurons. However, the upregulation of galanin 
after nerve injury may be indicative of an increased importance, especially if 
considered in combination with the loss of neuropeptides, such as SP and CGRP 
(Doughty et al., 1991; Fitzgerald et al., 1985), and the down-regulation of pre-
synaptic (inhibitory) GALR1 and post-synaptic (excitatory) GALR2. 
The contribution of upregulated galanin to nociception following nerve injury 
has been investigated. For example, Flatters et al., (2003) reported either a 
potentiation or inhibitory response with galanin application to peripheral receptive 
field of convergent neurons following spinal nerve ligation. Spinal nerve injury 
increased the proportion of inhibitory responses (Figure M), as a higher proportion of 
neuronal cells were inhibited by galanin administration following SNL compared 
with Sham or naïve animals. Specifically, injection of galanin (0.1-10 µg) into hind 
paw receptive fields inhibited responses to innocuous mechanical, noxious 
mechanical and noxious heat stimuli in a proportion of neurons in each group and, 
furthermore facilitated the remaining neurons. However, a higher proportion of 
neurons (80%-90%) were inhibited by peripheral galanin administration in SNL rats 
compared with naive (45%-55%) or sham (70%-80%) rats (Flatters et al., 2003)
(Figure M). This trend towards inhibition after SNL was mirrored in the periphery 
and the dorsal horn, although a less dramatic increase in inhibition was seen when 
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recording from peripheral neurons compared with recording from the dorsal horn 
(Flatters et al., 2003). 
Although galanin receptor subtypes were not characterised in this study, the 
significant switch to inhibition evoked by galanin is suggestive of activity on a 
negative-coupled receptor, such as GALR1. This is in accord with observations that 
post-synaptic GALR1 are upregulated following nerve injury (Holmes et al., 2003; 
Landry et al., 2006), and with down regulation of GALR2, become the primary 
population of receptors onto which galanin will bind and signal. Flatters et al., (2003) 
concluded that two distinct populations of peripheral C-fibres exist, in terms of their 
response to galanin. The end result may therefore be anti-nociception in the spinal 
cord, via inhibition of second-order signalling. Behavioural studies have been carried 
out to determine the consequences of the inhibitory celluar action of upregulated 
galanin following nerve injury. 
1.8.6 – Consequences of galanin upregulation following nerve injury 
Behavioural evidence is needed to add weight to immunohistochemical and 
electrophysiology data for an inhibitory role for galanin in nociception after nerve 
injury. Importantly, Shi et al., (1999) inversely correlated galanin immunoreactivity 
after nerve injury with the severity of tactile allodynia in rats in different models of 
nerve injury. Furthermore, intrathecal galanin reduced spinal hyperexcitablity (Xu et 
al., 1990) and alleviated peripheral allodynia-like behaviours in rats with partial 
peripheral nerve injury (Hao et al., 1999). In addition, intrathecal galanin antagonist 
or antisense oligonucleotides to rats after spinal nerve injury increased autonomy 
behaviours, used as an indication of pain (Ji et al., 1994; Verge et al., 1993). 
Such behavioural evidence in conjunction with some of the 
electrophysiological evidence from nerve injury models (Flatters et al., 2003) 
supports the proposed role for galanin in modifying hypersensitivity in the spinal cord 
following injury. However, evidence from genetically modified animals is conflicting 
between pro- or anti-nociceptive function of galanin, as found with certain 
electrophysiological data. Some of these contradicting studies are outlined in Section 
1.8.7. 
With the extensive upregulation of galanin following nerve injury, other 
central functions of galanin become important and warrant consideration. For 
example, galanin has a number of important central functions with links to injury, 
including in development of neurons, in cognition and ageing (reviewed by Hökfelt, 
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2005). Indeed, there is an increasing body of evidence which collectively suggests 
that galanin plays developmental and survival roles within neuronal subpopulations of 
the peripheral and central nervous systems (Hobson et al., 2008). In addition, galanin 
is thought to play a neuroprotective role specifically in the hippocampus following 
excitotoxic injury, mediated by activation of GALR2 (Elliott-Hunt et al., 2004). 
Furthermore, adult sensory neurons are dependent, in part, on galanin for neurite 
extension and this crucial physiological process is thought to be mediated by 
activation of the GALR2 receptor in a PKC-dependent manner (Mahoney et al., 
2003). This is in contrast to GALR1-knock out animals which display no apparent 
reduction in their regenerative capacity following a nerve crush injury (Blakeman et 
al., 2003) nor any impairment in neuritogenesis in vitro (Mahoney et al., 2003). These 
observations suggest that GALR2 response rather than GALR1 is responsible for 
mediating the regenerative role played by galanin. However, given that GALR2 are 
lost with nerve injury, these observations seem somewhat contradictory if galanin 
plays a significant role in mediating repair. Nevertheless, these functional responses 
to galanin should be considered following nerve injury as upregulation of galanin in 
addition to dynamic changes in GALR1/GALR2 expression may change the injured 
environment over time, and consequently introduce variables as function capacity is 
gradually restored. 
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Figure M: Neuronal populations from naïve, sham and spinal nerve ligation (SNL) rats 
whose responses were inhibited or facilitated following peripheral galanin application 0.1, 1 
and 10 μg dissolved in 20 μL saline). A higher proportion of the neuronal population was 
inhibited after galanin in SNL rats compared with a similar neuronal population in naïve rats. 
Same trend was found for each dose of galanin. Innocuous Mechanical = Von Frey 8.51g; 
Noxious mechanical = Von Frey 28.84 g; Noxious heat = 45°C water stream for 15 seconds. 
Taken from: Flatters et al., 2003. 
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1.8.7 – Evidence for galanin in nociception, from genetic studies 
As galanin is rapidly upregulated with peripheral nerve injury, modelling galanin 
over-expression through genetic manipulation has provided useful information of the 
consequences of galanin upregulation following nerve injury. Uninjured mice that 
over-express galanin exhibited a moderately reduced sensitivity to noxious heat in 
one study (Hygge-Blakeman et al., 2004). Furthermore, after partial nerve injury,
these mice over-expressing galanin showed reduced peripheral allodynia (Hygge-
Blakeman et al., 2004). This evidence can be compared with earlier research where 
spinal implants secreting galanin significantly decreased allodynia after CCI (Eaton et 
al., 1999). Separately, Holmes et al (2003) employed two different strains of mice 
engineered to over-express galanin; one with inducible over-expression of galanin in 
response to injury (up to 40x normal response), and the second involved over-
expression of galanin in spinal cord and DRG in the uninjured animal, through RET-
gene over-expression (OE) (RET drives galanin gene expression). The second, RET-
gene OE model, targets galanin expression in non-peptidergic, IB4 cells, and most 
likely in other larger cells that express RET although this was not directly 
demonstrated in the wild-type animals (Holmes et al., 2003). Both strains showed 
significantly increased mechanical and thermal baseline thresholds compared wild 
type controls. After SNI, the RET-gene OE animals had reduced mechanical 
withdrawal thresholds when compared with baseline measurements, although these 
observations are complicated by the higher baseline withdrawal thresholds (Holmes et 
al., 2003). Furthermore, galanin expression in the DRG of the RET-gene OE animals 
did not significantly alter after SNI (Holmes et al., 2003). Collectively, their 
behavioural observations are in accord with the hypothesis that galanin plays an 
inhibitory role in nociception in the intact animal and in states of nerve injury. 
Holmes et al., (2003) also presented data from galanin knockout animals who 
demonstrated an increased sensitivity to baseline modalities, in accord with an earlier 
paper by Kerr et al., (2000). Following partial and full nerve injury, autonomy was 
reduced in this strain of knockout animals (Kerr et al., 2000), and similarly the strain 
used by Holmes et al., (2003) failed to demonstrate the development of peripheral 
mechanical hyperalgesia following injury. However a later paper by Kerr et al., 
(2001b) demonstrated that galanin was a crucial neuromodulator involved in the 
development of central sensitization. Indeed, both windup and the facilitation of 
spinal reflexes following conditioning stimulation were significantly impaired in 
knockout animals following peripheral nerve injury (Kerr et al., 2001b). Galanin had
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no direct effect on basal spinal excitability, using the flexor withdrawal model, after 
nerve injury. However, as the development of central sensitization is important in the 
underlying pathophysiology of neuropathic pain sensations, the lack of effect might 
be rationalised. 
These knockout data allude to an important role for galanin in maintaining
baseline sensitivity thresholds. However following nerve injury, effect of galanin is 
complicated in these animals by the additional properties of galanin on neurite 
outgrowth and repair (see Sections 1.8.5). Kerr et al., (2001b) discuss the 
contradiction and present data that galanin plays an important role during phenotype 
development of the nervous system and, as such, knockout animals may have a 
decreased regulatory capacity for preventing erroneous connections and ectopic 
activity. Also, during early development in knockout animals, phenotype 
abnormalities may occur and, also, compensation for galanin by other 
neurotransmitters. Specifically, galanin expression is high during prenatal 
development, and knockout animals develop 15% fewer DRG cells (see Wynick et 
al., 2001), questioning how representative these knockout models are with such a 
deficit of sensory fibres. However, no difference between animals over-expressing 
galanin and wild-type mice in baseline flexor reflex was reported (Grass et al., 2003), 
despite other reports of these animals having an increased sensitivity to baseline 
modalities (Kerr et al, 2000; Holmes et al., 2005). 
These genetic data highlight clearly the complexities of galanin expression in 
injured and uninjured animals, and furthermore that galanin may contribute 
significantly to nociception and/or neurite regrowth following injury. Mediators 
involved in the specific regulation of galanin following nerve injury are now 
discussed. 
1.8.8 – What is regulating changes in galanin expression after nerve injury? 
The down-regulation and loss of peptides, e.g., SP and CGRP, from peptidergic fibres 
following nerve injury can almost completely be attributed to a loss of the target-
derived NGF and the consequences of NGF loss. This can be demonstrated by 
supplementing NGF to isolated DRG cells which increases expression of SP and 
CGRP (Lindsay et al., 1989), or NGF administered to hindpaw of rat increases CGRP 
IR in lumbar DRG (Amann et al., 1996). In addition, supplementing exogenous NGF 
prevents the decrease of SP protein following axotomy (Wong et al., 1991). As 
galanin is principally expressed in peptidergic cells immediately after injury (Villar et 
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al., 1989), the incomplete regulation of galanin by NGF (Kerekes et al., 1997; Verge 
et al., 1995) seems contradictory. 
As discussed in Section 1.7.5, cytokines, such as IL6 and LIF, can drive 
galanin up-regulation both in vitro (Corness et al., 1998; Kerekes et al., 1999; Rao et 
al., 1993) and in vivo (Kato et al., 2002; Sun and Zigmond, 1996; Thompson et al., 
1998). For example, in mouse DRG cultures, exogenous LIF significantly increased 
galanin expression (Kerekes et al., 1999) and anti-LIF serum added to embryonic rat 
DRG cell cultures caused decreased galanin mRNA expression compared with 
control cultures (Corness et al., 1998). The combination of anti-NGF and cultured 
cells from LIF-knockout animals countered the increase in galanin mRNA found in 
control cultures of sympathetic neurons, but not completely (Rao et al., 1993). 
Notably, Rao et al., (1993) reported a small but significant increase in galanin and in 
VIP expression in cultures and DRG sections of LIF knockout DRG supplemented 
with anti-NGF. 
In vivo data support a role for LIF in regulating galanin expression. For 
example, intra-neural LIF increased galanin expression in DRG cells (Thompson et 
al., 1998) and galanin-immunoreactivity was predominantly confined to those 
neurons which retrogradely transported and accumulated LIF (Thompson et al., 
1997). LIF also caused upregulation of a novel metallopeptidase, damage-induce 
neuroendopeptidase (DINE), in trkA-positive (i.e., peptidergic) fibres (Kato et al., 
2002), where more than 80% of DINE mRNA-positive neurons simultaneously 
demonstrated galanin immunoreactivity after nerve injury. Collectively, these data 
suggest LIF cannot account fully for galanin upregulation following axotomy, even 
accounting for negative regulation by NGF. It is possible that LIF cannot produce the 
full response due to low efficacy.
Studies investigating the regulation of galanin by IL6 include a report from 
Murphy et al., (1999b), who injected IL6 into the subarachnoid space of naïve
animals and recorded an increase in galanin mRNA in 32% of medium/small 
diameter lumbar DRG neurons. After CCI, IL6 knockout animals have enhanced 
galanin expression, not a decrease as you might expect if IL6 is regulating galanin 
expression (Murphy et al., 1999b); however this may be due to promiscuity of LIF 
signalling in combination with loss of NGF. Murphy et al., (1999b) concluded that 
endogenous IL6 contributes to increase of galanin in dorsal horn and when removed, 
as shown by their knockout studies, is probably countered by LIF. This is in 
agreement with the model of redundancy for cytokines, discussed in Section 1.7.
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Also, IL6 knockout mice showed decreased allodynia and galanin expression in the 
dorsal horn compared to wild-type mice (Ramer et al., 1998). 
The regulation of galanin by neuropoietic cytokines particularly in non-
peptidergic nociceptors is not clear-cut and data available indicate complexities and 
contradictions that require further investigation. Particularly if specific members of 
the neuropoietic family are most efficacious at driving galanin expression in given 
subsets of DRG cell. Reg2 is another peptide which has shown to be regulated by 
members of the neuropoietic cytokine family, and in addition, has been shown to be 
selectively upregulated in non-peptidergic nociceptors immediately following sciatic 
nerve injury. Reg2 is discussed further below in Sections 1.8.9-1.8.9.10. 
1.8.9 – Reg2 
Reg2 (regenerating gene; also known as pancreatitis associated protein I 
(PAP I)/hepatocarcinoma-intestine-pancreas (HIP) and pituitary peptide 23) is a 
secreted, C-type lectin protein having molecular weight of approximately 16kD 
(Livesey et al., 1997). Reg2 belongs to a family of similar calcium-dependent 
proteins (Reg I; Reg III, Reg IV) associated with the pancreas and gastrointestinal 
(GI) tract. Reg2 mRNA was first identified in inflammatory pancreatitis (Iovanna et 
al., 1991). This was notable as pancreatic proteins are generally down regulated with 
inflammatory pancreatitis. Reg2 has since been shown to act as an acute phase 
reactant protein (Broekaert et al., 2002), as an anti-apoptotic factor e.g., for pancreatic 
-cells (Malka et al., 2000), and as a growth factor for neuronal cells. Notably, Reg2 
also acts as a Schwann cell mitogen (Livesey et al., 1997). Targeted disruption of 
Reg2 (Reg-III) gene in mice however, demonstrated that motor neuron survival was 
unaffected up to 28 weeks after birth by gene ablation. However, the efficacy of 
CNTF for reducing neuronal cell death following axotomy was lost in these knock-
out animals, highlighting that Reg2 is most important for the survival function of 
CNTF (Tebar et al., 2008).
Reg2 is expressed in developing neurons at a late stage, compared with other 
motor neuron markers. In the adult animal Reg2 is expressed solely in regenerating
sensory and motor neurons, and is not expressed in established fibres (Nishimune et 
al., 2000). After nerve injury, Reg2 is upregulated in sensory neurons, initially in non-
peptidergic IB4 cells before switching 5-days after injury to larger-diameter, 
myelinated cells (Averill et al., 2002). Expression in more than one population over a 
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temporal course of an injury may suggest regulation by different mediators produced 
in injury. 
1.8.10 – Upregulation of Reg2 in vitro and in vivo after nerve injury
Reg2 can be upregulated via gp130-STAT3 activation (Aggarwal et al., 2001; Dusetti 
et al., 1995). Accordingly, the majority of neuropoietic cytokines can promote Reg2 
expression in cultured motor neurons (Nishimune et al., 2000) acting via the gp130 
pathway (Figure N). Furthermore, two functional IL6 response elements have been 
identified in the promoter region of the rodent Reg2 gene (Dusetti et al., 1995). 
As outlined above, Reg2 is upregulated in sensory neurons after sciatic nerve 
injury, initially in non-peptidergic IB4 cells before switching 5-days after injury to 
larger-diameter, myelinated cells (Averill et al., 2002). Reg2 is also upregulated with 
inflammation, selectively in non-peptidergic IB4 cells (Averill et al., 2008). Although 
the complete functional significance of Reg2 after injury is not fully known, 
inhibiting Reg2 in vivo with anti-Reg2 polyclonal antibody significantly hindered 
regeneration of Reg2-positive neurons after sciatic nerve injury, implicating a key 
role in the injury and repair (Livesey et al., 1997). Reg2 is thought to affect survival 
of motor neurons via NFB, although the receptor target for Reg2 is unknown. 
However, it is unknown if this pathway is important for regulation of sensory 
neurons. Furthermore, it is unknown whether the pathway by which Reg2 acts to 
promote motor neuron survival after injury and during development are different 
(Schweizer et al., 2002). For example, STAT3 phosphorylation is essential for motor 
neurons survival after axotomy but is not required during development. In developing 
motor neurons, the neuropoietic cytokine, CNTF, has been shown to be an essential 
intermediate of the Reg2 signalling pathway (Nishimune et al., 2000) and signalling 
involves LIFR (Schweizer et al., 2002). This is in accord with later date from Reg2 
knockout animals, highlighting Reg2 is most important for the survival function of 
CNTF (Tebar et al., 2008). 
The functional significance of Reg2 expression in sensory neurons following 
nerve injury and inflammation remains to be clarified, and warrants further 
investigation. Indeed, the stimuli promoting Reg2 upregulation after nerve injury are 
also unclear, as is the target where Reg2 is acting (Figure N). 
Given the specific but dynamic expression of Reg2 during the temporal time-
course of injury, multiple stimuli might be involved in promoting Reg2 expression in 
different populations of sensory or motor neurons. However, the stimuli promoting 
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Reg2 upregulation is most likely a factor generated after axotomy and inflammation 
to account for Reg2 upregulation in both of these types of injury model, specifically 
in sensory neurons. Due to the in vitro data highlighting members of the neuropoietic 
family being signalling intermediates (Livesey et al., 1997), and furthermore the 
initial upregulation in non-peptidergic cells, strong candidates are the neuropoietic
cytokines, given these DRG cells may express receptor components for some 
members of this family (Qui et al., 1997; Scott et al., 2000; Priestley, 2008). 
Furthermore, as the Reg2 promoter contains 3 IL6 response elements, IL6 may be 
involved, especially as IL6 is upregulated after both inflammation and nerve injury. 
As such, the relationship between IL6 expression and Reg2 upregulation in non-
peptidergic cells needs to be investigated further. 
Figure N: A proposed relationship between motoneuron survival and Reg2, acting via an 
autocrine or paracrine mechanism. Proposed relationship involves CNTF-related cytokines 
acting via JAK/STAT pathway to promote Reg2 expression. Reg2 then acts via an unknown 
mechanism/receptor system to promote survival; survival pathway involves NFB, and 
kinases (PI3K and Akt). CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1; LIF, 
leukaemia inhibitory factor; OsM, oncostatin-M; ‘?’ indicates unknown mediators. Taken 
from: Nishimune et al., 2000. 
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1.9. Summarising comments 
Small diameter DRG cells transmit nociceptive sensory information following injury. 
The distinct characteristics of these nociceptors are suggestive that they relay discrete 
sensory information, despite their polymodal characteristics. Therefore identifying 
differences in the two primary populations of small diameter DRG cells – peptidergic 
and non-peptidergic - following injury may provide key insight into understanding
transmission of nociception following injury. 
Dynamic changes in expression of neuropeptides following nerve injury have 
been linked with changes in nociception. One particular example which has also been 
linked to anti-nociception is galanin. Galanin is rapidly upregulated after nerve injury 
in peptidergic DRG cells. Reg2, a Schwann cell mitogen is upregulated transiently in 
non-peptidergic DRG cells after both inflammation and nerve injury. NGF does not 
upregulate Reg2 or galanin as found with other peptides, but on the contrary galanin 
expression is partially suppressed by NGF. Given the rapid expression of galanin in 
peptidergic cells following nerve injury, the incomplete regulation of galanin by NGF 
seems contradictory. Neuropoietic cytokines, such as IL6 and LIF, can modulate 
galanin expression in vivo and in vitro; however receptor components for these 
cytokines are not expressed on peptidergic DRG cells and may therefore account for 
galanin expression in another population of DRG cells. 
Both galanin and Reg2 switch the populations of DRG cell in which they are 
expressed after nerve injury as both peptides are found in larger diameter, non-
nociceptive DRG cells at around 1 week post-injury, whilst also being expressed in 
smaller diameter, nociceptive-specific DRG cells. A comparative analysis of Reg2 
and galanin expression following complete nerve injury has not been conducted. 
Furthermore, mediators that drive the differential temporal expression of these two 
proteins following nerve injury should be investigated further. 
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1.10. Hypothesis and Project aims 
Although some work has looked at expression of galanin and Reg2 after nerve injury, 
few studies have fully classified the populations of DRG cells in which these peptides 
are expressed after spinal nerve injury, or which injury-generated factors are 
regulating the changes in expression. There are no data reporting the regulation of 
Reg2 following L5 SNL or contrasting the expression with that of galanin in this 
model. As neurobiological changes were of particular interest, the L5 SNL model was 
used to enable direct immunohistochemical assessment of changes that occur after 
injury in injured (L5) versus uninjured (e.g., L4, L6) DRG. 
The formulated hypothesis for this project is that a neuropoietic cytokine, 
possibly IL6, is released from macrophages or products of degeneration after nerve 
injury and can cause upregulation of peptides, galanin and Reg2, in specific 
populations of DRG cells. This upregulation of galanin and/or of Reg2 is
subsequently important to nociception. However, parallel to IL6-driven galanin 
upregulation in specific populations of DRG cells, a loss of target-derived NGF 
drives upregulation of galanin in IB4-negative, peptidergic DRG cells. I specifically 
looked at IL6, as this cytokine has roles in both inflammation (not investigated 
herein) and nerve injury, is rapidly induced in both injury states, and from literature 
reviewed, IL6 is timely-expressed to drive rapid changes in galanin and Reg2 
expression seen after both types of injury. 
The overall aim of the project is to investigate this hypothesis, and the 
specific objectives are outlined below.
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1.10.1 – Objectives
The specific objectives of the project are: 
 Investigate changes in neuropeptides, CGRP, galanin and Reg2, at 1- and/or 
7-days after L5 spinal nerve injury.
 Investigate how changes in neuropeptides after L5 spinal nerve injury differ 
in the two primary populations of small diameter nociceptors (peptidergic 
and non-peptidergic). 
 Investigate neuropeptide regulation by the cytokine IL6 in subpopulations of 
DRG cells in vitro, at different time points, using dissociated, cultured DRG 
cells. 
 Investigate a potential role for non-neuronal cells, especially macrophages, in 
evoking changes in neuropeptide expression after nerve injury in vivo.
 Propose how changes in neuropeptides may relate to nociception after nerve 
injury.
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2. METHODS: IN VIVO
2.1. Animal surgery
All animal surgery was carried out in strict accordance with UK home office 
regulations (United Kingdom Animal Procedures Scientific Act 1986). Animals were 
caged in groups of 5 on a 12 hour light/dark cycle, and allowed water and food ad 
libitum.
Adult male Wistar rats (1–3 month old; 200–400g average weight; n=3-5 per 
experimental group) underwent unilateral L5 spinal nerve ligation (SNL), under 
isoflurane anaesthesia (4% induction; 2–3% maintenance). The L5 spinal nerve was 
exposed via removal of the transverse process of the L5 vertebra, the spinal nerve was 
ligated with a 4.0 silk suture 5mm distal to the ganglia, and then the L5 nerve was cut 
distal to the ligature. 1- or 7-days later, rats were anaesthetised with carbon dioxide 
(5%) and perfused through the ascending aorta with 30 ml vascular rinse followed by 
300 ml 4% paraformaldehyde (PFA) solution (under gravity) until all blood had been 
displaced. Success of perfusion was observed by the clearing of the liver and muscle 
spasms. Naïve male Wistar rats (n=3) were anaesthetised with carbon dioxide (5%) 
and perfused through the ascending aorta with 30 ml vascular rinse followed by 
300 ml 4% PFA solution without undergoing unilateral L5 spinal nerve injury to act 
as controls. All solutions were prepared as outlined in Section 2.4.
Dissection of brain, spinal cord, ipsilateral and contralateral lumbar DRG (L3, 
L4, L5, L6) was carried out immediately after perfusion, under a dissection 
microscope. Tissue was immediately placed in 4% PFA for post-fixation period of 1-
2 hours. Carcases were disposed of in accordance with Home Office regulations.
2.2. Slide preparation protocol
After 1-2 hours post-fixation tissues (brain; spinal cord; ipsilateral and contralateral 
DRG L3, L4, L5, L6) were cryoprotected in 25% (w/v) sucrose solution sucrose in 
0.1 M phosphate buffered saline (PBS) containing 0.02% (w/v) sodium azide 
overnight at 4°C, and then frozen in OCT and stored at –80°C. When required, 
cryoprotected DRG were mounted on a cryostat (Lecia). DRG sections (8-10 µm)
were cut on the cryostat at 4°C and thaw-mounted on polylysine-coated (Polysine®; 
VWR International, Leicestershire, UK) Superfrost® slides. Every 3rd section was 
thaw-mounted onto labelled slides, with 6-10 sections placed on each slide. 
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Contralateral and ipsilateral sections were placed on the same slide to enable direct 
comparison and to act as a control to compare immunohistochemical staining. 
Until required, prepared slides were stored in cryoprotectant at –20°C.
2.3. Immunohistochemistry: tissue sections
All slides onto which tissue sections were mounted were stained using indirect 
immunofluorescence. Incubations involved 1hr in normal donkey serum (10%) 
followed by 18-48hrs in primary antibody and 2-4hrs in developing secondary 
antiserum. Normal donkey serum was used to block non-specific binding by the 
secondary antisera, as all secondary antisera were raised in donkey. Slides were 
washed on a rocking platform (3x 10mins), in fresh PBS between each antibody 
incubation step. Indirect antibody staining was carried out at room temperature and
incubated overnight at 4°C. 
Preliminary experiments were carried out to determine the reliability of the 
slide preparations firstly using CGRP and SP, peptides known to be expressed by 
DRG tissue (Priestley et al., 2002). In addition, preliminarily experiments involved 
incubation of slides with normal donkey serum and secondary antibodies alone, to 
ensure no immunoreactivity was present in the absence of primary antibody. The 
majority of primary antisera used have been highly characterised and their specificity 
has been reported or reviewed in the following publications: rabbit anti-galanin 
polyclonal antibody (Holmes et al., 2003); goat anti-CGRP and rabbit anti-CGRP 
polyclonal antisera (Kiasalari et al, 2010); guinea pig and rabbit anti-P2X3 polyclonal 
antisera (Vulchanova et al., 1997); mouse anti-ED1 (anti CD68, Damoiseaux et al., 
1994); rabbit anti-Reg2 antibody (Livesey et al., 1997); mouse anti-NF200
(neurofilament) (Kiasalari et al, 2010); rabbit anti-VRL1 (TRPV2) polyclonal 
antibody (Caterina et al., 1999); mouse anti--tubulin (type III) polyclonal antibody
(Banerjee et al., 1988). Therefore immunoadsorption experiments, whereby 
antibodies are incubated with corresponding antigens before application to tissue to 
ensure no immunoreactivity occurs, were not carried out. However they would have 
provided an additional control to ensure antibodies were binding to correct antigens
when applied to tissue. 
Dilution experiments were conducted using antibody concentrations around a 
standard value used in literature and from the product information. These experiments 
were carried out to determine an optimum concentration of each primary antibody to 
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achieve consistent, reproducible immunostaining. These experiments were carried out 
to reduce the possibility of counting false-positive cells. 
After these preliminary experiments the following dilutions were used for 
immunohistochemical experiments detailed herein. Primary and secondary reagents 
were diluted from stock solutions in PBS containing 0.1% sodium azide and 0.2% 
triton, as preservative (PBS-Az). 
Primary antibody preparations used were: rabbit anti-galanin polyclonal 
antibody (BMI-GA1161, Biomol International, Exeter, UK; 1:1,000-1:30,0003); 
biotinylated Griffonia Simplicifolia IB4 lectin (Sigma-Aldrich Company, Ltd, Dorset, 
UK; 1:250); goat anti-CGRP polyclonal antibody (sc-8857, Santa Cruz, CA, USA; 
1:100); guinea pig anti-P2X3 polyclonal antibody (RA 10108, Neuromics, MN, USA; 
1:5,000); rabbit anti-glial fibrillary acidic protein (GFAP) polyclonal antibody 
(Chemicon International [now Millipore, Hertfordshire, UK]; 1:1,000); mouse anti-
ED1 monoclonal antibody (MCA341R, anti CD68, AbD-Serotec, Kidlington, UK; 
1:600); rabbit anti-Reg2 antiserum (1:25,000; or 1:100,000 for tyramide signal 
amplification [TSA], see below); Gift; Prof. S. Hunt); rabbit anti-CGRP polyclonal 
antibody (Affiniti, Exeter, UK; 1:3,000; or 1:50,000 (TSA)); rabbit anti-P2X3 
polyclonal antibody (RA10109, Neuromics; 1:2,000; or 1:50,000 (TSA)); mouse anti-
N52 (NF-200) polyclonal antibody (N-0142, Sigma-Aldrich; 1:5,000); rabbit anti-
VRL1 (TRPV2) polyclonal antibody (Gift; Prof. D. Julius 1:3,000). 
Secondary antibodies used were: donkey anti-rabbit-TRITC (Jackson 
ImmunoResearch, PA, USA; 1:400-800) or -FITC (Jackson ImmunoResearch; 
1:400); avidin-extra FITC (Sigma-Aldrich; 1:600); donkey anti-guinea pig FITC 
(Jackson ImmunoResearch; 1:400); donkey anti-mouse- TRITC (Jackson 
ImmunoResearch; 1:400-600) or -FITC (Jackson ImmunoResearch; 1:400); donkey 
anti-goat FITC (Jackson ImmunoResearch; 1:400); and biotinylated donkey anti-
rabbit TRITC (Jackson ImmunoResearch; 1:400). Each new antibody batch was 
compared during preliminary experiments to staining of previous batch, to ensure 
comparability between experiments and similar staining characteristics. One batch of 
galanin antibody was found to be non-reactive, and returned to the manufacturer. No 
tissue experiments using this batch of antibody are detailed herein and slides prepared 
with this antibody were disposed of. 
                                                  
3 Lower concentrations for tyramide-signal amplification (TSA) technique
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Tyramide signal amplification (TSA) staining is a powerful amplification 
technique that enhances chromogenic and fluorescence signals on slide-based assays. 
The technique was employed to enable slides to be double-stained with two 
antibodies raised in a rabbit, with minimised risk of cross-reactivity. 
TSA staining involved using a standard kit (NEN Life Sciences, MA, USA). 
Slides were incubated in primary antibody (30-40hrs), followed by biotinylated 
secondary antibody (90 mins). ABC (avidin-biotin-complex) reagents (Vectastatin®, 
Vecor labs CA) (1:5 working solution, diluted in PBS) were incubated for 1hr 
followed by 7-mins in tyramide solution (1:75 made with supplied diluting agent). 
Finally, slides were incubated for 2hrs in Avidin Extra FITC (Jackson 
ImmunoResearch; 1:600). Between each step, slides were washed in PBS 
(3x10mins). 
Dilution experiments using TSA solutions and rabbit anti-galanin antibody at 
concentrations of 1:5k;1:10k;1:20k;1:30k;1:40;1:50;1:100k were carried out to 
determine a suitable concentration. Galanin antibody with TSA at a concentration of 
1:30,000 was selected, as this concentration was the lowest to provide bright, 
consistent staining comparable with indirect immunohistochemistry used for other 
experiments using galanin antibody and a secondary antibody raised in rabbit, in both 
visual appearance and percentage expression. 
After immunostaining, slides were mounted with cover slips using 1:8 
solution of PBS glycerol. Unused slides were stored in cryoprotectant at –20 until 
needed. 
2.4. Fixative and general solutions
Cyroprotectant: 120g sucrose were added to 200mL PBS and 120mL ethylene 
glycol then mixed thoroughly. 
Paraformaldehyde (PFA): 80g of paraformaldehyde powder (BDH lab supplies4, 
Poole, UK) were added to 500mL distilled water in the fume hood. Mixture was 
heated to 65C whilst being stirred. Sodium hydroxide solution was added until 
mixture cleared. After cooling to room temperature, 500mL 0.2M phosphate buffer 
                                                  
4 All powder preparations for routine solutions were obtained from BDH (VWR International company)
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was added to the mixture, giving a 4% solution. The PFA solution was filtered and 
stored in cold room (4C) until use. 
Phosphate-Buffered Saline (PBS) (2L solution): 17.52g Sodium chloride (NaCl) 
and 400g potassium chloride (KCl) were added to 100mL 0.2M phosphate buffer
(below) and 1900mL distilled water.
0.2M Phosphate Buffer: (A) 27.6g sodium dihydrogen orthophosphate was mixed in 
1L distilled water. (B) 286.8g disodium hydrogen orthophosphate was mixed in 4L 
distilled water. Solutions were used at ratio (A:B) of 19:81mL. pH neutral was 
checked after mixing.
Saline: 9g of NaCl were added to 1L of distilled ultra-purified water, giving 0.9% 
solution.
2.5. Microscopy and quantification
Slides were viewed on a Leica epifluorescence microscope using Y3 (TRITC), L3 
(FITC) and A (DAPI) filter blocks, or on the confocal microscope, using the same 
filter blocks. Dry- and oil- objectives were used to enhance the visibility of images 
captured. Representative images were captured using Hamamatsu C4742-95 digital 
camera and plates were assembled using Adobe® Photoshop® (CA, USA). 
The proportion of DRG profiles (here after referred to as ‘cells’) expressing 
galanin, CGRP, IB4, P2X3, Reg2, N52 and/or TRPV2 were determined by counting 
the number of immunoreactive and non-immunoreactive cells. The number of 
positive cells was then calculated as a percentage of the total number of counted cells. 
Double labelling was determined by switching between TRITC and FITC filter 
blocks. At least 500 cells were counted from each animal, taken from an average of 
50 images. DRG cells did not need to have a nucleus to be counted, and therefore the 
possibility that 1 DRG cell was counted more than once cannot be excluded. 
However, this is very unlikely as multiple slides were prepared from each ganglion
and consecutive sections were mounted onto different slides. 
2.6. Profile area analysis 
Using Scion Image Analysis software (Scion Corporation, MD, USA), DRG profile 
areas from immunoreactive and/or non-immunoreactive and/or double-labelled
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captured images were measured. Images were captured using Hamamatsu C4742-95 
digital camera directly off the microscope at 40-times magnification, and plates were 
assembled using Adobe® Photoshop®. Profiles were outlined manually using a 
computer mouse and analysed, using appropriate scaling to account for magnification. 
At least 200 cells of each type were counted. Categorisation of DRG as small (area 
≤800mrelated diameter ≤31.9mmedium to large (area >800 – 1999m2
[related diameter 31.2-50.49m]) and large (≥2000m2 [related diameter ≥50.5m])
was used (Priestley et al., 2002). Profile area information was imported into 
Microsoft® Excel® and analysed using these standardised categories to produce
histograms. 
2.7. Statistical methods
Data were analysed using InStat® statistical analysis package (GraphPad Software 
Inc. CA, USA). Significance was calculated for simple comparisons, using one- or 
two-tailed Student’s unpaired t-test, where P<0.05 was considered significant, 
P<0.01 considered very significant and P<0.001 considered extremely significant.
Standard deviation (SD) and standard error of the mean (SEM) were calculated for 
each mean of combined data. Welch’s correction was applied to the t-test if SDs were 
considered different. Multiple comparisons were analysed using one-way analysis of 
variance (ANOVA) with Tukey-Kramer post-hoc analysis, where P<0.05 was 
considered significant, P<0.01 considered very significant and P<0.001 was 
considered extremely significant. Multiple comparisons to naïve expression were 
carried out using Dunnett’s analysis, where P<0.05 was considered significant.
The relative difference between time points was calculated as least mean 
difference, where P<0.05 was considered significant. All data are expressed as 
mean±SEM unless otherwise indicated. 
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3. METHODS: IN VITRO
3.1. Preparation of DRG cultures
DRG cultures were prepared according to the methods of Gavazzi et al., (1999). DRG 
were dissected from male Wistar rats (1-3 month old; 200–300g), sacrificed with CO2
(4%). Ganglia were removed from all spinal levels under the dissection microscope
and stored in Ham’s F12 (Gibco, Paisley, UK). After trimming the DRG roots in 
Ham’s F12 using dissection scissors under a dissection microscope, cells were 
chemically dissociated with 0.125% collagenase (Sigma-Aldrich) (2x45 mins in a 
humidified 37C atmosphere containing 5% CO2). After washing the DRGs three 
times with Ca2+/Mg2+-free PBS, removing the serum and collagenase, further 
enzymatic dissociation was achieved with 0.25% trypsin (Sigma), in Ca2+/Mg2+ free 
PBS for 30 minutes at 37ºC. After washing (3x) in 1 mL F12, ganglia were then 
mechanically dissociated by trituration with a Gilson pipette (P1000). The cell 
suspension was centrifuged (5-mins; 400 rev.min-1), the culture media was replaced 
by carefully extracting the media using a pipette, and re-suspended in 1ml of defined 
media (BSF2 - 1% N2 supplement (Invitrogen, UK), 0.3%BSA (bovine serum 
albumin) Fraction V (Sigma), 100 unit ml-1 penicillin/100 μg ml-1 streptomycin 
(Sigma) in Ham’s F12 media recipe taken from Bottenstein and Sato, 1979). The 
resultant cell suspension was re-centrifuged (1000 r.p.m.; 10mins) through a cushion 
of 15% bovine serum albumin (BSA; Sigma-Aldrich); this procedure eliminates much 
of the cell debris and results in an enriched pellet of dissociated neurons. 
The medium was removed and replaced with BSF2 (1mL) containing 2% 
foetal calf serum (Sigma, UK). DRG cell density was estimated after second 
centrifuge step, using a Neubauer haemocytometer and the light microscope. Mean 
number of cells, per mL of suspension, was calculated. A 10μl sample of final cell 
suspension was applied to the Neubauer haemocytometer. 
The Number of cells in suspension = Mean number cells x104 ml-1 in volume 
of suspension. 
From this, the number of cells per μl was calculated to determine the volume 
of cell suspension required to give an average density of between 800–1,200 cells per 
well. This range was maintained throughout all in vitro culturing experiments. 
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Eight-well Lab-Tek™ chamber slides (Chamber Slide™ System, Nunc, NY, 
USA) were pre-coated with poly-L-lysine (5μg/mL; Sigma-Aldrich) in Ham’s F12 
medium under UV light overnight. Chamber slides were rinsed with distilled water 
three times using a Pasteur pipette and slides were left to air dry in the tissue culture 
hood. Culture slides were either stored wrapped airtight for future use or coated with 
10 μg/ml laminin (Sigma-Aldrich), in Ham’s F12 medium, for 1.5 hrs and then 
washed off with Ham’s F12 Medium. Wells were thoroughly aspirated before use. 
The dissociated neurons were plated on laminin-coated Lab-Tek™ slides at
concentration of 800-1,200 cells/well. 
3.2. In vitro protocols
Neuronal cultures were incubated for 24-72 hrs at 37C in humidified atmosphere 
containing 5% CO2 prior to fixation with 4% PFA or ice-cold methanol (kept at 
4°C). The culture media comprised either BSF2 containing 2% foetal calf serum 
(Gibco, UK), or BSF2 enriched with 2% foetal calf serum and supplemented with 
interleukin 6 (IL6; NIBSC, Hertfordshire, UK). IL6 (40 ng/mL) was added to BSF2-
supplemented media and cells were grown for between 18–72hrs. This concentration 
was selected as physiologically relevant from literature searches, reference value 
supplied with cytokine from manufactures, and known concentrations of IL6 used by 
colleagues. 
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3.3. Fixation procedure
DRG cultures can be fixed after a given growth period in a number of different 
fixatives, and control experiments were carried out using 4% PFA and ice-cold 
methanol (stored at 4°C). Ice-cold methanol may reduce background interference, and 
improve clarity of staining. To determine the most appropriate fixative, DRG cell 
cultures were fixed with ice-cold methanol or 4% PFA and stained for axonal 
markers, such as -tubulin, or peptides, such as galanin (discussed in Section 3.4).
Staining for -tubulin was comparable between two fixatives. However, 4% PFA 
produced higher quality staining for peptides (Figure O) in comparison with ice-cold 
methanol. Therefore to maintain consistency, limit variability and produce highest
clarity images 4% PFA was used throughout. 
Figure O: Representative microscope image of primary adult DRG cells cultured and fixed 
after 48hrs growth with 4% paraformaldehyde (PFA, left) or ice-cold (4°C) methanol (right)
and immunostained using indirect immunofluorescence for galanin. Note clear granular 
appearance of galanin staining (indicated with arrows) of the PFA-fixed cells, compared to 
the diffuse staining shown after ice-cold methanol fixation. Scale bar represents 50 m. 
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3.4. Immunostaining: Cultures 
Using standard single- or double-stained indirect immunofluorescence, incubations 
involved 18-48 hrs in primary antibody and 2-4 hrs in developing secondary antisera. 
As with tissue sections, preliminary control experiments were carried out 
(Section 2.3). Neither normal donkey serum nor secondary antibodies caused 
immunoreactivity when incubated on cultures slides alone. 
Slides were washed on a rocking platform (3x 10mins), in fresh PBS between 
each antibody incubation step. Indirect antibody staining was carried out at room 
temperature and incubated overnight at 4°C. Primary and secondary reagents were 
prepared from stock solutions in PBS-azide. Dilution experiments were conducted 
using antibody concentrations around a standard value used in literature, dilutions 
used in in vitro experiments, and the following concentrations were used. 
Primary antisera preparations were: rabbit anti-galanin polyclonal antibody 
(BMI-GA1161, Affiniti; 1:1,000); mouse  anti--tubulin (type III) polyclonal 
antibody (T8660, Sigma-Aldrich; 1:1,000); biotinylated Griffonia Simplicifolia IB4 
lectin (Sigma-Aldrich; 1:250); goat anti-CGRP polyclonal antibody (sc8857, Santa 
Cruz, CA, USA; 1:100); mouse anti-ED1 monoclonal antibody (anti CD68, 
MCA341R, Serotec; 1:700); rabbit anti-Reg2 monoclonal antibody (1:5-10,000; Gift 
Prof. S. Hunt); rabbit anti-p-STAT3 (Cell Signaling Technology, Hertfordshire, UK;
1:50-1:2,000); rabbit anti-NPY polyclonal antibody (NA1233, Affiniti; 1:2,000). 
Secondary antibodies used were: donkey anti-rabbit-TRITC (Jackson 
ImmunoResearch; 1:400-600) or –FITC (Jackson ImmunoResearch; 1:400); avidin-
extra FITC (Sigma-Aldrich; 1:600); donkey anti-guinea pig FITC (Jackson 
ImmunoResearch; 1:400); donkey anti-mouse- TRITC (Jackson ImmunoResearch; 
1:600-400) or -FITC (Jackson ImmunoResearch; 1:400); donkey anti-goat FITC 
(Jackson ImmunoResearch; 1:400).
All cultures were counterstained with 4,6-diamino-2-phenylindole (DAPI) 
(Sigma-Aldrich; 1:15,000) to show cell nuclei. After staining, slides were mounted 
with cover slips using 1:8 solution of PBS glycerol. Slides were viewed as outlined in 
Section 2.5. Slides were stored in PBS (4°C) until immunostained. 
3.5. Quantification: neurite outgrowth 
Neuronal cells were analysed for cell survival, branching pattern and neurite 
outgrowth. Beta-tubulin-positive neurons double stained with DAPI were counted to 
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determine cell survival. Although cells were plated at a fixed density of 800-1,200 
cells/per well, counts for cell survival was normalised to percentage cell survival at 
given time points. This made cultures directly comparable since any variation in 
plating of cells had been removed. 
Proximal outgrowths from the cell soma were counted to determine the mean 
number of outgrowths per cell at a given condition or time point. The overall neurite 
pattern of each -tubulin positive neuron was identified using three categories: none 
(soma only), simple (somas with a proximal outgrowth but without secondary 
branching), or complex (somas where at least one proximal outgrowth has secondary 
branching). Early cultures (18-24 hrs) were analysed for presence of neurite 
outgrowths in presence and absence of IL6. 
3.6. Quantification: Peptide expression 
Peptide expression in cultured DRG cells was determined by counting proportion of 
-tubulin-positive cells co-expressing either CGRP, galanin, IB4 or P2X3 in their cell 
bodies. DAPI stain was used to differentiate between neuronal and non-neuronal cells 
in the culture, by the size of the cell nucleus under the microscope. The number of 
positive cells was then calculated as a percentage of the total number of counted cells. 
Double staining was determined by switching between TRITC and FITC filter blocks. 
Data were analysed and statistical significance calculated as outlined in Section 2.7.
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Aim 1: To investigate changes in galanin expression in subpopulations of DRG cells, 
immediately after L5 spinal nerve ligation (SNL) 
4. RESULTS: IN VIVO DATA
4.1. Galanin is expressed in DRG of uninjured (naïve) rats
Galanin immunoreactivity (IR) was identified in 4.9% of DRG cells from non-injured
animals (Figure 1; Table 1). Galanin-IR cells showed distinct immunostaining 
characteristics confined mainly to smaller cells. Some immunoreactivity was also
observed in some satellite cells around DRG. 
Figure 1. Micrographs depicting galanin expression in DRG cells from naïve animals. (A) 
Scale bar represents 100 µm; (B) scale bar represents 50 µm. Arrows indicate positive cells. 
Note galanin-positive cells are predominantly the smaller cells.
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4.2. Galanin expression increases in DRG cells, 1-day post L5 SNL
Galanin expression increased in ipsilateral DRG cells, 1-day post L5 SNL to 20.3%, a 
significant increase in 15.4% of DRG compared with naïve levels (Table 1 and 
Figure 2). Galanin-IR in contralateral DRG remained low (7.28%) and not 
significantly different from naïve expression (P>0.05). Galanin-IR presented with 
distinct vesicular characteristics as observed from naïve sections. Under the light 
microscope some differences were noted between galanin characteristics from 
contralateral and ipsilateral sections. Subcellular localisation was accordingly 
analysed using the confocal microscope.
1 day L5 SNL
NAÏVE 
(n=3)
IPSILATERAL 
(n=4)
CONTRALATERAL 
(n=4)
%DRG = GAL 4.870.8 20.271.4** 7.280.2
Mean increase 
from naïve 
– 15.40% 2.41% 
**P<0.01 compared with naïve or with contralateral. 
Table 1: Galanin (GAL) expression (mean %±SEM) in DRG profiles of naïve animals, and 
DRG profiles of animals 1 day after L5 SNL. 
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Figure 2. Micrographs depicting galanin immunoreactivity in L5 DRG profiles. (A,B) 
Naïve animals, (C,D) contralateral L5 DRG, 1 day after L5 spinal nerve ligation (SNL); (E,F) 
ipsilateral DRG, 1 day post L5 SNL. Left side panels (A,C,E) scale bar represents 100 m; 
right side panels (B,D,F) scale bar represents 50 m.
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4.2.1. Galanin has distinct subcellular characteristics between naïve DRG and 1
day post-L5 SNL
Galanin expression was observed in two distinct staining characteristics from 
ipsilateral and contralateral DRG sections, 1-day post L5 SNL (Figure 3). ‘Punctate’, 
spot-like staining was commonly seen in contralateral sections (Figure 3A), 
compared with ‘patchy’ staining visualised on the ipsilateral side (Figure 3B). 
Irrespective of the subcellular distribution characteristics, galanin was visualised in 
smaller cells, and DRG area analysis was carried out to investigate the relationship 
between galanin-IR in ipsilateral and contralateral cells. It was not investigated in 
detail, but faint galanin immunoreactivity was occasionally observed in satellite cells 
around DRG cells. 
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Figure 3. Micrographs depicting subcellular characteristics of galanin in: (A) control 
(contralateral [contra]); and (B) injured, ipsilateral L5 DRG profiles, 1 day after L5 spinal 
nerve ligation (1day L5 SNL). ‘Punctate’, vesicular-like staining can be seen on contralateral 
side (A), compared with ‘patchy’, Golgi-like staining on ipsilateral side (B). See text for more 
details. Scale bar represents 10 m. 
L
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4.2.2. DRG area distribution remained similar following L5 SNL 
As a control, the size of DRG were analysed to determine if a shift in cell-size 
distribution occurs following L5 SNL. The distribution of DRG on the ipsilateral side 
1 and 7 days post-L5 SNL was similar to naïve distribution (Table 2) with the 
exception of large area DRG (≥1,200 μm2 naïve vs. 1 day L5 SNL). 
DRG area
(μm2)
Naïve
(n=5)
1day ipsi
L5 SNL 
(n=4) 
7day ipsi
L5 SNL
(n=4) 
0-800 54.0 ± 3.9 61.2 ± 1.0 58.5 ± 1.0
801-2000 32.8 ± 4.4 35.1 ± 1.3 38.5 ± 3.8
>2000 12.9 ± 9.3 3.6 ± 1.4* 9.0 ± 3.0
Table 2: Profile area distribution (mean ± SEM) in m2) of DRG profiles, from naïve, 
ipsilateral (ipsi) 1 day and 7 day post L5 SNL; n=4 per group. *P<0.05 vs. naïve. 
4.2.3. Galanin is expressed in small sized DRG cells following L5 SNL 
Confirming visual observations, more than 85% of galanin-positive DRG in both 
naïve and ipsilateral profiles from 1 day L5 SNL animals had small area (≤800m2
[diameter ≤31.9m]; Table 3). Mean (±SD) diameter of galanin-positive DRG 1 day 
post L5 SNL was 23.5 ± 5.8m.
DRG area
(m2)
Naïve galanin
(%)
1day ipsi
galanin (%)
0 –800 86.03 ± 3.7 83.09 ± 4.9
801-1200 13.05 ± 3.6 16.0 ± 3.6
>1200 0.95 ± 0.5 1.00 ± 0.2
Table 3: Area distribution (mean ± SEM in m2) of galanin-positive DRG, from naïve and 
ipsilateral (ipsi) 1 day spinal nerve injury animals; n=4 per group.
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4.3. IB4 and P2X3 identify the same population of small DRG cells
Small diameter DRG cells were characterised using CGRP to identify peptidergic 
DRG, and lectin IB4 or P2X3 to identify non-peptidergic DRG. The correlation 
between IB4 and P2X3 was confirmed in initial experiments from naïve animals. 
Analysis determined >90% of P2X3-positive DRG cells co-expressed IB4 
(P2X3=IB4 91.3%±0.6; Figure 4A), although visually the characteristics of the two 
antibody stains were distinct. The proportion of IB4 cells expressing P2X3 was 
slightly lower (%IB4=P2X3 75.0±4.3). IB4 was characterised with patchy staining 
often located in the periphery of cells, compared with the diffuse staining across the 
cell body for P2X3. Profile area analysis demonstrated significant overlap between 
the two DRG populations (see Figure 4B). Furthermore, mean (±SD) diameter of 
P2X3 DRG (30.0±8.5m) was not significantly different from IB4 DRG
(30.4±5.9m). 
Percentage analysis of ipsilateral IB4-IR, 1 day after L5 SNL indicated a 
slight, but non-significant, down-regulation (see Table 4). However, 1-day post L5-
SNL, there was no significant difference between IB4 and P2X3 percentage 
expression on ipsilateral side (35.22%±3.0 vs. 32.30%±1.6, respectively; Table 4). 
Percentage expression and profile distribution analysis for P2X3 were found to be 
unchanged during the time frame analysed (see Table 4) (naïve, 1day, 7day; Tukey-
Kramer P>0.05), indicating that P2X3 was a stable marker of the same population of 
cells up to 7 days following L5 SNL injury, although a downward trend was seen on 
the ipsilateral side by Day 7. IB4 immunoreactivity was completely lost by day 7 post 
L5 SNL, as expected from the literature. Collectively, these data were interpreted to 
confirm that P2X3 provides a consistent representation of the small diameter non-
peptidergic cells for up to 7 days following L5 SNL. 
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Figure 4. Comparing IB4 and P2X3 populations in naïve DRG. (A) Micrographs illustrating 
IB4/P2X3 co-expression in naïve DRG profiles: (A) P2X3 immunostaining; (B) IB4 lectin 
staining. Note: the majority of cells are co-labelled. Arrow indicates a rare IB4-positive, 
P2X3-negative cell. Scale bar represents 50 micrometers. (B) Profile area analysis illustrating 
P2X3 (red) and IB4 (blue) correlation in naïve DRG; n=4 per group; error bars represent 
SEM. 
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4.4. Galanin is expressed in different categories of DRG cells, 1 day post
L5 SNL
Galanin expression was markedly increased 1 day after L5 SNL, however relatively 
few of the galanin cells (<15%) colabelled for IB4 (Table 4; Figure 5) or P2X3 
(Table 4). In contrast, more than half of all galanin cells colabelled for CGRP 
(61.6±10.4% on the ipsilateral side; Table 4; Figure 6). This represents nearly half 
(48%) of the CGRP-cells analysed (%CGRP=GAL), although overlap will exist 
between populations (Figure 7). 
Supporting the co-labelling of IB4/P2X3-cells, no significant difference was 
found between the percentage of galanin cells double-labelled with IB4 or P2X3, on 
the ipsilateral side 1 day after L5 SNL (%GAL=IB4, 14.07±2.7% vs. %GAL=P2X3 
14.62±5.8%; P=0.933; see Table 4). Furthermore, no significant difference was 
found between the proportion of IB4 or P2X3 populations expressing galanin 
(%IB4=GAL vs. %P2X3=GAL, difference 1.52%; P=0.754; Table 4). Upregulation 
of galanin 1 day ipsilateral vs. 1 day contralateral expression was significant in the 
IB4 population (2.0 vs. 9.9; P<0.05) but not in the P2X3 population. 
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1 DAY L5 SNL
NAÏVE 
(n=3)
IPSILATERAL 
(n=4)
CONTRALATERAL
(n=4)
%DRG = GAL 4.870.8 20.271.4** 7.280.2
% DRG = IB4 41.333.3 35.223.0 43.424.5
% DRG = P2X3 32.840.7 32.301.6 34.903.3
% DRG = CGRP 26.640.40 31.501.8 29.011.0
% GAL = IB4 10.004.3 14.07±2.7 13.39±1.2
% GAL = P2X3 13.62.3 14.625.8 10.424.0
% GAL = CGRP 68.164.8 61.6±10.4 69.2210.2
% IB4 = GAL 1.100.76 9.912.4* 2.020.38
%P2X3 = GAL 1.430.13 8.394.0 1.990.65
% CGRP = GAL 17.051.2 48.0±13.8* 20.053.0
Data are shown as percentage meanSEM. * = P<0.05; ** = P<0.01 compared with 
naïve. There was no significant different between contralateral and naïve expression for 
any marker.
Table 4: Immunohistochemical analysis of galanin (GAL), IB4, P2X3 and/or CGRP 
expression in adult rat DRG naïve (uninjured) profiles and 1-day ipsilateral and contralateral 
expression post L5 spinal nerve ligation (L5 SNL).
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Figure 5. Micrographs depicting galanin and IB4 expression in L5 DRG profiles 1 day after 
L5 spinal nerve ligation (SNL). (A,C) IB4 (green) and (B,D) galanin (GAL; red) expression in 
contralateral (A,B) and ipsilateral (C,D) L5 ganglia. Some galanin immunoreactivity can be 
observed in satellite cells around DRG. Note: in general cells are not double labelled, 
although asterisk indicates a rare double-labelled cell. Scale bar represents 50 m.
*
m
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Figure 6. Bar chart representation of galanin (GAL)-positive DRG profiles co-expressing, 
IB4, P2X3 or CGRP. Data are expressed as percentage of entire DRG, at 1 day post-L5 spinal 
nerve ligation (L5 SNL); green section of each bar represents percentage GAL-positive cells 
expressing second marker, red section of each bar represents GAL-positive cells not 
expressing second marker. Naïve GAL expression is given as a comparison on left-hand side; 
error bars represent SEM for galanin expression of each bar. Galanin expression is not 
significantly different across three groups (P=0.231). Combined mean±SEM = 20.27±1.4%.
Ipsi 1-day L5 SNL
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Figure 7. Micrograph depicting CGRP (green) and galanin (GAL; red) expression in 
contralateral (A,B) and ipsilateral (C,D) L5 DRG profiles 1 day after L5 spinal nerve ligation
(SNL). Note: in general, cells are double-labelled especially compared with Figure 5. Scale 
bar represents 50 m.
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4.4.1. Galanin and CGRP have distinct subcellular characteristics, at 1 day
post L5 SNL
CGRP and galanin co-expression was widely identified in both contralateral and 
ipsilateral DRG sections, 1 day after L5 SNL (GAL = CGRP 50-70%). Using 
scanning confocal microscopy, DRG cells co-expressing galanin and CGRP showed 
distinct characteristics (Figure 8). 
CGRP showed predominately ‘patchy’ Golgi-like staining in both 
contralateral (control) and ipsilateral DRG cells (see Figure 8b,d). This contrasts the
‘punctate’ vesicular-like characteristic of galanin on the contralateral side (see Figure 
8a). In ipsilateral DRG cells, galanin can be seen in ‘patchy’ staining, similar to, and 
in correspondence with CGRP staining (see Figure 8c). This is likely indicative of 
the fact that the CGRP/galanin cells 1 day after L5 SNL are expressing newly-
synthesised galanin. As at 1 day on the confocal microscope, galanin was not 
observed in satellite cells around DRG.
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Figure 8. Micrographs depicting confocal images of galanin (GAL, red) and CGRP (green) 
immunostaining in control (contralateral; a,b) and ipsilateral (c,d) L5 DRG profiles, 1 day 
after L5 spinal nerve ligation (L5 SNL). Arrows indicate double-labelled cells. Note that in 
both control and injured ganglia, the galanin immunoreactive cells are also CGRP 
immunoreactive. In control ganglia, the CGRP-cells have ‘punctate’ galanin staining. In the 1 
day L5 SNL, the CGRP-cells have ‘patchy’ galanin staining. Note difference in galanin 
staining characteristics (a,c), compared with same characteristic CGRP staining (b,d) after 
injury. Scale bar represents 10 m.
99
Aim 2: To determine if galanin is upregulated in different populations of DRG cells 
at 7 days after L5 spinal nerve ligation, than found immediately after nerve injury
4.5. Galanin is upregulated in DRG cells, 7 day post L5 SNL
Galanin-IR was visualised in ~50% of DRG cells 7 day after L5 SNL (48.29±1.7%; 
see Table 5). This represented a highly significant increase compared with naïve 
(mean increase 43.43%; P<0.001) and to expression in ipsilateral DRG, 1 day post L5 
SNL (mean increase 28.02%; P<0.001). 
Subcellular characterisation using confocal microscopy showed the majority 
of ipsilateral galanin-positive cells had ‘patchy’ (Golgi) staining (Figure 9B). Few
ipsilateral cells had ‘punctate’ (vesicle) staining (Figure 9A). Contralateral 
distribution was similar to 1 day contralateral distribution, where the majority of cells 
showed ‘punctate’ (vesicle) characteristics. 
Figure 9. Micrographs depicting subcellular characterisation of ipsilateral galanin (GAL), 7 
days after L5 spinal nerve injury. (A) Examples of ‘punctate’ galanin staining (arrowheads) 
(B) Examples of ‘patchy’, Golgi-like staining (arrows). Scale bars represents 20 m.
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4.5.1. Galanin is upregulated in some medium-area DRG, 7 days after L5 SNL
Profile analysis of galanin-positive DRG cells 7 days post L5 SNL showed an ~10% 
increase in medium- and large-sized DRG (area ≥800 m2), relative to naïve 
expression (23.5% vs. 14.0% respectively; Figure 10), however mean diameter of 
galanin-positive DRG cells 7-days post L5 SNL was 23.5±6.2m, similar to 
ipsilateral 1 day L5 SNL (23.5 ± 5.8m). Double labelling was thus needed to 
characterise the cell populations in which galanin was expressed at 7 days post L5 
SNL compared with at 1 day. 
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Figure 10. Histogram representing profile area analysis of galanin-positive DRG profiles, in 
ipsilateral L5 DRG 7 day post L5 spinal nerve ligation (SNL) (red; n=5) or in naïve DRG 
(blue; n=4); error bars represent SEM.
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4.6. Galanin is expressed in different categories of DRG cells, 7 days 
post L5 SNL
Galanin was upregulated in different DRG populations 7-days post L5 SNL (Table 
5). A significant increase in P2X3 cells co-expressing galanin was found, compared 
with both naïve and 1 day L5 SNL (P<0.05 for both; see Table 5, Figure 11), with 
nearly 30% of galanin cells co-labelled with P2X3 by 7 days post L5 SNL (103% 
population increase from co-expression at 1 day post-L5 SNL). As expected, IB4 
staining was near completely lost from ipsilateral DRG at 7 days post L5 SNL 
(%DRG = IB4: 0.29±0.1%, highly significant decrease compared with 1 day L5 SNL 
and with contralateral; P<0.001 respectively). P2X3 was used to represent the small 
diameter, non-peptidergic population (see Section 4.3).
At 1 day after L5 SNL, 62% of galanin cells coexpressed CGRP (Table 5). At
7 day post L5 SNL, this percentage halved (31.5±5.0%; see Table 5, Figure 11). 
However, this information is somewhat misrepresentative due to the large 
upregulation of galanin. When analysing the percentage of CGRP cells expressing 
galanin in the ipsilateral DRG 1 and 7 day after L5 SNL, no significant difference 
was found (%CGRP = GAL; 48.0% vs. 42.7%, respectively; P>0.05 see Table 5). 
This suggests a similar proportion of CGRP cells (43-48%) that upregulate galanin 
immediately after L5 SNL, still express galanin at Day 7. 
Profile analysis 7 days post-L5 SNL showed an increase in galanin expression 
in some large area DRG (Figure 10). In agreement with this, a significant increase in 
N52/galanin co-expression was found (increase of 10.2% co-expression from 
contralateral; Table 5, Figure 12). However, upregulation was noted more readily in 
medium diameter cells compared with larger diameter (Figure 10). These DRG 
profiles were characterised further with TRPV2. 
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Table 5: Immunohistochemical analysis of galanin (GAL) and/or P2X3, IB4, CGRP, N52 
and TRPV2 expression in adult DRG profiles, 7 day post L5 spinal nerve ligation (L5 SNL). 
Data are meanSEM; n=3-7, unless otherwise specified. Significance was calculated using 
unpaired Student t-test, or one-way ANOVA with Tukey-Kramer post-hoc analysis.
1 day L5 SNL 7 day L5 SNL
IPSILATERAL IPSILATERAL CONTRALATERAL
% DRG = GAL 20.161.4 48.29±1.7***† 4.820.4
% DRG = P2X3 32.301.5 39.42.8* 27.82.2
% DRG = IB4 35.223.0 0.290.1***† 37.46±1.6
%DRG = CGRP 31.501.8 35.894.2 32.691.8
%DRG = N52 46.5 (n=2) 39.402.4 44.551.1
%DRG = TRPV2 - 14.330.4 12.942.4
%GAL = P2X3 14.625.8 29.751.6* 12.723.4
%GAL = CGRP 61.6±10.4 31.464.9**‡ 76.974.9
%GAL = N52 4.03 (n=2) 13.561.6**† 3.361.0
%GAL = TRPV2 – 9.440.4** 1.040.6
%P2X3 = GAL 8.394.0 35.773.1**† 1.870.7
%CGRP = GAL 48.0±13.8 42.692.5* 11.482.3§
%TRPV2 = GAL – 33.68±1.2*** 0.42±0.3
* = P<0.05; **=P<0.01; ***= P<0.001 compared 7 day ipsilateral with respective contralateral 
(control) data. ‡P<0.05 compared 7-day ipsi L5 SNL with 1-day ipsilateral data; †P<0.001 compared 
7-day ipsi vs. 1-day ipsilateral data. §P<0.01 compared with 1-day ipsilateral (see Table 4 contralateral 
data). 
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Figure 11. Micrographs depicting galanin co-expression in ipsilateral L5 DRG profiles, 7 
days after L5 spinal nerve ligation. (A,B) Co-expression of galanin (A) in CGRP cells (B). 
(C,D) Co-expression of galanin (C) in TRPV2 (VRL1) cells (D). (E,F) Co-expression of 
galanin (E) in P2X3 cells (F). Scale bars represent 50 m. Arrows indicate some of the 
double-labelled cells.
           E        F
           C        D
           A        B
TRPV2
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Figure 12. Micrographs depicting galanin (GAL; red) and N52 (green) (co)expression, in 
ipsilateral DRG profiles, 1- (A,C,E) and 7 (B,D,F) days after L5 spinal nerve ligation. A,B 
and C,D show green and red filters separately, respectively; E and F images show merged
images. Scale bars represent 100 m. Note lack of co-expression at 1-day (angled arrows; E) 
and presence of co-expression (indicated by horizontal arrows and yellow cells) after 7-days; 
F).
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4.6.1. Galanin is upregulated in TRPV2 DRG cells, 7 days after L5 SNL
DRG profile analysis 7 day post-L5 SNL showed that large DRG (area ≥1200m2; 
diameter ≥39.1m) did not generally express galanin-IR. This suggested myelinated 
(N52) cells expressing galanin are most likely medium-diameter myelinated cells 
(area of 800-1200m2). An interesting population of thinly myelinated, medium-
diameter cells are the Apopulation that uniquely express the high-threshold 
temperature sensor, TRPV2 (medium to large diameter mean±SEM: 29.1±0.6m; 
Caterina et al., 1999). 
A significant increase in galanin cells co-expressing TRPV2 was found at 7 
day post-L5 SNL (accounting for ~10% of galanin-positive cells; see Table 5, Figure 
11). The overall expression of TRPV2 DRG cells remained unchanged between 
contralateral (control) and 7 day ipsilateral DRG sections (mean difference 1.34%; 
see Table 5; P>0.05).
4.6.2. Subcellular analysis of galanin in P2X3 cells, 7 day post L5 SNL
Galanin/P2X3 cells analysed by confocal microscopy showed the majority of galanin-
IR in P2X3-positive cells was ‘patchy’ (Golgi-like) (example Figure 13C). Galanin 
staining showing ‘punctate’ characteristics was rarely identified in P2X3-positive 
DRG (Figure 13B). This is similar to the patchy staining observed for galanin in 
some CGRP cells from ipsilateral DRG, 1 day post L5 SNL (for comparison see
Figure 9 c,d). 
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Figure 13. Confocal micrographs of galanin (GAL; red) expression in ipsilateral P2X3
(green)-positive and P2X3-negative DRG profiles, 7 day post-L5 spinal nerve ligation. (A) 
Characteristic P2X3 staining; (B) characteristic GAL staining, showing ‘punctate’ 
characteristic (arrowhead) in P2X3-negative cells, and patchy, Golgi-like characteristic in 
P2X3-positive cells. (C) P2X3/GAL double labelling. Scale bars represent 10 m.
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Aim 3: To investigate similarities and differences between expression of Reg2 with 
that of galanin after L5 spinal nerve ligation
4.7. Reg2 expression 1 and 7 days post-L5 SNL
Reg2 expression was rare in DRG from naïve animals (<1% DRG). Reg2 expression 
was upregulated 1 day after L5 SNL to 8.0% (n=2) of ipsilateral DRG cells 
(Figure 14; Table 6). Staining was visualised with a distinct pattern in this small 
proportion of cells. Profile analysis confirmed expression was primarily in ‘small’ 
cells (area ≤800m2) (see Figure 15). 
At 7 days post L5 SNL, preliminary observations showed Reg2 expression 
remained similar to 1 day post L5 SNL (7.2±0.5%; Table 6), although due to low n-
number at 1 day statistical significance could not be investigated. 
The types of DRG cell in which Reg2 was expressed differed between 1 and 7 
days, indicating dynamic changes in expression (Figure 15). Reg2 was located in 
larger cells at 7 days post L5 SNL compared with at 1 day. Analysis confirmed that 
72.1% had profile area ≥1200m2 compared with 76.5% of Reg2-positive cells being 
<1200m2 at 1 day (Figure 15). This population of DRG cells overlapped with the 
majority of myelinated N52 cells (see Figure 16). However closer inspection of these 
data shows the peak distribution of the Reg2-positive population was below that for 
N52-population (1000m2 Reg2 compared with 1500m2 N52). Accordingly, mean 
(±SD) diameter was lower for Reg2-positive DRG at 7 days L5 SNL (46.0±7.4m) 
compared with N52-positive DRG (48.6±12.0m). The N52 population did not 
change significantly on ipsilateral side with L5 SNL (Table 5).  
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Figure 14. Micrograph images showing Reg2 expression in ipsilateral DRG profiles: (A) 
1 day post-L5 SNL; and (B) 7 days post-L5 spinal nerve injury. Arrows show positive cells. 
Note the larger cell area for 7 days compared with 1 day. Scale bar represents 50 m for both 
(A) and (B).
1 day L5 SNL 7 day L5 SNL
CONTRA IPSI CONTRA IPSI
%DRG = Reg2 1.00.4 8 (n=2) 0.470.1 7.2.0.5***
%DRG = GAL 7.290.4 20.161.4** 4.820.4 51.721.1
%Reg2 = GAL 0 <1 8.332.3 48.385.1***
%GAL = Reg2 0 <1 0.280.3 4.880.9*
%Reg2 = TRPV2 – – <1 (n=2) <1 (n=2)
*= P<0.05; ***= P<0.001 vs. respective contralateral. CONTRA = contralateral (control); 
IPSI = ipsilateral. 
Table 6: Percentage expression of Reg2 in DRG cells, 1 and 7 days after L5 spinal nerve 
ligation (SNL). Reg2 co-expression with galanin (GAL) and TRPV2, 1- and 7-days after L5 
spinal nerve injury is also shown; n=3-4 unless otherwise specified. 
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Figure 15. Histogram representing DRG profile area distribution (in m2) for Reg2-positive 
DRG (% expression), 1- (blue) and 7- (purple) days after L5 spinal nerve injury; n=2-4.
Figure 16. Line graph representation of percentage Reg2 and N52 profile area distributions 
for ipsilateral sections from 7 days post-L5 spinal nerve ligation (n=4 for each). Note: N52 
population distribution does not change significantly on ipsilateral side after injury compared 
to naïve (uninjured) distribution (Table 5).
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4.8. Reg2 is co-expressed with galanin 7 days post-L5 SNL
Very few Reg2/galanin double labelled cells were present at 1 day after L5 SNL. 
However, Reg2 showed high coexpression with galanin 7 days after L5 SNL (48.38% 
Reg2 = GAL; see Table 6; Figure 17). In comparison, only 4.9% of galanin 
population were Reg2 positive (see Table 6). The upregulated galanin population was 
ten-fold larger than Reg2. 
Reg2 was identified in medium-diameter (800-1200 μm2) cells 7 days post L5 
SNL, when profile diameter was analysed (Figure 15), as found for galanin. 
However, the characteristics of these DRG cells were different. Reg2 was not found 
coexpressed in TRPV2 DRG cells (see Table 6; Figure 18). This is in contrast to
9.4% of galanin cells co-expressing TRPV2 at 7 days after injury (see Table 5). Reg2 
was also minimally co-expressed in CGRP-positive DRG cells 7 days post L5 SNL 
(Figure 18). This is also in contrast to that found with galanin. As only a few Reg2 
cells were identified however, statistical analyses were not carried out and these 
observations can only be considered as preliminary. 
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Figure 17. Micrograph images depicting Reg2 and galanin coexpression, 7 days post-L5 
spinal nerve injury in ipsilateral DRG sections. (A,B) Scale bar represents 100 m. (C,D) 
Scale bar represents 50 m. Arrows indicate double-labelled cells. Note: Reg2-positive cells 
not indicated by arrows are all galanin negative.
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Figure 18. Micrograph images showing Reg2 expression in ipsilateral DRG cells, 7 days after 
L5 spinal nerve ligation; (A,B) Reg2 independent expression from TRPV2-positive cells; 
(C,D) Reg2 independent expression from CGRP-positive cells. Arrows indicate 
independently-stained cells. Scale bar represents 50m for all panels
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5. DISCUSSION 1: IN VIVO DATA
Aim 1: To investigate changes in galanin expression in subpopulations of DRG cells, 
immediately after L5 spinal nerve ligation (SNL)
This study confirms the rapid and selective upregulation of galanin in ipsilateral, 
small diameter DRG cells by 1 day after L5 SNL, in agreement with other published 
studies immediately after different types of complete nerve transection (Averill et al., 
2002; Hökfelt et al., 1987; Kashiba et al., 1992; Shortland et al., 2006; Villar et al., 
1989). Percentage expression of galanin 1 day after L5 SNL (20%) was similar to that 
reported by others using this model after 1 day (17%: Shortland et al., 2006). Similar
galanin upregulation in L5 DRG have been recorded using the sciatic nerve injury 
model, which damages the majority of fibres projecting to L4-L6 DRG (Averill et al., 
2002 reported 22.5% and Villar et al., (1989) reported ~25% sciatic nerve crush). 
Contralateral galanin did not change after L5 SNL from that found in naïve (<5% of 
DRG). This observation is also in agreement with other published data showing 
galanin expression in non-injured DRG remains low (Averill et al., 2002; Hökfelt et 
al., 1987; Kashiba et al., 1992; Shortland et al., 2006; Villar et al., 1989). This 
consistency with other data helped to validate the reliability of the 
immunohistochemical methods and products used herein. 
The L5 SNL model was used throughout due to the advantages for analysing 
changes in adjacent injured and uninjured DRG. Galanin staining observed in DRG 
cells using the light microscope was granular and characteristic of that published by 
others (e.g., Shi et al., 2006; Verge et al., 1995; Villar et al., 1989; Zhang et al., 
1995a). 
To differentiate clearly whether newly-expressed galanin in DRG showed 
distinct characteristics compared with galanin in the naïve or contralateral DRG, 
scanning confocal microscopy was used. We observed distinct storage and
distribution patterns of galanin 1-day after L5 SNL. Firstly, galanin appeared ‘patchy’ 
primarily in ipsilateral DRG. The ‘patchy’ localisation was hypothesised to be 
representative of newly-synthesised protein in the Golgi. This hypothesis is supported 
by the characteristic being rare on the uninjured contralateral side. Secondly, a
‘punctate’ characteristic was also identified in ipsilateral DRG cells widely and 
evenly distributed within the DRG soma. Due to the widespread localisation and 
presence on the contralateral side, and almost exclusively in naïve sections, the
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‘punctate’ characteristic was hypothesised to represent vesicular galanin packaged 
and distributed for release or transport. These assumptions are supported by data 
reporting that galanin can be stored and located in vesicles (Zhang et al., 1995b) and 
that galanin turnover in the normal animal is low, due to minimal release in the basal 
state (Hope et al., 1994; Hygge Blakeman et al., 2001). Using antibodies specific for 
the storage vesicles could further support these conclusions, or ultra-structural
analysis using electron microscopy. 
In contrast to the clear difference in galanin staining after injury between 
contralateral and ipsilateral sections under the confocal microscope, CGRP was 
principally found as ‘patchy’, Golgi-like staining in DRG from both contralateral and 
ipsilateral sections. In line with the hypothesis that ‘patchy’ staining is peptide being 
synthesised in the Golgi, data have been presented to suggest that CGRP is not widely 
stored in DRG after injury. Indeed, it has been discussed that CGRP turnover is high 
(Ma and Bisby, 1998), with continuous transport of CGRP to peripheral terminals and 
release (Mason et al., 1984). However it is possible that the antibody used may not 
recognise CGRP when packaged into vesicles. The overlap of CGRP with galanin 
staining in ipsilateral DRG cells suggested co-localisation in vesicles, in agreement 
with previous electron microscopy studies (Zhang et al., 1995b). Some galanin 
immunoreactivity could be seen in satellite cells around DRG in naïve animals, and 1 
or 7 days after nerve injury. This staining was not specifically investigated, and more 
in depth analyses and absorption controls would need to be carried out to confirm this 
visual observation as the staining was not generally seen under the confocal 
microscope.
A distribution range was produced for the normal and injured state that
correlated with known categories (small, medium, large) of DRG cells (see Lawson 
2002; Priestley et al., 2002; Shimosato et al., 2005). Although some variations were
noted across large diameter cells, the general range of DRG cells was similar before 
and after L5 SNL. 
Over 80% of galanin-positive DRG of naïve animals were below 800m2 in 
area (~31.9m diameter), consistent with other reports (Yoon et al., 2003), and at 1 
day after injury (Villar et al., 1989). These cell size data were taken to reinforce 
immunohistochemical data that galanin was expressed near exclusively in small-
diameter cells immediately after injury and in the naïve state, as presented by others 
(Averill et al., 2002; Hökfelt et al., 1987; Kashiba et al., 1992; Shortland et al., 2006; 
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Villar et al., 1989). Indeed, less than 1% of galanin-positive DRG cells at 1-day after 
L5 SNL had a large size (≥1200m2, ~39.1m diameter) in the range conventionally 
associated with the DRG cells of innocuous, myelinated fibres (see Lawson 2002; 
Priestley et al., 2002). 
Using double-labelling techniques with well characterised (Lawson 2002; 
Priestley et al., 2002; Stucky and Lewin 1999) immunohistochemical markers, 
galanin was found principally in CGRP-positive DRG cells immediately after injury, 
in-line with data reported previously (Villar et al., 1989; Villar et al., 1991; Yoon et 
al., 2003). CGRP identifies small-diameter peptidergic DRG cells (Kilo et al., 1997; 
Ohtori et al., 2007), and size was confirmed by area analysis. Almost 50% of the 
CGRP-positive DRG cells expressed galanin 1 day after L5 SNL, from an uninjured 
percentage of ~20%. This 30% increase in galanin co-labelling may correspond to the 
majority of newly-expressed galanin 1 day after L5 SNL, as indicated by a non-
significant increase in either IB4/P2X3 or N52 cells expressing galanin compared 
with uninjured expression. Data should be interpreted in light of the overlap which 
exists among DRG cell populations (Figure E). This rapid upregulation after injury 
of cells expressing galanin may indicate that galanin is newly synthesised. Indeed, 
confocal microscopy was interpreted to show that the majority of galanin in the 
uninjured state is in vesicular form. An alternative conclusion could be that the 
majority of galanin is formed and/or stored in a configuration before injury that is 
unrecognisable to the antibody. However, the antibody used should detect galanin 
precursor protein as well as the primary peptide (Biomol International, anti-rabbit 
Galanin antibody, Product Information, 2003), and therefore this should be unlikely. 
The focus of the project was the non-peptidergic IB4/P2X3-positive DRG 
cells. P2X3 was confirmed as a marker of the IB4-population of DRG cells for up to 
1 week after injury; with >90% of P2X3 cells expressing IB4. The percentage of IB4 
cells coexpressing P2X3 was slightly lower (75%) in the uninjured tissue. An
explanation for this discrepancy could be derived from the high overall expression of 
IB4 comprising 40% of naïve DRG cells, compared with 32% for P2X3. In published 
reports non-peptidergic cells comprised 30%-35% DRG cells (30% see Priestley et 
al., 2002; 35% see Bradbury et al., 2000). Alternatively, the inconsistency could be 
partly due to the P2X3 antibody recognising a ligand-gated ion channel, whereas 
lectin IB4 recognises a surface carbohydrate (Bradbury et al., 1998; Burnstock, 2000; 
Stucky and Lewin 1999). 
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P2X3 was used as a secondary marker for the non-peptidergic population at 
all time points as by 7 days after injury, IB4 was down-regulated and near completely 
lost on the ipsilateral side (<1% expression), as expected from the literature. 
Investigating a correlation between P2X3 with IB4 was deemed an important control 
as Bradbury et al., (1998) reported a 50% down-regulation of P2X3 after sciatic 
axotomy (Bradbury et al., 1998). This down-regulation was observed at 14 days 
following sciatic nerve injury and therefore outside the time window used in the 
present experiments. A non-significant downward trend for P2X3 was noted by 7 
days post L5 SNL, and experiments at later time points post-injury might likewise 
show loss of P2X3 staining with injury. It has been suggested that expression of 
P2X3 receptors on the cell membrane is significantly enhanced following spinal 
nerve injury, while the total expression of P2X3 channels remained unchanged (Kage 
et al., 2002). Thus, enhanced trafficking of P2X3 channels might be an important 
mechanism contributing to the increase in receptor function after nerve injury (Chen 
et al., 2005) and may also alter the expression observed at a given time point. Using 
staining for FRAP, or for the tyrosine kinase RET, which is expressed specifically by 
non-peptidergic cells (Durbec et al., 1996), to characterise the non-peptidergic 
population would provide a comparative control, with the dynamic changes reported 
and seen in both IB4 and P2X3. The time-dependent upregulation of galanin was 
investigated further at 7 days following L5 SNL. 
Aim 2: To determine if at 7 days after L5 spinal nerve ligation, galanin is 
upregulated in different populations of DRG cells than found immediately after nerve 
injury 
Galanin was upregulated and expressed in nearly 50% of DRG cells at 7 days post L5 
SNL; a significant upregulation from 1 day after L5 SNL. This expression is in line 
with other data after sciatic nerve injury (Averill et al., 2002 [1 day: GAL = 22.5%, 
7 day: 40.4%) Thompson et al., 1998 [1 day: GAL 11.53%, 28.07% 6 day]). The 
higher percentage found in the present experiment using the selective L5 SNL model 
might be expected as sciatic nerve injury damages fewer (40-60%) fibres in the L5 
DRG. 
Through confocal analysis, the majority of ipsilateral galanin was ‘patchy’, 
supporting the hypothesis drawn from 1-day data that ‘patchy’ expression is 
representative of newly-synthesised peptide. Galanin was slightly less distinct than 
117
found at 1 day, and this was likely due to use of a different antibody batch. However,
confocal microscopy facilitated differentiation between ipsilateral and contralateral 
sections (‘patchy’ vs. ‘punctate’), as observed after 1 day L5 SNL. 
Shortland et al., (2006) reported >70% of all DRG cells expressed galanin in 
ipsilateral DRG, 14 days after L5 SNL, and proposed that all DRG cells will express 
galanin if the entire nerve bundle has been severed. These data at 7 days post-L5 SNL
are consistent with a rapid upregulation within the first week after injury, and 
furthermore our confocal analysis shows a rapid synthesis of new protein in-line with 
this hypothesis. Others have shown galanin expression persists for up to 50 days 
following axotomy (Breecht et al., 1997). It would be interesting to investigate later 
time points of 2, 3 and 4-weeks post-injury using this selective L5 injury model to 
investigate whether or not 100% of DRG can express galanin. Further experiments 
are needed to confirm that galanin is transported from the DRG to peripheral and/or 
central terminals (Ma and Bisby, 1999). Although not confirmed in the present 
experiment, Villar et al., (1991) reported that galanin was upregulated in both the 
dorsal roots and sciatic nerve 14 days after spinal nerve transection, suggesting the 
lesion caused an increased transport of the newly-synthesised peptide both into the 
central and peripheral branches of the primary sensory neurons.
To support these immunohistochemical observations of peptide upregulation, 
identification of corresponding galanin receptors needs to be carried out to show that 
peptides have the ability to provide a physiological response. Investigating which 
subcategories of galanin receptors are present is particularly important given the 
negative or positive coupling of different receptor subtypes (Figure K). Furthermore, 
dynamic changes in galanin receptors have been noted following different types of 
nerve injury (Kar and Quirion, 1994; Zhang et al., 1998), potentially altering the end 
result for galanin signalling following injury. Investigations should also be correlated 
in different nerve injury models to compare and contrast the relative upregulation of 
galanin in different categories of DRG cell. For example, although the number of 
galanin positive cells increases in the DRG after a partial nerve injury, the proportion 
is substantially less than after complete sciatic nerve section (Hao et al., 1999; Shi et 
al., 1999). Accordingly, endogenous galanin may not play a significant role in 
suppressing nociceptive input after partial nerve injury, as the upregulation of galanin 
is moderate (Hao et al., 1999). The dynamic changes in galanin expression following 
L5 SNL have been correlated to changes in nociceptive sensation (Shortland et al., 
2006). However, Shortland et al., (2006) did not fully discriminate the categories in 
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which galanin was upregulated at 7 days post L5 SNL. Although the physiological 
role of galanin following nerve injury remains to be confirmed, the differential 
expression was investigated. 
Data herein demonstrate that galanin is upregulated in P2X3-labelled DRG by 
7 days after L5 SNL. This observation confirms indirect evidence that these non-
peptidergic cells should express galanin after nerve injury, based on the accumulation
of LIF in IB4 cells (Thompson et al., 1997), and the ability of intraneural LIF to 
upregulate galanin (Thompson et al., 1998). This is an important observation as non-
peptidergic cells are not regulated by NGF, and therefore the observation that galanin 
can be expressed in this sub-population of DRG cells is also suggestive of a separate 
mechanism contributing to galanin upregulation following nerve injury. 
Galanin was also upregulated in over 30% of TRPV2-positive DRG cells 
within 1-week of injury. Although the relevant analyses were not carried out, one 
may deduce that subcellular analysis of galanin in TRPV2 cells would show a similar 
characteristic of newly-synthesised (‘patchy’) peptide, based on the low expression of 
galanin in TRPV2 cells recorded on the contralateral side. Triple labelling analyses 
(e.g., using rabbit anti-TRPV2 plus rabbit (TSA) anti-galanin and mouse anti-N52) 
would confirm the cells are also thinly-myelinated. Thinly myelinated A-population 
are thought to be regulated by either NGF-trkA or GDNF-GFR (Figure E; Priestley 
et al., 2002), and determining in which TRPV2 cells galanin is expressed (e.g., trkA
or GFαR/TRPV2/galanin labelling) would be an interesting observation to determine 
which mediator(s) is driving this upregulation. Indeed, these cells are also regulated 
by NT3 via trkC and, thus this co-expression warrants further investigation. 
With a generalised loss of target-derived NGF following complete nerve 
injury, and considering experiments with NGF antibody in vitro showing that NGF 
negatively regulates galanin expression (Corness et al., 1998; Kerekes et al., 1997), 
one may deduce that NGF withdrawal contributed to the upregulation of galanin 
found immediately after nerve injury in trkA-regulated (peptidergic) cells. An 
independent mechanism must be responsible for the additional galanin upregulation 
in non-peptidergic DRG cells by 7-days after injury. This can be deduced as only a 
very small overlap of non-peptidergic cells expressing trkA has been identified 
(Priestley et al., 2002). Given non-peptidergic cells may express receptor components 
for neuropoietic cytokines (Qui et al., 1997; discussed by Priestley 2008), the 
influence of cytokines on galanin expression is discussed in CHAPTER 7. 
119
In summary, by 1 and 7 days after L5 SNL, newly-synthesised galanin was 
expressed in different populations of DRG cells that have been linked to transmission 
of nociception following nerve injury (Chen et al., 2005; Kage et al., 2002; Shimosato 
et al., 2005; Tominaga and Caterina 2004): small diameter, peptidergic and non-
peptidergic DRG cells, thinly-myelinated, peptidergic DRG cells, and thinly-
myelinated, high temperature threshold DRG cells recognised by TRPV2 (these DRG 
cells are not mutually exclusive). The fact that galanin was expressed in non-
peptidergic cells is an important observation, given that these cells do not express 
peptides basally. Indeed, peptides may not be expected to be expressed in these non-
peptidergic cells. As galanin has a number of important central functions with links to 
injury, including in development of neurons, in cognition and ageing, in addition to a 
putative role in nociception (reviewed by Hökfelt, 2005), the upregulation of galanin 
following nerve injury in differently regulated categories of sensory fibres warrants
further investigation.
Aim 3: To investigate similarities and differences between expression of Reg2 with 
that of galanin after L5 spinal nerve ligation
Contrasting expression of Reg2 with galanin, preliminary observations showed that 
expression in the naïve animal was low (Reg2 0-1% DRG), similar to that found with 
galanin (<5% DRG), however upregulation immediately after L5 SNL differed from 
galanin. Co-expression of Reg2 and galanin was widely found, at 7 days after L5 
SNL but not at 1 day. 
At 1 day after L5 SNL, preliminary experiments showed an average of 8% of 
DRG cells expressed Reg2. Only a low n-number (n=2) was achieved for Reg2 
immunohistochemical analysis in the present study for 1 day time point, and thus 
experiments would need repeating before firm conclusions can be drawn in the L5
SNL model. In particular, as other data might suggest Reg2 should show higher 
expression at 1-day, based on data from the sciatic nerve model (14.1%; Averill et al., 
2002). Indeed, the L5 SNL model might be expected to cause higher expression of an 
injury marker such as Reg2 than the sciatic nerve injury model. As discussed in 
CHAPTER 1, the selective L5 SNL model injures 100% of fibres in the L5 DRG 
compared with 50-80% of fibres from the L5 DRG when using the sciatic nerve 
injury model. Using ATF3 antibody would have confirmed that all fibres were injured 
in the L5 DRG, as would be expected. 
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The Reg2 observations should also be considered preliminary as during in 
vitro experiments, Reg2 antibody gave some inconsistent results (see Chapter 7). 
One possible explanation might be that the Reg2 antibody had decayed and was not 
fresh enough to work optimally. The antibody was made up from frozen (stored at –
80°C) stock, and diluted to a stock solution and stored at 4°C until needed. 
Alternatively, the influence of storage and/or incubation temperature on antibody 
reactivity with Reg2 may have unduly influenced the staining. Incubation of all 
primary antibodies was carried out principally at room temperature. This could 
provide another explanation behind the low expression recorded, although a clear 
upregulation of Reg2 after L5 SNL was observed in some DRG cells. For example, 
the faint Reg2 staining may have resulted in cells not being counted, although Reg2 
expression was present. This may have contributed to the low expression recorded 
and only strongly-positive cells being counted. 
Reg2 expression in the basal state and 1 day after L5 SNL was near 
exclusively in small diameter cells. Although these cells were not further
characterised using immunohistochemical markers, other reports have categorised
Reg2 expression in naïve animals, and 1 day after sciatic nerve injury predominately
in IB4-positive cells (95% Reg2 = IB4; Averill et al., 2002). As galanin was found 
primarily in small-diameter peptidergic (CGRP-positive) DRG cells immediately 
after injury (1 day >50%), coexpression should be minimal if Reg2 was primarily 
expressed in IB4 cells. Indeed, galanin cells expressing Reg2 at 1 day after sciatic 
nerve injury was only 1.3% (Averill et al., 2002). The relevant Reg2/P2X3 double-
labelling experiments would need to be carried out to confirm these assumptions. 
At 7 days post-L5 SNL, preliminary data found galanin co-expressed in 
nearly 50% of Reg2 positive cells. However this observation needs to be interpreted 
in light of the fact that, as for 1-day data, the percentage expression of Reg2 
compared with sciatic nerve injury data was low (7.2% vs. 10%, Averill et al., 2002). 
Particularly as discussed above, the L5 SNL should produce a more extensive 
upregulation of an injury marker, given that 100% of fibres are damaged. However, in 
accord with our preliminary observations, coexpression of Reg2 with galanin 
following sciatic nerve injury was similar (Reg2 = GAL: 48.6%; Averill et al., 2002). 
With the rapid upregulation of galanin, the lower percentage expression of Reg2 in 
galanin cells (~5%) is to be expected as Reg2 showed a more limited expression. This 
is also consistent with sciatic nerve injury (%GAL = Reg2: 9.4%; Averill et al., 
2002). As data herein show, galanin was newly expressed in non-peptidergic DRG at 
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7 days, and Reg2 is expressed by some non-peptidergic cells at 7 days post sciatic 
nerve injury (Averill et al., 2002). Given this assumption, a logical suggestion would 
therefore be that the DRG in which Reg2 and galanin are co-expressed after L5 SNL 
are non-peptidergic cells. Indeed, it has recently been reported that Reg2 
immunoreactivity is upregulated in DRG following CFA inflammation (detected at 1 
day, peaked at 3 days, in 11.6% of DRG neurons) (Averill et al., 2008), almost 
exclusively in IB4 cells. Reg2 is unusual in being expressed in IB4 cells both with 
nerve injury and inflammation, and this may suggest a common mediator produced in 
both injury models is driving expression (Averill et al., 2002; Averill et al., 2008). 
Profile analysis of double-labelled galanin/Reg2 DRG would lend weight to 
our observation that these cells are non-peptidergic DRG. However, profile analysis 
of Reg2 expression overall after 7 days suggested expression was in many DRG of 
medium- to –large diameter DRG cells (1200-2400 m 2), not consistent with 
widespread expression in small-diameter, non-peptidergic cells. Although the data are 
initial observations, Reg2 was not co-expressed with TRPV2 or CGRP after L5 SNL. 
The mutually-exclusive staining contrasted with that of galanin. Thus, co-labelling 
experiments with N52 or other markers are needed to confirm the characteristic of 
cells in which Reg2 is expressed post L5 SNL.
A limitation of this section was that the Reg2 antibody produced less 
consistent staining than other immunohistochemical agents. Reg2 expression was 
present or absent in the injured tissue, with little variation in character under the 
microscope. In addition, only a small n-number was achieved suitable for analysis 
especially at 1 day time point and, to confirm these data, experiments at the early time 
point need repeating. Accounting for these limitations, Reg2 expression in the L5 
SNL model needs investigating further. As Reg2 has been shown to be induced in 
39% of DRG neurons with LIF, 62% of which were non-peptidergic cells (Averill et 
al., 2008), regulation of Reg2 by neuropoietic cytokine IL6 was investigated in vitro.
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5.1. Chapter Summary
Galanin and Reg2 were upregulated at 1 and 7 days after L5 SNL. The limited n-
number means any assumptions from Reg2 data are tentative. Reg2 expression was 
low in comparison with galanin; however some elements of expression were similar.
Galanin and Reg2 were immediately expressed in small DRG, before more wide-
spread expression in medium to large DRG cells. Examining expression using
specific DRG cell markers showed some clear differences but also highlighted high 
co-expression. Galanin was observed particularly in CGRP cells 1-day after SNL. At 
7 days, galanin was upregulated in IB4 and TRPV2 cells, although not further 
upregulated in CGRP cells from that seen at 1-day. Reg2 was not observed in 
TRPV2-positive DRG 7 days after L5 SNL, or in CGRP-positive cells. However, half 
of Reg2 cells co-labelled with galanin, and the hypothesis is that these cells are most 
likely IB4 cells. 
Using a model in which all DRG fibres are damaged, the differential 
regulation of galanin and Reg2 in different sub-types of DRG cell suggests specific 
mediators might be generated to drive these changes. However, with high co-
expression of galanin with Reg2 observed at 7-days after L5 SNL, I sought to 
determine whether a common mediator could be responsible for the up-regulation of 
these two mediators. Data from the literature suggest the neuropoietic cytokines (IL6, 
LIF, CNTF) can regulate both galanin (Thompson et al., 1998; Corness et al., 1998; 
Kerekes et al., 1999) and Reg2 (Averill et al., 2008; Nishimune et al., 2000). 
Furthermore, as the Reg2 promoter contains two binding sites for IL6 (Dusetti et al., 
1995), IL6 was investigated using isolated DRG cells grown in vitro to facilitate
cytokine supplementing. 
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Aim 4: To determine whether isolated adult DRG from uninjured rats provide a 
suitable model for investigating peptide expression characteristics seen in vivo
6. RESULTS: IN VITRO DATA
6.1. Cultured DRG cells grow in vitro with given characteristics
Isolated adult rat DRG cells were grown in vitro on laminin-coated culture plates. 
Initial experiments determined phenotypic and morphological characteristics shown 
by DRG cells when grown with time. These experiments helped optimise the growth 
period necessary for investigating peptide expression. 
DRG cells showed different morphological characteristics when fixed
between 18-72 hrs (see Figure 19). Cells initiated simple (non-branching) outgrowths 
after 18hrs (Figure 19A). After 24hrs, branched processes were evident, but the 
majority of outgrowths were simple (see Figure 19B). Abundant neurite outgrowths 
were visible after 48hrs (Figure 19C) and complex, multiple branching
characteristics were observed after 72hrs (Figure 19D). Elongated neurites were 
visible from 18hrs, and extended extensively with time. 
Figure 19: -Tubulin stained, cultured adult DRG cells after: (A) 18hrs; (B) 24hrs; (C) 48hrs; 
(D) 72hrs culture growth, grown in BSF2 media (supplemented with 2% foetal calf serum). 
Scale bars represent 50 m.
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6.2. Different peptides are expressed in cultured DRG cells grown for 
48-72hrs
DRG cultures were stained for CGRP, galanin and for neuropeptide Y (NPY) – a 
peptide that is upregulated after axotomy (e.g., Kashiba et al., 1994; Marchand et al., 
1999; Shi et al., 1999; Wakisaka et al., 1991). All three peptides were identified after 
48 and 72hrs growth (Figure 20-22). At both time points, peptides showed ‘patchy’ 
characteristics under the microscope. CGRP and NPY were expressed in 
approximately 30% of DRG cells analysed at both 24 and 48hrs, whereas galanin 
expression increased significantly with time (Table 7). 
Figure 20. CGRP staining (red) in tubulin-positive (green) isolated cultured adult DRG cells 
grown for 48hrs in BSF2 media (supplemented with 2% foetal calf serum). DAPI (blue) was 
used to identify all cellular nuclei in the growing culture (neuronal and non-neuronal). Scale 
bar represents 100 m. Note diffuse CGRP staining in neurite and characteristic ‘patchy’
staining in cell body.
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Figure 21. Micrographs showing neuropeptide Y (NPY) (red) expression in -tubulin-
positive (green) cultured adult DRG cells, grown for 72hrs in BSF2 media (supplemented 
with 2% foetal calf serum). DAPI (blue) was used to identify all cellular nuclei in the growing 
culture (neuronal and non-neuronal). Scale bar represents 50 m. Arrows indicate NPY-
positive cells. Note NPY staining has ‘patchy’ characteristic thought to be representative of 
Golgi localisation.
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Figure 22. Galanin (red) expression in tubulin-positive (green) cultured adult DRG cells 
grown for 72hrs in BSF2 media (supplemented with 2% foetal calf serum). DAPI (blue) was 
used to identify all cellular nuclei in the growing culture (neuronal and non-neuronal). Arrows 
indicate galanin-positive cells, arrowhead shows galanin immunonegative cell. Scale bar 
represents 50 m.
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Aim 5: To investigate galanin expression characteristics in cultured adult DRG after 
24-72 hrs growth
6.3. Galanin expression increased with time in cultured DRG cells
Galanin expression was consistently detected in cells across different experimental 
days. A highly significant increase in galanin-positive cells was found between 24-
and 48hrs (relative increase of 19.4%; P<0.001) and between 48- and 72hrs (a 
relative increase of 12.8%; P<0.001) (Table 7). 
Two different distribution patterns of galanin were observed using the light 
microscope, as illustrated in Figure 23. One pattern showed a circular distribution of 
galanin-IR around the cell nucleus (arrow head, Figure 23), the second showed 
galanin-IR packaged into one side of the cell (arrow, Figure 23). Both patterns were 
‘patchy’ Golgi-like in characteristics, similar to the staining observed during in vivo
experiments for newly synthesised peptide after L5 SNL. 
Culture growth (time)
% Galanin
expression
N
24hrs 4.33±0.86 4
48hrs 23.691.9*** 9
72hrs 36.47±1.8*** † 9
***= P<0.001 compared with 24hrs; †P<0.001 compared with 48hrs. 
Table 7: Percentage expression of galanin in tubulin-positive cultured adult DRG after 24, 
48- and 72-hrs culture growth. Data are shown meanSEM.
128
Figure 23. Micrograph depicting two characteristic staining arrangements for galanin in 
primary cultured adult DRG, after 48hrs growth in control media (BSF2 supplemented with 
2% foetal calf serum). Scale bar represents 50 m.
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6.4. Cultured DRG cells can be characterised with small cell markers  
Using well-characterised markers for small-diameter cells (IB4, CGRP) (Priestley et 
al., 2002) control experiments showed IB4 and CGRP expression remained stable 
between 48- vs. 72-hrs culture growth (Table 8), although a non-significant 
downward trend was noted between 48- and 72-hrs culture growth for IB4 (mean 
decrease of 10.4%; P=0.0785) and CGRP (mean decrease of 5.33%; P=0.065) 
(Table 8). 
Double-staining showed that nearly half of galanin-expressing cells were 
CGRP-positive after 48hrs (%GAL = CGRP 46.9%; see Table 8, Figure 26). 
Between 48 and 72hrs, a significant decrease in galanin-positive cells expressing 
CGRP was recorded (%GAL = CGRP 28.8%; mean decrease of 18.1%; P=0.0392). 
However, as galanin was significantly up-regulated in this time period, the proportion 
of CGRP cells expressing galanin remained not significantly different, although the 
errors around the mean are relative large (%CGRP = GAL mean difference 48 to 72 
hrs: +8.89%; Table 8). A small population of galanin-positive cells co-labelled with 
IB4 at 48 and 72 hrs; expression did not change with time (%GAL = IB4 7.5-8.1%; 
see Table 8, Figure 25). IB4 cells co-labelled with galanin significantly increased 
from 7% at 48hrs, to 13% at 72hrs (relative increase 5.6%; P<0.05; %IB4 = GAL 
Table 8). 
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48 hours 72 hours
% DRG cells = GAL
23.69±1.9
(n=9)
36.47±1.8*** 
(n=9)
% DRG cells = IB4 27.824.19 17.392.57
% DRG cells = CGRP 32.791.4 27.451.9
%GAL = IB4 8.122.5 7.461.7
%IB4 = GAL 7.051.8 12.692.3*
%GAL = CGRP 46.906.0 28.800.64*
%CGRP = GAL 35.537.3 44.426.2
*= P<0.05; *** = P<0.001 between cultures grown for 48 and 72 hrs; 
Table 8: Peptide expression in primary adult DRG cell cultures grown in BSF 2 media 
(supplemented with 2% foetal calf serum) after 48- and 72-hour growth. Cells were fixed and 
double-stained for galanin and IB4 or CGRP; data are shown meanSEM. N = 3-5 unless 
otherwise indicated.
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Figure 24. Micrographs showing galanin (red) and CGRP (green) co-expression in primary 
adult DRG cell cultures, grown in BSF2 media (supplemented with 2% foetal calf serum) for 
48hrs. Arrows indicate double-labelled cell, arrowhead indicates single labelled galanin cell. 
Scale bar represents 50 m.
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Figure 25. Micrograph images showing cultured adult DRG grown for 48hrs in BSF2 media 
(supplemented with 2% foetal calf serum) and immunostained with IB4 (green) and galanin 
(GAL; red). DAPI (blue) shows all cell nuclei. Scale bar represents 50 m. Note 
independence of staining for IB4 and GAL.
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Aim 6: To determine whether galanin can be regulated by the cytokine IL6 in 
cultured DRG cells  
6.5. IL6 accelerates galanin upregulation in cultured DRG cells
Cells cultured in the presence of IL6 (40 ng/mL), added to FCS-supplemented BSF2, 
showed a significant upregulation of galanin, compared with un-supplemented
cultures, at 24 and 48-hrs growth (Figure 26). In the presence of IL6, galanin-IR was 
detected in ~4% of cells after 18hrs (data not shown), but was completely absent in 
non-IL6 supplemented cultures (BSF2+2%FCS). Endogenous galanin expression was 
not upregulated further by IL6 at 72hrs growth (mean increase from 48hrs+IL6 to 
72hrs+IL6: 5.66 percent points). Furthermore, galanin expression was not 
significantly different from control cultures at this time point (+IL6 mean increase 
4.19 percentage points increase compared with BSF2+2% FCS alone) (Figure 26). 
In support of an endogenous neuropoietic cytokine, such as IL6, promoting 
upregulation via gp130-receptor mediated signalling pathway, widespread p-STAT3 
nuclear immunostaining was detected in both control (BSF2+2% FCS) and IL6-
supplemented cultures at 72hrs growth. 
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Figure 26. Bar-chart representation of percentage galanin expression in -tubulin-positive 
cultured adult DRG cells at 24, 48 and 72 hrs’ culture growth, in absence (blue) or presence 
(red) of IL6 (40ng/mL). Both conditions included BSF2+2% foetal calf serum (FCS). Error 
bars represent SEM. n=4-5. * = P<0.05 compared with respective BSF2.
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Aim 7: To investigate the bias for IL6-supplemented cells to express galanin, due to 
an effect of IL6 on early growth
6.6. IL6 does not increase early growth of DRG cells
Analysing percentage of cultured DRG cells expressing neurite outgrowths in IL6 -
supplemented and -non-supplemented cultures after 24hrs growth, showed that IL6 
did not significantly increase the number of cells with visible outgrowths, although 
comparison was borderline significant with n=3(P=0.055; Figure 27). Furthermore, 
initial observations suggested that IL6 did not increase the proportion of cells with 
neurites after 18hrs growth (n=2). 
The proportion of IL6-supplemented cells showing early neurite outgrowths 
and expressing galanin was not significantly different from controls (P>0.05; Figure 
27). In IL6-supplemented cultured cells, 24.6% of cells had processes and 3% of 
these expressed galanin (shown by blue proportion of bars; Figure 27). In 
comparison, for non-supplemented cultures, 16.3% of cells had neurite outgrowths
and of these cells only 1% expressed galanin. 
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Figure 27. Bar chart showing percentage of cultured (-tubulin-positive) DRG cells having 
visible process outgrowths, at 18 and 24 hrs growth (shown by the entire bar), and the 
proportion of these cells expressing galanin (shown by the blue section of the bar). Error bars 
represent SEM; n=3 for each. P=0.547 for comparison between cells expressing processes 
±IL6. Both conditions included BSF2+2% foetal calf serum. 
P=0.0547
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6.7. Cell density does not increase the proportion of cells expressing 
galanin, IL6
Control experiments were carried out to determine whether the total number of 
growing neurons (-tubulin-positive cells) per culture well was correlated with the 
proportion of these cells expressing galanin, after 48hrs and 72hrs growth. Regression 
line analysis showed no correlation between increased density and galanin expression 
in the presence or absence of IL6 (Figure 28) (r2 not significantly different from zero 
for regression analysis), suggesting a variation in cultured DRG cell density per slide 
well and among experiments, was unlikely biasing galanin expression at any time 
point. Thus, variation among culture slide wells was unlikely to account for the 
upregulation of galanin ±IL6 seen at each time point. 
137
BSF2 culture
R2 = 0.029
R2 = 0.1723
0
5
10
15
20
25
30
35
40
45
50
0 50 100 150 200 250 300 350 400
Total counted beta-tublin-positive cells per well 
Ga
la
ni
n 
ex
pr
es
si
on
 (%
)
48hr
72hr
Linear (48hr)
Linear (72hr)
IL6-treated cultures
R2 = 0.0303
R2 = 0.0303
0
5
10
15
20
25
30
35
40
45
50
0 50 100 150 200 250 300
Total counted beta-tublin-positive cells per wel
Ga
la
ni
n 
ex
pr
es
si
on
 (%
)
48hrs
72hrs
Linear (48hrs)
Linear (72hrs)
Figure 28. Scatter-plots showing X-Y correlation between number of growing cultured cells 
per slide well and galanin expression (as %) per well, at 48(▲), 72(♦) hours. (A) Control 
cultures; (B) IL6-supplemented (40 ng/mL) cultures. Both conditions included BSF2+2% 
foetal calf serum. Linear regression lines are shown. Each point represents a slide well; n= 4 
for each.
(B)
(A)
138
6.8. IL6 does not upregulate CGRP expression in cultured DRG cells
After 48hrs growth, the time point where the greatest difference in galanin expression 
in presence and absence of IL6 was seen (Figure 29), no significant difference in 
percentage expression of CGRP was found with the addition of IL6 (40 ng/mL) to the 
growth media (difference between means ±IL6 –0.66%) (Figure 29). Furthermore, 
CGRP expression did not change with time in the culture model as found with galanin 
(mean difference 48hrs vs. 72hrs; 5.33%; see Table 8).
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Figure 29. Bar chart representing change in percentage galanin (GAL) and CGRP expression 
in presence (red) and absence (blue) of IL6 (40 ng/mL), at 48hrs’ culture growth. Error bars 
represent SEM; n=4-7. * = P<0.05 for comparison between BSF2 and IL6.
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Aim 8: To investigate expression of Reg2 in cultured adult DRG cells compared with 
galanin 
6.9. Reg2 is expressed in cultured DRG cells
Reg2 was clearly identified in cultured DRG cells after 72hrs growth (Figure 30), 
with a distinct ‘patchy’ characteristic. (Figure 31). No significant difference was 
found between percentage expression of Reg2 grown in presence/absence of IL6 after 
72hrs growth (mean percent difference +/- IL6 72hrs 3.42 percentage points; P>0.05)
(Figure 30). This was similar to that reported above for galanin expression ±IL6 after
72hrs growth (Figure 26). Although other time points were investigated (18-72hrs), 
reproducible Reg2 immunostaining was not achieved. This is discussed in 
CHAPTER 7. 
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Figure 30. Bar chart representing -tubulin-positive cultured adult DRG expressing Reg2 
after 72 hrs’ growth in absence (blue) and presence (red) of IL6 (40 ng/mL) in BSF2 growth 
medium. Both conditions included BSF2+2% foetal calf serum. Error bars represent SEM; 
n=4 for each.
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Figure 31. Microscope images showing Reg2-positive (red) cultured adult DRG cells grown 
in BSF2 alone (A,B) or IL6-enriched (40 ng/mL) BSF2 (C,D). Both conditions included 
BSF2+2% foetal calf serum. DRG cultures are counterstained with neuronal marker -tubulin
(green). Arrows represent Reg2-positive cells. Scale bar represents 50 m. 
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7. DISCUSSION 2: IN VITRO DATA
Aim 4: To determine whether isolated adult DRG from uninjured rats provide a 
suitable model for investigating peptide expression characteristics seen in vivo
DRG cells were isolated and grown in vitro in BSF2 growth media supplemented 
with 2% FCS. Cells grown in vitro for up to 72hrs showed highly robust outgrowths 
and formed both simple outgrowths in early stages, and then more complex branching 
patterns contacting and networking with neighbouring cells. Cells showed 
characteristics consistent with other data for this method (Smith and Skene 1997; 
Gavazzi et al., 1999). Two distinct phases of growth have been reported for adult 
sensory neurons grown in culture: an initial neurotrophin-dependant neurite 
outgrowth stage (Mohiuddin et al., 1995; Gavazzi et al., 1999) characterised by 
highly branched processes with limited linear extension, and a subsequent 
neurotrophin-independent, elongating, or regenerative growth phase (Smith and 
Skene, 1997; Cafferty et al., 2001). We observed both characteristics for DRG cells 
grown for 72hrs, although early growth (<24hrs) was more characteristic of simple 
outgrowths suggesting neurotrophic-independent growth. 
DRG cultures in this study were incubated in the absence of any exogenous 
neurotrophic factors, although FCS was used which contains proteins and vitamins to 
support growth. Observations discussed below with respect to characteristics of 
neurite outgrowths and the expression patterns of peptides – particularly CGRP and 
galanin – indirectly suggests the presence of neurotrophins or similar neurotrophic 
growth factor in the culture media, in sufficient quantities to have a physiological 
effect. Cells were centrifuged through a BSA cushion, which might also have 
introduced proteins or other factors that could influence growth. Furthermore, the 
culturing procedure did not completely eliminate non-neuronal cells and cultures 
therefore contained a mixed population of neuronal/non-neuronal cells. Although no 
glia-specific markers were used in this study, it is likely that the nucleated, non-
neuronal cells (shown using DAPI) in culture were a combination of Schwann cells, 
fibroblasts and satellite cells. These cells may also be releasing mediators into the 
culture environment, which should be accounted for. Although some preliminary 
experiments were carried out to characterise these cells with non-neuronal cell 
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markers (data not shown), no firm conclusions were drawn. The non-specific 
neurotrophic response is an inherent limitation to these in vitro experiments. 
Repeating these experiments (1) without any foetal calf serum and/or (2) in 
the presence of neurotrophin sequestering agent(s) such as an NGF/trkA or 
GDNF/GFαR antibodies should be carried out to determine the presence of particular 
neurotrophic factors in the media. Also, additional experiments should be conducted 
to characterise the non-neuronal cells indicated by DAPI, and when identified 
culturing in the presence of mitotic inhibitors to prevent their proliferation. This may 
help to reduce some of the variability within the model. In addition, assaying the 
media with Western blot analysis or ELISA could help determine the mediators being 
generated within the culture model, potentially by the non-neuronal cells or the 
growing neurons. It is interesting that studies have reported cell survival of DRG 
cultures at 2 or 4 weeks in the absence of NGF (Buschmann et al., 1998; Lindsay 
1988). However, as these studies included media supplementation with serum, or 
were mixed neuronal and non-neuronal cultures, these may likewise have included 
some neurotrophic production within the cell environment to account for the growth 
support reported. 
From initial experiments, an optimum growth period of 48-72 hrs was 
selected for investigating expression of peptides. As shown with control experiments, 
cultured cells were well-established by this time window, but had not overwhelmed
their growth space to limit their ability to extend neurites. Using this time window 
also prevented any complications associated with the need to add more growth media, 
or change the culture media for cells to continue to grow. Changing the media could 
perturb the environment when investigating upregulation characteristics of peptides
and give biased incomparable results. 
Various peptides can be expressed in cultured cells (Schoenen et al., 1989) 
and galanin, CGRP and NPY were all identified in this study. These peptides showed 
‘patchy’ characteristics. Using the hypothesis derived during in vivo observations, this 
observation suggests peptides are being newly synthesised in the growing cells. With 
the cells being removed from their neurotrophic support during extraction, dynamic 
changes in synthesis of peptides might be expected, particular of cell growth 
supported by factors in the FCS. Furthermore, the extraction process may have 
disrupted any stored peptides, and the process of replacing these peptides might be 
triggered. Using markers for e.g., dense-core vesicles (Zhang et al., 1995b), or 
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sampling for galanin precursor mRNA would confirm whether or not galanin is being 
actively synthesised.
Galanin was identified in vitro, consistent with its presence reported by others 
(Corness et al., 1998; Kerekes et al., 1997) and is discussed in detail below. 
NPY is stored in vesicles and found co-expressed with galanin (Kashiba et al., 
1994). Even though NPY was not investigated specifically in vivo (and data are not 
reported herein), the immunohistochemical stain was used in vitro to help characterise 
neurons growing in culture. NPY was found in some cells having a larger-diameter, 
which did not express CGRP, consistent with other data (Kashiba et al., 1994; Zhang 
et al., 1995a). Published data outline a role for changes in the regulatory activity of 
NPY in synaptic transmission following nerve injury. Specifically NPY is 
upregulated following nerve injury (Wakisaka et al., 1991), and via action on
somally-distributed Y-receptors, NPY contributes to the development and/or 
persistence of symptoms characteristic of sympathetically-maintained pain 
(Marchand et al., 1999). Thus, further experiments using NPY/galanin double-
staining would be of interest in relation to the project aims, especially in the in vivo 
L5 SNL model. 
CGRP was identified reliably and consistently in cultured cells. Interestingly, 
CGRP was seen in both axonal varicosities and in the perinuclear region of cell 
bodies – in comparison with NPY and galanin which were not seen in the axonal 
processes, although studies have shown the proteins are transported from the DRG to 
the periphery for release (e.g., Ma and Bisby, 1999; Marchand et al, 1999). CGRP 
was detected at levels consistent with the uninjured state (~30%). However, without 
NGF to maintain expression CGRP is normally lost after nerve injury (Doughty et al., 
1991). For example, experiments using anti-NGF and cultured mouse cells have 
shown that NGF withdrawal results in a loss of CGRP expression (Sango et al., 
1994). Furthermore, CGRP loss can be countered by administration of exogenous 
NGF following injury or with addition of anti-NGF (Sango et al., 1994). NGF has 
also been shown to increase SP and CGRP expression in sensory neurons in vitro 
(Lindsay and Harmar 1989; Lindsay et al., 1989) and additionally anti-NGF 
administration decreases levels of CGRP (and SP) in intact animals (Shadiack et al., 
2001). As the methodology did not involve supplementing NGF, this observation 
suggests the presence of neurotrophic factors in the culture environment, either 
released from the growing cultured cells, from non-neuronal cells, or present in the 
supplemented growth media. Assaying the media after culturing for 48hrs, where 
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expression of CGRP was consistent with expression noted in vivo (Table 5), would 
confirm this hypothesis. 
The presence of some growth support within the culture conditions is further 
supported by IB4 expression, which is lost following nerve injury. IB4 was detected 
in 20-30% of cultured DRG cells (48-72hrs) compared with 32-40% in naïve animals 
(Table 5), and 30% reported in the literature (Priestley et al., 2002). IB4 expression 
was similar at both time points studied in vitro (48hrs and 72hrs) although a 10% 
downward trend was seen. As IB4 cells are regulated by GDNF, this observation 
could suggest NGF is not the only neurotrophic factor being generated within the 
culture media. Assaying the media and using Western blot techniques after culturing 
for 48hrs might confirm if, or which neurotrophic factors are present. Furthermore, 
supplementing cultures with GDNF and/or anti-GDNF or a sequestering antibody, 
and then analysing IB4 expression with galanin, would be an interesting comparison 
especially with IL6 experiments, discussed below. 
Aim 5: To investigate the characteristics of galanin expression in cultured adult 
DRG after 24-72 hrs growth
Galanin was significantly upregulated with time in cultured DRG cells. After 48hrs 
galanin was expressed in 25% of cultured cells, and by 72hrs in ~40%. This 
expression is consistent with an injury phenotype as recorded during in vivo
experiments in CHAPTER 4, rather than a non-injured phenotype. At 24hrs growth, 
galanin expression was more consistent with a non-injured phenotype showing 
expressing in 4% of cells (vs. naïve expression, 5%). However, by 48hrs growth the 
injury phenotype was well established. When DRG are isolated, they are removed 
from peripheral neurotrophic support. Indeed, both central and peripheral branches of 
the spinal nerve are severed, and the neurites growing from these isolated cell bodies 
would logically produce characteristics found with complete nerve injury. As the 
dynamic changes in peptide expression recorded with injury were of interest, the 
model was considered thus appropriate, taking into account the relative variables. 
Nearly half of all cultured cells expressing galanin co-expressed CGRP after 
48hrs culture growth. After 72hrs culture growth, galanin was clearly upregulated in a 
different population of cells as the expression in CGRP cells remained stable, while 
overall expression increased. This was similar to the relationship found after nerve 
injury (Table 5) and is discussed in CHAPTER 5. A significant increase in galanin 
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expression in IB4 cells was recorded (%IB4 = GAL at 72hrs 13% vs. 48hrs 7%), 
although this did not account for all cells newly expressing galanin at 72hrs. Indeed, 
as the observation was only just significant, increasing the n-number would aid the 
conclusion that galanin is upregulated in IB4 cells. Furthermore, repeating these 
culture experiments using P2X3, RET or FRAP as alternative markers for non-
peptidergic cells would also strengthen these observations. 
Although the relevant experiments would need to be conducted, the galanin-
expressing cultured cells unaccounted for with the double-labelling experiments 
carried out in the present experiments may represent some thinly-myelinated TRPV2 
cells, as identified in vivo, or as discussed, unidentified non-peptidergic cells. Some 
larger-diameter cells can express galanin, although generally 1 week after injury 
(Averill et al., 2002) and are thus unlikely to contribute significantly at 72hrs. 
Supporting this assumption, very few larger cells were visualised and preliminary 
observations with N52 and NPY showed minimal co-staining with galanin. 
Aim 6: To determine whether galanin can be regulated by the cytokine IL6 in 
cultured DRG cells  
Supplementing cells with IL6 increased the number of DRG cells expressing galanin
compared with cultures grown in BSF2 growth media supplemented with 2% FCS, 
after 18hrs, 24hrs and 48hrs growth. Indeed, IL6 supplementation more than doubled 
the percentage expression at 24hrs vs. cells grown in BSF2 supplemented with 2% 
FCS. By 72hrs growth, IL6 did not increase galanin expression beyond that seen with 
time. Indeed, the percentage expression after 72hrs growth was consistent with other 
published results in a different in vitro culture model at this time point (Kerekes et al., 
1999). 
The ability of IL6 to stimulate galanin expression is also in-line with reports 
suggesting another neuropoietic cytokine, LIF, has the ability to upregulate galanin in 
vitro using a mouse DRG culture model (Corness et al., 1998; Rao et al., 1993).
Furthermore, LIF mRNA has been detected in DRGs after sciatic nerve injury in the 
regions immediately proximal and distal to the lesion site (Banner and Patterson, 
1994). This upregulation is consistent in time course and magnitude with the changes 
in neuropeptide expression found in the ganglia after injury (Banner and Patterson, 
1994), suggesting a temporal correlation between LIF and peptide upregulation.  
146
During the writing up of this project it has been reported that under conditions 
without NGF, an increase in the proportion of GAL-positive neurons occurred with 
time, regardless of presence or absence of LIF (Engert et al., 2008). However, 
addition of LIF to the culture medium resulted in a faster upregulation within the first 
hours after cell dissociation, although this experiment used F12 culture medium 
supplemented with FCS, as shown herein for IL6 supplemented rat DRG cultures. As 
discussed above, providing FCS for growth support might also result in synthesis of 
trophic factors that may influence peptide expression. This should be duly considered 
while interpreting these observations by Engert et al., (2008). Repeating the present 
experiments and comparing galanin expression using LIF rather than IL6 would be an 
interesting comparison. Furthermore, adding a second IL6 supplementation between 
24-48hrs, might show if galanin expression can be further accelerated, or if 
expression could be produced in a higher (>50%) proportion of cultured cells than
demonstrated herein. Indeed, including a second infusion of IL6 may produce an 
environment more representative of an injury environment, when invading cells are 
thought to produce and release IL6 with time (Bolin et al., 1995; Ma and Quirion, 
2005; Reichert et al., 1996; Van Wagoner and Benveniste, 1999).
The time-dependent upregulation of galanin in the absence of IL6 must be 
driven by factors present and/or generated within the culture environment. If the DRG 
culture model is mimicking the axotomy response (Kerekes et al., 1999; Kerekes et 
al., 1997), loss or at least part loss of neurotrophic factor(s) support, such as NGF, 
following extraction and particularly during early growth would most likely
contribute to upregulation of galanin seen with time in peptidergic cells. This would 
be in-line with observations of galanin expression in peptidergic cells 1 day after L5 
SNL in vivo. However, indications that NGF might be generated within the media 
may have resulted in galanin being suppressed (Corness et al., 1998; Shadiack et al., 
2001) in these NGF-regulated cells. However Kerekes et al., (1999) also reported 
40% galanin expression in wild type mice cultures after 72hrs. Comparing with 37% 
expression after 72hrs in the present experiment, little difference is apparent. 
Suppression by NGF or other factor produced in the culture conditions, might also 
account for the non-significant difference observed between IL6 supplemented
cultures with control at this 72hrs time point. Accordingly, culturing DRG cells in the 
presence of NGF antibody/sequestering agent has been discussed above, and would 
have been an interesting control to see if a larger upregulation of galanin could be 
achieved, as found when culturing with LIF/anti-NGF in embryonic cultures grown 
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for 14 days (Corness et al., 1998). This model may also have produced a greater 
increase in galanin expression in the non-peptidergic population, assuming LIF is a 
driver for galanin expression in non-peptidergic cells. However, the change in 
dependency of sensory neurons on NGF during the post-natal period (Molliver and 
Snider, 1997) may produce different results in the embryonic cultures used by 
Corness et al., (1998) compared with the adult DRG cells used in the present 
experiments. Further experiments in this area, particularly investigating regulation of 
galanin expression in non-peptidergic cells, are therefore warranted. Some of these 
are outlined above, on Page 151.
The extent to which IL6 might have been produced in control culture media 
and therefore potentially contribute to the time-dependent expression of galanin 
observed, could be confirmed with Western blot or ELISA analyses to sample the 
contents of the culture media. Additionally, the presence of IL6 receptor (IL6R) 
would need to be confirmed, as lower concentrations of IL6 might be ineffective 
without functional receptor components (Flatters et al., 2004). Indeed, there may be a 
delay before the receptor components are expressed following injury, which may 
contribute to the delay in the consequences of IL6. Experiments have shown IL6 
mRNA in rat DRG culture models (Ma and Quirion, 2005; Murphy et al., 1995) 
supporting an assumption that IL6 can be released from either the non-neuronal cells 
proliferating in the model, or from the cell outgrowths. The source of IL6 was not 
defined in this early paper by Murphy et al., (1995) IL6 mRNA is increase following 
nerve injury (Arruda et al., 1998) and may therefore potentially be generated in the 
nerve injury model used. In support of the IL6 pathway being stimulated in the 
culture model, wide-spread p-STAT3 nuclear staining was observed in the current 
experiments under conditions ±IL6. However, as the majority of cells (>80%) were 
stained, further experiments are needed to quantify these observations, particularly
using inhibitors to the IL6-gp130 pathway (as schematically outlined in Figure I), 
such as JAK2 (e.g., AG 490) or MAP kinase inhibitors. 
Despite the limitations around non-specific growth factor(s) within the culture 
media, which would be present across control and IL6-supplementing experiments, a 
single application of IL6 was sufficient to upregulate galanin in cultured DRG cells. 
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Aim 7: To investigate the bias for IL6-supplemented cells to express galanin, due to 
an effect of IL6 on early growth
Previous work has highlighted the integral role played by gp130 cytokines IL6 and 
LIF in mediating elongation of neurite outgrowth (Cafferty et al., 2001, 2004; 
Gardiner et al., 2000; Wagner, 1996). Furthermore, IL6 has been shown to promote 
survival of dissociated newborn rat DRG neurons in vitro when given in combination 
with its soluble receptor (Thier et al., 1999). Therefore, the influence of adding IL6 to 
the early growth of cultured cells, and how this might bias cells to express galanin, 
was investigated. 
Examining cultured cells after 18hrs, no trend for more IL6-supplemented 
cultures to show simple visible process outgrowths was noted. Cells showing neurite 
outgrowths were not more likely to express galanin. This trend was also found after 
24hrs, although the observation was nearly significant at n=3. This observation is 
consistent with data from Cafferty et al., (2004) who showed that IL6 failed to initiate 
neurite outgrowth in cultures, after 18hrs in the presence or absence of its soluble 
receptor. In contrast, earlier data did suggest that IL6 can act as a growth mediator 
(Wagner 1996). Cafferty et al., (2004) demonstrated that inclusion of IL6 to cultures 
grown in the presence of neurotrophic factors (NGF or NT-3) resulted in dramatic 
neurite elongation, after 18hrs. Therefore, taking into account the observations by 
Cafferty et al., (2004), data presented herein which almost reached significance add to 
the conclusion that NGF or similar neurotrophic factor is being generated within these 
cultures. This conclusion is also supported by some of the peptide expression 
characteristics observed, and outlined above. Cafferty et al., (2004) used serum-free 
growth media (not containing BSF2 or similar supplement), a control experiment 
which should have been carried out to validate the present experimental observations 
using IL6 and the influence of IL6 on galanin expression with time. 
The role of IL6 following nerve injury is complex, particularly as a number of 
other cytokines have been shown to increase in the DRG following nerve injury, 
including interleukin-1 and IL8 in addition to NGF and other growth factors (Saab 
et al., 2009). The neuropoietic cytokine, LIF, has also been shown to alter the 
intrinsic growth status of regenerating neurons involving activation of signal 
transducers and STAT-3 (Gardiner et al., 2002; Cafferty et al., 2001). Importantly, 
although all sensory neurons express gp130, only small diameter cells express 
cytoplasmic LIFR (gp90) after injury (Gardiner et al., 2002) and therefore the effect 
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of LIF is specific to unmyelinated small calibre neurons. Whereas LIF requires 
heterodimerisation of gp130 and LIFR to elicit its effects, IL6 requires the presence 
of its high-affinity soluble receptor subunit (sIL6R) and subsequent 
homodimerisation of gp130 subunits. The fact that all sensory neurons expressed
gp130 confers the ability of IL6 to bind these neurons but not necessarily the ability 
to signal, unless co-receptors are shown to be present. Experiments to detect the 
presence of co-receptors are thus necessary. 
Upregulation of galanin following nerve injury may have functions apart from 
a putative role in nociception. Galanin expression was correlated with the number of 
growing neurons per slide well to determine if variable within the culture conditions 
was influencing the expression of galanin found. No correlation was found, although 
the variability between growing cells was low. This might suggest that the proportion
of cells that are lost within each culture run is minimal. This would be in-line with the 
observation that galanin may promote the survival of peripheral neurons and/or 
axonal outgrowth (Holmes et al., 2000). Therefore galanin expression detected in the 
growing neurons may themselves be supported by the upregulation and expression of 
peptides during early growth. For example, cultured DRG neurons from mice 
carrying a loss-of-function galanin mutation have demonstrated deficits in neurite 
number and length (Holmes et al., 2000). Furthermore, after crush injury to the sciatic 
nerve the rate of peripheral nerve regeneration was reduced by over one-third in these 
galanin knockout animals, with associated long-term functional deficits (Holmes et 
al., 2000). However, these adult mice carrying a loss-of-function mutation in the 
galanin gene show a 13% reduction in the number of cells in the DRG, and a 24% 
decrease in the percentage of neurons that express SP. In addition, mice lacking 
GALR2 also have decreased neurite outgrowth from adult sensory neurons (Mahoney 
et al., 2006; Hobson et al., 2008) further highlighting a role for galanin signalling in 
regeneration following injury. Given the rapid expression of galanin in peptidergic 
cells following axotomy, as shown in vivo, or in the culture experiments, the deficit in 
peptidergic cells in this model (Holmes et al., 2000) should be considered when 
interpreting these data. By promoting upregulation of galanin with IL6, galanin may 
itself have contributed to the increased number of cells expressing neurites in early 
growth in IL6-cultures, compared with non-supplemented cultures where galanin 
expression was not seen at 18hrs.
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IL6 was not found to promote upregulation of CGRP in cultured DRG cells
after 48hrs growth. This would be expected as CGRP is principally expressed in 
small-diameter trkA-positive cells, regulated by NGF (Sango et al., 1994; Verge et 
al., 1995). Therefore, upregulation of galanin by IL6 recorded was a specific response 
which was not seen for CGRP. The consequences of this upregulation to nociception 
and neurite regeneration, in addition to other putative roles of galanin following nerve 
injury, warrant further investigations. 
Aim 8: To investigate expression of Reg2 in cultured adult DRG cells compared with 
galanin  
Reg2 was expressed by cultured DRG cells and expression at 72hrs was not increased 
by supplementing with IL6. This observation was similar to that recorded for galanin 
at 72hrs. Expression of Reg2 was over double (20%) the 8% expression recorded in 
vivo. Being an injury-generated mediator (Averill et al., 2002; Nishimune et al., 2000; 
Simon et al., 2003) the high expression of Reg2 could be suggestive of the injury 
state of the growing cells. Indeed, given that 100% of cultured cells are axotomised 
during extraction, an even higher expression may be expected, as suggested by other 
in vitro observations using different culture models (Nishimune et al., 2000; Simon et 
al., 2003). Experiments were carried out between 24 and 48hrs; however clarity of 
Reg2 staining as seen at 72hrs was not reproduced. These data are therefore not 
included in the present thesis. Accordingly, observations recorded for Reg2 should be 
considered preliminary in lieu of the experiments being repeated. 
Although the signal for promoting Reg2 expression is unknown (Nishimune 
et al., 2000), the Reg2 gene promoter contains two functional IL6 response elements 
in the promoter region of the rodent Reg2 gene (Dusetti et al., 1995). Also, Reg2 is a 
signalling intermediate of IL6-gp130 cascade (Broekaert et al., 2002; Schweizer et 
al., 2002). 
IL6 was shown to upregulate galanin in vitro model of axotomy.  Supporting 
a common mediator regulated galanin and Reg2 in a subset of DRG cells, 
coexpression of galanin with Reg2 was nearly 50% in vivo, this provided the 
foundations for investigating whether IL6 can similarly upregulation of Reg2 in 
cultured DRG cells. We were unable to show that Reg2 was upregulated by IL6. 
Accordingly, these experiments need repeating with IL6 and in addition with other 
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cytokines of the same family, such as LIF. As LIF and IL6 require different co-
receptors to signal via gp130 (LIFR and IL6R, respectively; see Taga and 
Kishimoto, 1997) the individual cytokines have the potential to effect specific 
regulation through a common gp130 pathway. Indeed, during the writing up of this 
thesis it has been published that LIF can regulate Reg2 expression in vivo (Averill et 
al., 2008). Reg2 expression is not mediated by NGF (Livesey et al., 1997; Averill et 
al., 2008), and therefore although consideration of non-specific influence of growth 
factors within the culture media needs to be taken into consideration, as discussed
above, NGF is unlikely to be responsible for the robust Reg2 expression observed. 
The in vitro methodology could be adapted to include control experiments using 
serum-free conditions, or anti-NGF, anti-GDNF, or inhibitors of the gp130 signalling 
pathway. Also, classifying the type of DRG cells in which Reg2 was upregulated in 
the presence and absence of exogenous IL6 is required.
Of consideration, Reg2 has an anti-apoptotic role in vitro, and in vivo Reg2 is 
involved in maintaining survival of neurons after injury (Nishimune et al., 2000; 
Simon et al., 2003). This additional role is a consideration for culture models where 
expression of Reg2 in early cultures may be an influence on early growth and 
survival. As Reg2 is primarily a neurotrophic factor for motoneurons, expression in 
sensory fibres following injury is an interesting observation requiring further 
investigations. 
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7.1. Chapter Summary
Galanin was upregulated in DRG cells cultured for up to 72hrs, and a time-dependent 
upregulation was seen initially in CGRP-positive cells. Analysis showed percentage 
expression for galanin was more consistent with that seen after nerve injury than in 
uninjured animals, although CGRP expression was similar to that seen in the 
uninjured animal, possibly due to the generation of NGF within the culture medium. 
By supplementing IL6 to cultured cells, galanin upregulation was accelerated beyond 
that seen with time, up to 48hrs growth. Thus, IL6 provided a further drive for galanin 
expression, although the cell type was not fully characterised. Up-regulation of 
galanin by IL6 was a specific response to galanin which did not occur with CGRP. 
Further experiments are needed to support these observations. As discussed, repeating 
these experiments without any foetal calf serum, and/or in the presence of 
neurotrophin sequestering agent(s) should be carried out to determine the presence of 
any neurotrophic factors. Also, experiments need to be conducted to characterise the 
non-neuronal cells identified by DAPI and/or culturing in the presence of mitotic 
inhibitors to prevent their differentiation. Finally, comparative experiments including 
inhibitors to the IL6-gp130 pathway, such as IL6 sequestering agents, JAK2 or MAP 
kinase inhibitors, would determine the specificity of the response for IL6. 
Reg2 was identified in cultured DRG cells, with high expression compared 
with that seen in vivo after injury, supporting the injury-like phenotype of cultured 
cells. Reg2 was not upregulated by IL6 beyond that seen with time at 72hrs growth, 
and further experiments were planned to confirm IL6 regulation of Reg2. 
Notwithstanding the presence of NGF being generated within the culture 
media, and potentially suppressing the expression of galanin in peptidergic cells
(Corness et al., 1998), the influence of IL6 on galanin expression provides a potential 
candidate for mediating the galanin expression seen in vivo after L5 SNL particularly 
in non-peptidergic IB4 cells, which may express receptor components for gp130 
cytokines (discussed by Priestley 2008). One potential source of IL6 after SNL in 
vivo is the activated macrophage; an inflammatory cell known to produce mediators,
such as cytokines (including IL6) and known to be recruited to the site of injury 
readily and quickly after trauma (Lu and Richardson, 1993). It was therefore
investigated whether activated macrophages could be detected after nerve injury in 
vivo, using the L5 spinal nerve ligation model.
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Aim 9: To determine if macrophages are present in ipsilateral DRG after L5 spinal 
nerve ligation
8. RESULTS: IN VIVO ED1 DATA
8.1.  ED1 staining of uninjured (naïve) DRG cells
In normal DRG, activated macrophages were rare or absent (see Figure 32A,B). 
Using markers for other non-neuronal cells, such as glia cell marker GFAP (see 
Figure 32C,D) or S100 (also later Figure 36B), a non-neuronal population was 
clearly observed that was not recognised by ED1. DAPI staining was used to show 
these cells were nucleated. 
Figure 32. Micrographs showing non-neuronal cell staining in uninjured (naïve) DRG
profiles. (A) Note lack of ED1 (red) staining around ganglion cells; (B) ED1 and nuclei 
staining (DAPI, blue). (C) GFAP (green) identifying satellite glial cells around the ganglion
cells; (D) GFAP and DAPI (blue). Scale bar represents 100 m.
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8.2. ED1 staining is present adjoining ipsilateral DRG cells, 1 day after 
L5 SNL
One day post L5 SNL, ED1 staining along the axotomised nerve was sparse (hatched 
box areas; Figure 33). Examining sections at higher magnification showed moderate
ED1 staining within the spinal nerve shaft and some ED1-staining especially around
the ganglion (see arrows on Figure 34).
Figure 33. Longitudinal section through injured (ipsilateral) L5 nerve, 1 day after L5 spinal 
nerve ligation. (A) ED1 staining; (B) dark-field image (showing white matter [myelin]). Scale 
bars represent 200 m. Note: ganglia in hatched-area (lower right) with sparse ED1 staining, 
and moderate ED1 staining (in red box) in nerve shaft.
m
200μm
m
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Figure 34. Micrograph sections of ED1 staining through injured (ipsilateral) L5 nerve/DRG, 
1 day after SNL. (A) Longitudinal section shows moderate ED1 staining along nerve shaft. 
(B) Higher magnification image shows DRG cells with occasional ED1 staining detected 
around cells (arrows). Scale bars (A) represents 100 m; (B) represents 50 m.
(B)
(A)
m
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8.3.  ED1 staining is present along the cut nerve 7 days after L5 SNL
ED1 staining was widely visible along the cut nerve 7 days post L5 SNL (Figure 35, 
Figure 36) compared with a small proportion surrounding DRG 1 day after L5 SNL 
(see Figure 34 as comparison). As a control, to confirm ED1 identifies a cellular 
population of non-neuronal cells and that ED1 was not binding non-specifically e.g., 
to degenerating myelin, DAPI was used and clearly indicated the ED1-positive cells 
each had viable nuclei (Figure 36F). The glial cell marker S100 was used as an 
independent marker to differentiate other non-neuronal cells present after injury.
Clear independent ED1/glial cell staining can be seen (Figure 36D). ED1 
staining in contralateral DRG was minimal at both 1 and 7 day time points
investigated (see example Figure 36A). 
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(B)
(C)
Figure 35. Micrograph sections through injured L5 spinal nerve, 7 days after L5 SNL 
showing: (A) ED1-staining; (B) ED1 (red) and DAPI (blue) staining; (C) higher power ED1 
imaging. Hatched area indicates an area of ganglion cells. Scale bars represent (A,B) 400 m; 
(C) 100 m.
ED1
400μm
400μm
m
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Figure 36. Micrograph showing S100 staining (glial cells, green) and activated macrophage 
(ED1; red) in contralateral (A,B) and ipsilateral (C-F) tissue sections, 7-days after L5-SNL. 
Note lack of ED1 on contralateral side (A) and lack of co-expression of ED1 marker with that 
of S100 (F). Nuclei are shown by DAPI (blue). Scale bars A-D represents 100 m; E 
represents 50 m also for F.
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Aim 10: To determine if ED1 immunoreactivity seen in the ipsilateral L5 nerve is 
specific to the injured ganglia at 1- and 7-days after L5 spinal nerve ligation  
8.4. Macrophage staining is not present in adjacent DRG cells
One day post L5 SNL, ED1 staining was minimal in both adjacent ganglia (L4 and 
L6; Figure 37), compared with some ED1 staining identified in the injured L5 
ganglia (for comparison see Figure 33 and Figure 34). By 7 days post L5 SNL ED1 
staining was still minimal along the L4 and L6 spinal nerve branches and around the 
ganglion cells of the adjacent L4 and L6 DRG (Figure 38). The lack of ED1 staining,
but clear presence of glia with corresponding nuclei was comparable visually with 
that seen in the naïve and contralateral tissue (Figure 32). This is especially 
noteworthy when compared with the infiltration of ED1-positive cells observed along 
the L5 nerve branch at 7 days post L5-SNL and also around L5 ganglion cells seen in 
Figures 37 and 38. Adjacent L4 and L6 ganglia at 7 days post L5 SNL were 
comparable visually with the adjacent L4 and L6 ganglia at 1 day post L5 SNL. 
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Figure 37. Micrographs of ipsilateral tissue sections, 1 day after L5 SNL, showing ED1 and 
DAPI staining in L4 or L6 ganglia. (A, B) = L4: (A) ED1 staining; (B) DAPI; (C, D) = L6: 
(C) ED1 staining; (D) DAPI staining. Scale bar (A,B) represents 100 m; scale bar (C,D) 
represents 200 m. 
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Figure 38. Micrographs of ipsilateral DRG sections, taken 7 days after L5 SNL, showing 
ED1 and DAPI staining in adjacent L4 or L6 DRG/injured nerve. (A,B) = L4: (A) ED1 
staining; (B) DAPI staining. (C,D) = L6: (C) ED1 staining; (D) DAPI staining. Scale bar 
represents 200 m. Compare lack of ED1-positive cells invading nerve with mass infiltration 
seen in Figure 35. Hatched area indicates ganglion cells, as in Figures 33 and 35.
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9. DISCUSSION 3: IN VIVO ED 1 RESULTS
Aim 9: To determine if macrophages are present in ipsilateral DRG after L5 spinal 
nerve ligation 
Observations presented here indicate that ED1-positive cells are present at the 
DRG and degenerating nerve immediately after injury, and up to 7 days after L5 
SNL. The ED1 antibody identifies a surface marker on resident and blood-borne 
macrophages when they are in an ‘activated’ state, which can be visualised using 
high-power microscopy when the cells become ‘bushy’ in phenotype (see Coyle, 
1998; Hu and McLachlan, 2003). The specificity of ED1 antibody was supported with 
nuclei counter-staining. Looking in detail, all ED1-positive entities had corresponding 
nuclei. Although only sparse ED1 staining was observed in the uninjured ganglia, 
these data are generally consistent with other reports of longitudinally-oriented ED1-
positive cells sparsely distributed throughout naïve controls (Hu and McLachlan, 
2003; Lu and Richardson, 1993). 
Macrophages are phagocytic inflammatory cells recruited to a site of injury 
during the inflammatory cascade (Hu and McLachlan, 2003; Watkins et al., 2003). As 
such their presence after injury would be expected. Macrophages aid clearing debris, 
such as degraded myelin, and thus help promote healing of the injured area and return 
to a normal physiological state (Perry et al., 1987). Macrophage activation also 
parallels development of allodynia (Coyle, 1998; Liu et al., 2000) and it has been 
suggested that macrophage activity is important in initiating pain and other 
complications following nerve injury (Bennett, 2000). Although similar behavioural 
observations were not carried out herein, confirming the presence of ED1 cells was 
important for correlating with changes in peptides observed in populations of DRG 
cells following L5 SNL. 
At 1 day after L5-SNL, irregularly-shaped ED1 staining was observed in the 
ganglion section of the L5 DRG, with some staining detected on the L5 ipsilateral 
injured nerve shaft but sparse in contralateral (L5 nerve). Looking at the staining 
pattern at higher power magnification, specific ED1-immunoreactivity could be 
identified with fine processes at points around the L5 DRG cells. This staining pattern 
might correspond with reports that a population of resident macrophages exist within 
the DRG. These resident cells are detected by antibodies against activated surface 
antigen ED1, in addition to antibodies for a second antigen, ED2 (Hu and McLachlan 
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2003; Lee et al., 2005). As ED1 can be expressed by both resident and blood-borne 
macrophages after injury (Hu and McLachlan, 2003), and double-labelling 1 day after 
L5 SNL with ED2 and ED1 would support the suggestion that these cells surrounding 
the DRG represent resident macrophage population, principally responsible for 
phagocytising dead neurons. Resident macrophages may also provide trophic support, 
which is an important consideration to investigating dynamic changes in peptide 
expression following nerve injury, some of which may be a consequence of loss of 
neurotrophic support following removal from peripheral targets. As ED1 cells were 
detected 1 day after injury it seems likely that either these are an in situ population of 
cells, or cells that have immediately become activated and infiltrated the injured 
DRG. 
The speed of ED1 invasion into the DRG, as detected after 1 day, might 
suggest a paracrine signal is responsible, although the nature of this signal is 
unknown and not investigated herein. Indeed, a report published during the writing up 
of this project suggested that chemokine CCL2 is involved in neuroimmune 
activation of central microglia following CCI injury (Thacker et al., 2009), 
specifically transported anterogradely in damaged neurons and released from central 
terminals. Following peripheral nerve injury, spinal microglia activation is reported in 
regions where the damaged primary afferent fibres project. The L5 SNL model 
involves damaging 100% of peripheral nerve bundle, and microglia activation is 
known to be dependent upon DRG-mediated signals (Colburn et al., 1999). It would 
be interesting to determine if CCL2 is present in the L5 SNL model, to extend
observations from the CCI model (Thacker et al., 2009). Particularly as CCL2 was 
found in the DRG 1 day following a partial nerve ligation and specifically in P2X3 
DRG (Thacker et al., 2009), the population of nociceptors of particular interest in this 
report. Expression of CCL2 has also been correlated with the development of 
behavioural hyperalgesia linking immunohistochemical observations with 
behavioural hypersensitivity data, indicated using footpad withdrawal threshold to 
mechanical stimuli (Thacker et al., 2009). Both CCI and L5 SNL model result in 
intermingling of intact and degenerated axons in the nerve stump, and therefore 
provides a basis for comparison. 
Rapid activation of a population of non-neuronal cells is important to the 
investigations discussed herein as galanin was significantly up-regulated 1 day after 
injury the time line suggests rapid production of the mediator responsible for this 
galanin upregulation. Indeed, IL6 was shown to accelerate upregulation of galanin in 
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vitro after 24 hrs. Indeed, the ability of the body to respond quickly and effectively to 
damage is a crucial step in the recovery process, and the release of cytokines by a 
variety of cell types plays a critical role in the initial response to injury. For example, 
co-localization of IL6 with ED1 or with COX2 has been reported (Ma and Quirion, 
2005). Separately, invading peripheral macrophage-derived IL6 has been shown to 
play a critical role in vincristine-induced mechanical allodynia (Kiguchi et al., 2008). 
Thus, further characterising the ED1-positive cells around the DRG such as using 
ED2, would be an important further experiment to carry out.
The injured nerve itself is a potential source of mediators (Ma and Quirion, 
2005; Sun and Zigmond 1996). Although NGF is lost with nerve injury, NGF has 
been shown to be released from macrophages (see McMahon et al., 2005; Watkins 
and Maier 2003) and therefore a supply could prevent upregulation of galanin – at
least in part (Shadiack et al., 2001). As discussed above, NGF may negatively 
regulate galanin expression in peptidergic cells (Corness et al., 1998). With a 
corresponding down-regulation of peptides after injury, including CGRP by 7 days –
confirmed in the present experiments – and SP (Weissner et al., 2006; Wong and 
Oblinger, 1991), the NGF (and consequences of NGF generation) at least 
immediately after injury even with these resident cells being ‘activated’, cannot be
sufficient to prevent the down-regulation and loss of these peptides (SP/CGRP).
Therefore, the local NGF production may not be sufficient to prevent upregulation of 
peptides, such as galanin. 
Seven days post L5 SNL, a further increase in ED1 positive cells was 
visualised both in number and size, around the DRG. Although not quantified, these 
cell patterns are comparable to other data showing 1-week after spinal nerve 
transection, the number and brightness of ED1 cells were dramatically increased (Hu 
and McLachlan, 2003). Cells were likewise enlarged, and Hu and McLachlan (2003) 
classified 50% as ‘foamy’, although these characterisations were not carried out in the 
current experiments. As the nerve degenerates, myelin is broken down by 
macrophages and cleared from the injured area (Hu and McLachlan 2003; Lu and 
Richardson et al., 1993; Perry et al., 1987), although this is not the macrophages’ only 
role. Indeed, the ED1 cells likely provide cytokines and/or neurotrophic support to the 
degenerating nerve and DRG as a number of injury-generated factors, including 
cytokines and growth factors, are known to be released from activated macrophages
(Reichert et al., 1996; Ribeiro et al., 2000; also see Watkins et al., 2001), and also 
Schwann cells (Bolin et al., 1995). In addition to the visual evidence given showing a 
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considerable neuroimmune response at 7-days following L5 SNL, prolonged 
neuroinflammation has been reported along the damaged nerve trunk and back 
towards the sensory ganglia (Hu and McLachlan, 2003). 
Although it is a clear limitation that the ED1 staining was not quantified, a 
clear visual increase of ED1 cells could be seen and was captured on the microscope. 
Quantification experiments comparing injured vs. naïve sections at the 1 and 7 day 
time points would support the visual observations, that ED1 cells are rapidly 
upregulated following L5 SNL. Representative areas of the DRG could have been 
photographed at high (e.g., x 160) magnification cell size distribution determined and 
also cell density, according to the method outlined by Hu and McLachlan (2003). 
Mean representative values could have been derived for comparison. Furthermore, it 
would have added to the project to assay content of any mediators being generated at 
the DRG, especially which cytokine(s) and other trophic factors, such as that carried 
out for cytokine CCL2 by Thacker et al., (2009). Using ELISA to qualify the 
presence of mediators, such as IL6 or other neurotrophic factors in collected samples 
against standard samples, may be one technique. Also, using combinations of
antibodies against macrophages antigens, such as combinations of ED2, MHC II and 
ED1, could have been used to distinguish cell type. Indeed four functional subtypes 
of macrophage within the DRG have been distinguished, including the ED1-positive 
foamy cells that phagocytosed myelin after spinal nerve transection (Hu and 
McLachlan 2003). OX42 was investigated as an alternative marker for ‘activated’ 
macrophages, however control and injury experiments produced no staining, and it is 
believed that the antibody had not been developed properly, as others within the 
centre found similar problems. Control immunohistochemical experiments would also 
confirm the antibody was non-reactive with corresponding antigen.
Looking at later time points, for example 10 or 14 days post L5-SNL, to see if 
the cells fully surround the ganglion or reach a point where they stop infiltrating 
further towards the DRG cells, would strengthen these initial observations. Although, 
data suggest that cell infiltration peeks at 1-week following spinal nerve transection 
(Hu and McLachlan, 2003). Also, experiments to correlate the expression of 
ED1/ED2 cells with upregulation of given peptides in subcategories of DRG 
following injury would support the hypothesis that these cells are important for the 
dynamic changes in peptides recorded. The present observations are again in-line 
with data 7-days after spinal nerve transection by Hu and McLachlan (2003) showing 
ED1 cells increasing back towards the DRG from the spinal nerve.
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Aim 10: To determine if ED1 immunoreactivity seen in the ipsilateral L5 nerve is 
specific to the injured ganglia at 1- and 7-days after spinal nerve injury  
Examining the adjacent DRG to the L5 spinal nerve (L4 and L6 DRG), we observed a 
minimal change in ED1 expression more consistent with that seen in the naïve 
animal. Furthermore, no up-regulation of ED1 positive cells was found along the L5 
cut nerve shaft at 7 day post L5 SNL, into either adjacent DRG (L4 or L6) or into 
contralateral DRG. This observation might suggest that at least 1 week after L5 SNL, 
where galanin expression has reached 50% of all ipsilateral DRG cells of various
subcategories, that infiltration of macrophages is contained to the damaged nerve. 
This does not rule out a later infiltration of cells, perhaps as the number/amount of 
injury-related factors released in the injury environment are sufficient to produce 
longer-range signalling and ED1-positive cells migration. The literature is undecided 
of the contribution of the adjacent, non-injured DRG to sensory processing after 
injury as some evidence suggests the ipsilateral, adjacent DRG is involved especially 
in generating allodynia (e.g., Milligan et al., 2003; Obata et al., 2003). Further 
investigations into the contribution of the contralateral DRG in injury are thus 
needed. 
As outlined in the introduction, the L5 SNL model used provided a complete 
spinal nerve injury adapted from the model of Kim and Chung (2002), in which only 
the L5 nerve was selectively ligated and cut, in comparison to e.g., sciatic nerve 
ligation (Bennett et al., 1998a), spared nerve injury (Decosterd and Woolf 2000), or 
photochemical lesion (Gazelius et al., 1996), which damage fibres from more than 
one DRG. Data have shown a differentiation between the sciatic nerve model and the 
spinal nerve model, with respect to type and quantity of macrophages seen to invade 
the injured nerve (Hu and McLachlan, 2003). In this respect, the L5 model is ideal for 
investigating any damage or changes caused in the adjacent DRG – which should 
remain uninjured and therefore ED1/macrophage should be minimal as we observed. 
However, changes have been shown in the adjacent DRG following L5 SNL. For 
example, Shortland and colleagues showed changes in galanin, and the injury 
indicating mediator, ATF3, was expressed in the adjacent DRG (i.e., L4) (Shortland 
et al., 2006) by 14 days post L5-SNL. Shortland et al., (2006) do conclude that 
phenotypic changes in the adjacent DRG alone are unlikely responsible for generating 
neuropathic pain characteristics, due to the lack of correlation with pain behaviours 
and also the cell-size mismatch between the damaged and adjacent DRG. The galanin 
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changes are more likely related to cell survival and regeneration. Further, signalling 
for macrophage invasion into DRG, and potentially the contralateral nerve, may be 
mediated by lost motoneurons or by interneurons (Dubovy et al., 2007). It would be
interesting to investigate any upregulation of blood-borne macrophages into adjacent 
DRG at these later time points, and especially at 14 days when galanin is significantly 
upregulated in the adjacent, L4 ipsilateral DRG (Shortland et al., 2006). 
Based on results from different models of nerve injury, more than one 
mechanism is likely responsible for coordinating the invasion of ED1-positive 
macrophages into the DRG, potentially including retrograde transport of factors
produced during Wallerian degeneration or their delivery by blood flow. As discussed 
above, chemokine CCL2 is one mediator shown to be involved in neuroimmune 
activation of central microglia following CCI injury (Thacker et al., 2009), 
specifically transported anterogradely in damaged neurons and released from central 
terminals. Furthermore, Reg2 may itself be an influence on ED1 infiltration (Livesey 
et al., 1997) and, although Reg2 expression was modest in comparison with other 
peptides, the specific expression may suggest a very specific role following injury. 
Thus, the contribution of increased Reg2 found following nerve injury should be 
investigated further. 
9.1. Chapter Summary
ED1-positive cells were identified in the injured L5 ganglia and along the axotomised 
nerve shaft, particularly at 7 days after L5 SNL. A smaller population of ED1-
staining was seen immediately after injury surrounding the ipsilateral ganglion cells, 
but not in adjacent DRG to that injured (L4 and L6), or in contralateral DRG of the 
same level (L5) as that injured. ED1 cells were not detected in the adjacent DRG, but 
this does not exclude a later infiltration of cells. Quantification experiments, and 
further immunohistochemical sub-characterisation of ED1-positive cells, are needed 
in order for any firm conclusions to be drawn from these observations. 
168
10. CONCLUSIONS
The overall aim of this project was to investigate upregulation of neuropeptides, 
galanin and Reg2, after spinal nerve injury and furthermore to investigate 
mechanisms by which they might be regulated after nerve injury. Accordingly, a 
number of observations have been recorded. 
Galanin is newly synthesized and upregulated within 1 week of L5 spinal 
nerve injury in both peptidergic and non-peptidergic, small diameter DRG cells. At 1 
day expression is predominantly in peptidergic DRG cells, but increases in non-
peptidergic DRG cells at 7 days. Additionally, galanin was upregulated in the 
population of thinly-myelinated, DRG cells identified by TRPV2. Although 
suggested indirectly by others, by confirming galanin is synthesised in non-
peptidergic and thinly-myelinated TRPV2 cells after L5 SNL, a gap in the extensive 
literature for galanin has been confirmed. Reg2 was minimally upregulated after L5 
SNL, but at 7 days post-injury half of the Reg2 cells co-expressed galanin. IL6 was 
shown to up-regulate galanin in dissociated DRG cells in vitro, to levels comparable 
with that seen in the injured animal, although there is a limitation that NGF was likely
being generated within the cell culture. As such, these experiments should be repeated 
before firm conclusions can be drawn. By 7 days after injury non-neuronal cells were 
observed in the axotomised nerve shaft and around the ipsilateral DRG. These cells 
are thought to be macrophages based on their surface morphology and recognition by 
the ED1 antibody. 
Although the relevant experiments were not carried out to directly identify 
factors that regulate galanin and Reg2 in vivo, the complex temporal profile of 
expression in different cell populations is very informative in itself. Since galanin 
upregulation in CGRP cells is extensive by 1 day after injury and precedes the 
macrophage (ED1) presence, I conclude that it is most likely to be a direct response to 
the axotomy and withdrawal from target-derived NGF. This could be confirmed by 
supplementing with NGF to prevent this upregulation. Subsequently, by 7 days, a 
cytokine such as one from the IL6-family may be produced by ED1 cells or other 
non-neuronal cells activated with injury, to upregulate galanin in the IB4/P2X3 cells. 
This could be confirmed using antibodies to IL6 and/or LIF. As all cells expressed
gp130, this effect would be dependent on expression of IL6R/sIL6R. The formulated
conclusion for the thesis is shown schematically in Figure P. 
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Figure P: Schematic representation of the project results. Injury (1) causes (2) loss of target 
derived NGF, which may drive initial upregulation of galanin (3) in IB4-negative DRG cells. 
Injury (1) also causes (4) activation and infiltration of macrophages (M), which (5) release 
e.g. interleukin 6 (IL6) into the tissue, to act on (6) IB4 positive DRG cells and increase 
expression (7) of galanin (GAL) and Reg2. IL6 may (?) also increase expression (3) of 
galanin in IB4-negative DRG cells. Cytokines likely evoke (8) self-perpetuating release of 
further cytokines from macrophages (M). Reg2 may also aid recruitment of further 
macrophages to the injured area.
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(C,D) Co-expression of galanin (C) in TRPV2 (VRL1) cells (D). (E,F) Co-expression of 
galanin (E) in P2X3 cells (F). Scale bars represent 50 m. Arrows indicate some of the 
double-labelled cells. .............................................................................................................103
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F)............................................................................................................................................104
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1 day post-L5 SNL; and (B) 7 days post-L5 spinal nerve injury. Arrows show positive cells. 
Note the larger cell area for 7 days compared with 1 day. Scale bar represents 50 m for both 
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Figure 15. Histogram representing DRG profile area distribution (in m2) for Reg2-positive 
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population distribution does not change significantly on ipsilateral side after injury compared 
to naïve (uninjured) distribution (Table 5).............................................................................109
Figure 17. Micrograph images depicting Reg2 and galanin coexpression, 7 days post-L5 
spinal nerve injury in ipsilateral DRG sections. (A,B) Scale bar represents 100 m. (C,D) 
Scale bar represents 50 m. Arrows indicate double-labelled cells. Note: Reg2-positive cells 
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Figure 19: -Tubulin stained, cultured adult DRG cells after: (A) 18hrs; (B) 24hrs; (C) 48hrs; 
(D) 72hrs culture growth, grown in BSF2 media (supplemented with 2% foetal calf serum). 
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Figure 20. CGRP staining (red) in tubulin-positive (green) isolated cultured adult DRG cells 
grown for 48hrs in BSF2 media (supplemented with 2% foetal calf serum). DAPI (blue) was 
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bar represents 100 m. Note diffuse CGRP staining in neurite and characteristic ‘patchy’ 
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Figure 21. Micrographs showing neuropeptide Y (NPY) (red) expression in -tubulin-
positive (green) cultured adult DRG cells, grown for 72hrs in BSF2 media (supplemented 
with 2% foetal calf serum). DAPI (blue) was used to identify all cellular nuclei in the growing 
culture (neuronal and non-neuronal). Scale bar represents 50 m. Arrows indicate NPY-
positive cells. Note NPY staining has ‘patchy’ characteristic thought to be representative of 
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grown for 72hrs in BSF2 media (supplemented with 2% foetal calf serum). DAPI (blue) was 
used to identify all cellular nuclei in the growing culture (neuronal and non-neuronal). Arrows 
indicate galanin-positive cells, arrowhead shows galanin immunonegative cell. Scale bar 
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primary cultured adult DRG, after 48hrs growth in control media (BSF2 supplemented with 
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Figure 24. Micrographs showing galanin (red) and CGRP (green) co-expression in primary 
adult DRG cell cultures, grown in BSF2 media (supplemented with 2% foetal calf serum) for 
48hrs. Arrows indicate double-labelled cell, arrowhead indicates single labelled galanin cell. 
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Figure 25. Micrograph images showing cultured adult DRG grown for 48hrs in BSF2 media 
(supplemented with 2% foetal calf serum) and immunostained with IB4 (green) and galanin 
(GAL; red). DAPI (blue) shows all cell nuclei. Scale bar represents 50 m. Note 
independence of staining for IB4 and GAL. ...........................................................................132
Figure 26. Bar-chart representation of percentage galanin expression in -tubulin-positive 
cultured adult DRG cells at 24, 48 and 72 hrs’ culture growth, in absence (blue) or presence 
(red) of IL6 (40ng/mL). Both conditions included BSF2+2% foetal calf serum (FCS). Error 
bars represent SEM. n=4-5. * = P<0.05 compared with respective BSF2...........................134
Figure 27. Bar chart showing percentage of cultured (-tubulin-positive) DRG cells having 
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proportion of these cells expressing galanin (shown by the blue section of the bar). Error bars 
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±IL6. Both conditions included BSF2+2% foetal calf serum. ...............................................135
Figure 28. Scatter-plots showing X-Y correlation between number of growing cultured cells 
per slide well and galanin expression (as %) per well, at 48(▲), 72(♦) hours. (A) Control 
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in presence (red) and absence (blue) of IL6 (40 ng/mL), at 48hrs’ culture growth. Error bars 
represent SEM; n=4-7. * = P<0.05 for comparison between BSF2 and IL6. ........................138
199
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medium. Both conditions included BSF2+2% foetal calf serum. Error bars represent SEM; 
n=4 for each. ..........................................................................................................................139
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in BSF2 alone (A,B) or IL6-enriched (40 ng/mL) BSF2 (C,D). Both conditions included 
BSF2+2% foetal calf serum. DRG cultures are counterstained with neuronal marker -tubulin 
(green). Arrows represent Reg2-positive cells. Scale bar represents 50 m..........................140
Figure 32. Micrographs showing non-neuronal cell staining in uninjured (naïve) DRG 
profiles. (A) Note lack of ED1 (red) staining around ganglion cells; (B) ED1 and nuclei 
staining (DAPI, blue). (C) GFAP (green) identifying satellite glial cells around the ganglion 
cells; (D) GFAP and DAPI (blue). Scale bar represents 100 m...........................................153
Figure 33. Longitudinal section through injured (ipsilateral) L5 nerve, 1 day after L5 spinal 
nerve ligation. (A) ED1 staining; (B) dark-field image (showing white matter [myelin]). Scale 
bars represent 200 m. Note: ganglia in hatched-area (lower right) with sparse ED1 staining, 
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Figure 34. Micrograph sections of ED1 staining through injured (ipsilateral) L5 nerve/DRG, 
1 day after SNL. (A) Longitudinal section shows moderate ED1 staining along nerve shaft. 
(B) Higher magnification image shows DRG cells with occasional ED1 staining detected 
around cells (arrows). Scale bars (A) represents 100 m; (B) represents 50 m...................155
Figure 35. Micrograph sections through injured L5 spinal nerve, 7 days after L5 SNL 
showing: (A) ED1-staining; (B) ED1 (red) and DAPI (blue) staining; (C) higher power ED1 
imaging. Hatched area indicates an area of ganglion cells. Scale bars represent (A,B) 400 m; 
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Figure 36. Micrograph showing S100 staining (glial cells, green) and activated macrophage 
(ED1; red) in contralateral (A,B) and ipsilateral (C-F) tissue sections, 7-days after L5-SNL. 
Note lack of ED1 on contralateral side (A) and lack of co-expression of ED1 marker with that 
of S100 (F). Nuclei are shown by DAPI (blue). Scale bars A-D represents 100 m; E 
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Figure 37. Micrographs of ipsilateral tissue sections, 1 day after L5 SNL, showing ED1 and 
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